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Abstract
The hybridization of magnetic resonance imaging (MRI) with positron emission to-
mography (PET) or single photon emission computed tomography (SPECT) enables
the collection of an assortment of biological data in spatial and temporal register.
However, both PET and SPECT are subject to photon attenuation, a process that de-
grades image quality and precludes quantification. To correct for the effects of attenu-
ation, the spatial distribution of linear attenuation coefficients (µ-coefficients) within
and about the patient must be available. Unfortunately, extracting µ-coefficients from
MRI is non-trivial. In this thesis, I explore the problem of MRI-based attenuation
correction (AC) in emission tomography.
In particular, I began by asking whether MRI-based AC would be more reliable in
PET or in SPECT. To this end, I implemented an MRI-based AC algorithm relying
on image segmentation and applied it to phantom and canine emission data. The
subsequent analysis revealed that MRI-based AC performed better in SPECT than
PET, which is interesting since AC is more challenging in SPECT than PET.
Given this result, I endeavoured to improve MRI-based AC in PET. One problem
that required addressing was that the lungs yield very little signal in MRI, making it
difficult to infer their µ-coefficients. By using a pulse sequence capable of visualizing
lung parenchyma, I established a linear relationship between MRI signal and the
lungs’ µ-coefficients. I showed that applying this mapping on a voxel-by-voxel basis
iii
improved quantification in PET reconstructions compared to conventional MRI-based
AC techniques.
Finally, I envisaged that a framework for MRI-based AC methods would poten-
tiate further improvements. Accordingly, I identified three ways an MRI can be
converted to µ-coefficients: 1) segmentation, wherein the MRI is divided into tissue
types and each is assigned an µ-coefficient, 2) registration, wherein a template of µ-
coefficients is aligned with the MRI, and 3) mapping, wherein a function maps MRI
voxels to µ-coefficients. I constructed an algorithm for each method and catalogued
their strengths and weaknesses. I concluded that a combination of approaches is de-
sirable for MRI-based AC. Specifically, segmentation is appropriate for air, fat, and
water, mapping is appropriate for lung, and registration is appropriate for bone.
Keywords: PET/MRI, SPECT/MRI, hybrid imaging, attenuation correction, lung
density, segmentation, registration, mapping
iv
Co-Authorship
None of the research chapters contained herein were produced alone. The following
credits all co-authors and details their contributions, followed by my contributions.
Chapter 2 was co-authored by Dr. Robert Z. Stodilka, Dr. Jean The´berge, Dr.
Eric Sabondjian, Dr. Alexandre Legros, Ms. Lela Deans, Ms. Jane M Sykes, Dr.
R. Terry Thompson, and Dr. Frank S. Prato. Drs. Stodilka, The´berge, Legros,
Thompson, and Prato helped conceive, formalize, and develop the idea, Drs. Stodilka,
The´berge, and Sabondjian, Ms. Deans, and Ms. Sykes assisted with the experimental
design, Drs. The´berge and Sabondjian, Ms. Deans, and Ms. Sykes partook in data
collection, Drs. Stodilka and Sabondjian contributed to the data analysis, and Drs.
Stodilka, The´berge, Thompson, and Prato critically reviewed the manuscript. I col-
lected the data, coded the attenuation correction algorithm, designed and conducted
the analysis, and wrote the manuscript.
Chapter 3 was co-authored by Dr. Frank S. Prato, Ms. Lela Deans, Dr. Jean
The´berge, Dr. R. Terry Thompson, and Dr. Robert Z. Stodilka. Drs. Prato and
Stodilka helped conceive, formalize, and develop the idea, Drs. Prato, Stodilka, and
The´berge, and Ms. Deans assisted with the experimental design, Ms. Deans partook
in data collection, and Drs. Prato, The´berge, Thompson, and Stodilka contributed to
the data analysis in addition to critically reviewing the manuscript. I conceived the
idea, designed the experiment, collected the data, coded the attenuation correction
v
algorithms, designed and conducted the analysis, and wrote the manuscript.
Chapter 4 was co-authored by Dr. Frank S. Prato, Mr. John Patrick, Dr. David
Laidley, Mr. John Butler, Dr. Jean The´berge, Dr. R. Terry Thompson, and Dr.
Robert Z. Stodilka. Dr. Stodilka and Mr. Patrick helped conceive, formalize, and
develop the idea, as well as assisting with the experimental design, Mr. Patrick and
Mr. Butler partook in data collection, Dr. Laidley contributed to the data analysis,
and Drs. Stodilka, The´berge, Thompson, and Prato, and Mr. Patrick critically
reviewed the manuscript. I conceived the idea, designed the experiment, collected
the data, coded the attenuation correction algorithms, designed and conducted the
analysis, and wrote the manuscript.
vi
To Laura,
for filling my life
with love and laughter.
vii
Acknowledgments
No man is an island, and a veritable archipelago of individuals have helped make this
thesis a reality. First and foremost, I would like to thank my supervisor, Dr. Rob
Stodilka. Whenever I ran into a problem, big or small, he was always there to guide
me through it. Moreover, despite remaining mindful of the challenges imposed by my
tight timeline, Rob still granted me a great deal of independence, encouraging me to
pursue the problems that interested me. This not only made my entire Ph.D. lots of
fun, but was indispensable in building my confidence as a young scientist. So thank
you Rob for all you’ve done; you are ever an inspiration to me.
Next, I would like to thank my advisory committee members, Dr. Frank Prato,
Dr. Terry Thompson, and Dr. Ian Cunningham. At our first meeting, you were all
very kind and encouraging, which was exactly what I needed as a nervous student just
starting his project. By the time our second meeting came about, I thought I knew
much more than I had before, and entered with a swagger. Within ten minutes, my
cocksure attitude has dissipated, and by the time I departed I was an empty, broken
shell of a man. There’s nothing like an advisory committee to teach humility, and I
got that lesson in spades. But, as before, it was exactly what I needed. It taught me
to be cautious in my assertions, prudent in my claims, and wary of my assumptions,
qualities that have served me well ever since (especially in subsequent committee
meetings). In all seriousness though, thank you for your insightful comments and
viii
critiques, they have been of tremendous value. It is also to you that I attribute my
understanding of what a thesis should be.
Additionally, though he did not sit on my advisory committee, Jean The´berge
played just as important a role in my work. Whether he was revising manuscripts,
helping plan experiments, or conveying some aspect of his vast knowledge of MRI,
Jean has been helping me since the beginning, and for that I am very grateful.
And speaking of MRI, I would not have been able to conduct any of my experi-
ments without John Butler. Not only did he teach me how to use the Verio, he spent
countless hours helping me fiddle with pulse sequences to get them working properly.
Further, he was kind enough to run the scanner whenever I required patient data.
His professional demeanour clearly put them at ease, and made collecting data for
Chapter 4 a pleasure.
The other key piece of imaging equipment I required was, of course, the PET/CT.
I owe a great debt to Jenn Hadway, Dr. Aaron So, and Dr. Steve Ross, all of whom
altruistically imparted their expertise regarding the operation of the Discovery VCT.
A special thank you to Jenn for tolerating my many, many emails to the effect of
“Can I use the PET/CT tonight?”.
With respect to PET/CT skills, however, I did not hold a candle to the nuclear
medicine techs, Don Kuhl, Ben Reyes, Gina Iacobelli, Karen Keys, Peter Masters,
Paul Sery, and Jessica Wall. Not only did they patiently endure my frequent questions
and missteps, they were responsible for all the patient PET/CT data in Chapter 4.
Incidentally, I would not have been able to recruit any patients for my study if not
for Lindsay Douglas and Tracy Zurbrigg, the masters of the nuclear medicine front
desk. Lindsay, thank you for organizing and mailing that endless stream of letters of
intent, and Tracy, thank you for allowing me to sit next to you as I lay in wait for
my next unsuspecting victim.
ix
Assuredly, many of my experiments relied on dogs, not patients. It is the exper-
tise Lela Deans, Jane Sykes, and Terrie Ann Campbell that these experiments were
made possible. They deftly navigated the complex, obtuse world of animal use proto-
cols, and were nothing short of exceptional when handling the canines, which in one
case involved the swift administration of propofol to a dog who was awaking in the
PET/CT, followed by cardiopulmonary resuscitation when that same dog crashed in
the MRI. Thanks to the vet techs’ unmatched talent, the dog was just fine.
I would also like to thank my lab for their support. Eric Sabondjian, Omar El-
Sherif, and John Patrick have been outstanding colleagues and collaborators. It was
Eric who taught me the ins and outs of working with γ-ray emitters, as well as how
to operate the SPECT/CT. I always felt I could turn to him when I was stuck, a
bit like an older brother. If Eric was like an older brother, then Omar was more like
a twin sibling. Our similar ages, academic stages, and interests made him an ideal
person to commiserate with over the trials and tribulations of graduate school, though
I’m glad we got to celebrate its benefits on the tropical sands of Hawai’i and in the
frigid air of Sweden. Finally, despite his seniority in a strict chronological sense, I
believe that initially I was to John as Eric was to me. Now, having passed on all
the information I have, it remains an absolute pleasure to speak with John about
MRI-based attenuation correction, amongst life’s other points of interest.
Numerous others have helped shape this project, be it through discussion, plan-
ning, revision, or otherwise. In particular, I would be remiss not to acknowledge Dr.
William Pavlosky, Dr. Gerry Wisenberg, Dr. David Laidley, Dr. Irina Rachinsky,
Dr. Jean-Luc Urbain, Dr. James White, Dr. Donna Goldhawk, Dr. Kim Blackwood,
and Dr. Jodi Miller. Additionally, thank you to Brenda Dubois, Michele Avon, and
Shelagh Ross for assisting me with all things administrative.
Also, I cannot in good faith fail to state my appreciation for my peers (and former
x
peers) in the M.D./Ph.D. program. Notably, Dr. Derek Cool, Dr. Tom Appleton, Dr.
Michael Berger, Dr. Matt Lanktree, and Dr. Piya Lahiry have all served as mentors,
helping guide me through the program. I am equally grateful for my other brothers-
and sisters-in-arms, perhaps especially Pencilla Lang, one of the few M.D./Ph.D.
students who shares the frustrations of working in medical imaging. Finally, without
the outstanding (former) leadership of Dr. Jim Lewis and administrative gifts of
the seemingly omniscient Vicki Vanstrien, our program would not exist at all, and
Western would be worse for it.
But for all the aptitude, intelligence, emotional support, and goodwill on Earth,
no research would ever get done without money. For their generous financial contri-
butions, I would like to thank my sources of funding, including the Natural Sciences
and Engineering Research Council of Canada, the Canada Foundation for Innova-
tion, the Canadian Institutes of Health Research, the Ontario Research Fund, and
Multi-Magnetics Incorporated.
In closing, I wish to thank those closest to me, for without them I surely would
have gone mad a few months in. Nate and Kate Denig, Chris Rennick, and Sandra
Rohfrietsch, thank you for being the best friends I could have asked for. I hope that
in the years and decades to come, that never changes. Mom, thank you for supporting
me not just through my Ph.D., but through my whole life prior. You and Dad have
been tremendous parents to me since the very beginning. And last but certainly not
least, to my wife Laura, thank you for everything: for your love, devotion, patience,
and kindness. Thank you for helping me rise early and get to bed at a reasonable
hour, thank you for interrupting my work with your hugs and lovely smile, and thank
you for rescuing me from my dearth of common sense. But most of all, thank you for
giving a simple nerd a beautiful life.
xi
Contents
Certificate of Examination ii
Abstract iii
Co-Authorship v
Dedication vii
Acknowledgments viii
Contents xii
List of Tables xvi
List of Figures xvii
List of Appendices xix
Nomenclature xx
1 A Bird’s Eye Perspective of Attenuation Correction in PET/MRI 1
1.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1
1.2 The Value of Quantitative PET/MRI . . . . . . . . . . . . . . . . . . 4
1.2.1 Oncology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4
1.2.2 Neurology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7
1.2.3 Cardiology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10
1.3 Factors Influencing Quantification . . . . . . . . . . . . . . . . . . . . 14
1.3.1 PET Physics Primer . . . . . . . . . . . . . . . . . . . . . . . 14
1.3.2 Physical Factors . . . . . . . . . . . . . . . . . . . . . . . . . . 20
1.3.2.1 Photon Statistics . . . . . . . . . . . . . . . . . . . . 20
1.3.2.2 Spatial Resolution and the Partial Volume Effect . . 23
1.3.2.3 Observed Radiopharmaceutical Distribution . . . . . 27
1.3.3 Biological Factors . . . . . . . . . . . . . . . . . . . . . . . . . 28
1.3.4 Technical Factors . . . . . . . . . . . . . . . . . . . . . . . . . 31
1.3.4.1 Image Reconstruction . . . . . . . . . . . . . . . . . 31
xii
1.3.4.2 Quantitative Model . . . . . . . . . . . . . . . . . . . 36
1.3.4.3 Data Acquisition . . . . . . . . . . . . . . . . . . . . 37
1.3.5 Human Factors . . . . . . . . . . . . . . . . . . . . . . . . . . 38
1.4 Attenuation Correction . . . . . . . . . . . . . . . . . . . . . . . . . . 39
1.4.1 Definition of Attenuation . . . . . . . . . . . . . . . . . . . . . 39
1.4.2 How Attenuation Is Corrected . . . . . . . . . . . . . . . . . . 46
1.4.3 How the µ-Map Is Obtained . . . . . . . . . . . . . . . . . . . 47
1.4.3.1 Transmission Scan Primer . . . . . . . . . . . . . . . 47
1.4.3.2 Without a Transmission Scan . . . . . . . . . . . . . 48
1.4.3.3 Geometric Considerations for Transmission Scans . . 51
1.4.3.4 Energy Considerations for Transmission Scans . . . . 54
1.4.3.5 Problems Specific to X-ray CT Transmission Scans . 57
1.5 MRI-Based Attenuation Correction . . . . . . . . . . . . . . . . . . . 58
1.5.1 Relation to Transmission Scans . . . . . . . . . . . . . . . . . 58
1.5.2 MRI to µ-Map Conversion . . . . . . . . . . . . . . . . . . . . 60
1.5.2.1 By Segmentation . . . . . . . . . . . . . . . . . . . . 60
1.5.2.2 By Registration . . . . . . . . . . . . . . . . . . . . . 64
1.5.2.3 By Mapping . . . . . . . . . . . . . . . . . . . . . . . 65
1.5.3 Ongoing Problems and Future Work . . . . . . . . . . . . . . 68
1.6 Conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 72
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 74
2 A Comparison of MRI-Based Attenuation Correction in PET Versus
SPECT 95
2.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 95
2.2 Imaging Protocol . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 97
2.2.1 Animals . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 97
2.2.2 Phantom . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 98
2.2.3 PET/CT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 98
2.2.4 SPECT/CT . . . . . . . . . . . . . . . . . . . . . . . . . . . . 99
2.2.5 MRI . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 99
2.3 Image Processing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 100
2.3.1 µ-Map Generation . . . . . . . . . . . . . . . . . . . . . . . . 100
2.3.1.1 CT-Based . . . . . . . . . . . . . . . . . . . . . . . . 100
2.3.1.2 MRI-Based . . . . . . . . . . . . . . . . . . . . . . . 100
2.3.2 Registration . . . . . . . . . . . . . . . . . . . . . . . . . . . . 102
2.4 Assessment of MRI-Based AC Quality . . . . . . . . . . . . . . . . . 103
2.4.1 Error Analysis . . . . . . . . . . . . . . . . . . . . . . . . . . . 103
2.4.1.1 Global . . . . . . . . . . . . . . . . . . . . . . . . . . 103
2.4.1.2 Local . . . . . . . . . . . . . . . . . . . . . . . . . . 104
2.4.2 Sensitivity Analysis . . . . . . . . . . . . . . . . . . . . . . . . 104
2.5 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 106
2.6 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 112
xiii
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 121
3 Variable Lung Density Consideration in Attenuation Correction of
Whole-Body PET/MRI 124
3.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 124
3.2 Materials and Methods . . . . . . . . . . . . . . . . . . . . . . . . . . 125
3.2.1 Experimental Protocol . . . . . . . . . . . . . . . . . . . . . . 125
3.2.2 Subjects . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 127
3.2.3 Imaging . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 127
3.2.4 Image Registration . . . . . . . . . . . . . . . . . . . . . . . . 129
3.2.5 Image Segmentation . . . . . . . . . . . . . . . . . . . . . . . 129
3.2.6 Quantitative Analysis . . . . . . . . . . . . . . . . . . . . . . . 130
3.3 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 132
3.4 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 141
3.5 Conclusion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 145
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 146
4 To Segment, Register, or Map? A Comparison of Three MRI-Based
Attenuation Correction Methods for Whole-Body PET 150
4.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 150
4.2 Materials and Methods . . . . . . . . . . . . . . . . . . . . . . . . . . 151
4.2.1 Data Acquisition . . . . . . . . . . . . . . . . . . . . . . . . . 151
4.2.2 MRI-Based µ-Maps from Segmentation . . . . . . . . . . . . . 153
4.2.3 MRI-Based µ-Maps from Registration . . . . . . . . . . . . . 155
4.2.4 MRI-Based µ-Maps from Mapping . . . . . . . . . . . . . . . 155
4.2.5 Processing the MRI-Based µ-Maps . . . . . . . . . . . . . . . 156
4.2.6 Data Analysis . . . . . . . . . . . . . . . . . . . . . . . . . . . 157
4.3 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 158
4.3.1 Overview . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 158
4.3.2 Global . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 158
4.3.3 Local . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 164
4.4 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 166
4.4.1 Overview . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 166
4.4.2 Lungs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 166
4.4.3 Fat . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 167
4.4.4 Water . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 167
4.4.5 Bone . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 168
4.4.6 Lesions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 169
4.4.7 Hybrid Approaches . . . . . . . . . . . . . . . . . . . . . . . . 169
4.4.8 Errors from Image Registration . . . . . . . . . . . . . . . . . 170
4.5 Conclusion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 171
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 172
xiv
5 Expanding Horizons 175
5.1 MRI-Based AC in SPECT . . . . . . . . . . . . . . . . . . . . . . . . 175
5.1.1 Where We Stand . . . . . . . . . . . . . . . . . . . . . . . . . 175
5.1.2 Where To Go . . . . . . . . . . . . . . . . . . . . . . . . . . . 175
5.2 MRI-Based AC in the Lungs . . . . . . . . . . . . . . . . . . . . . . . 177
5.2.1 Where We Stand . . . . . . . . . . . . . . . . . . . . . . . . . 177
5.2.2 Where To Go . . . . . . . . . . . . . . . . . . . . . . . . . . . 178
5.3 MRI-Based AC Algorithms . . . . . . . . . . . . . . . . . . . . . . . . 179
5.3.1 Where We Stand . . . . . . . . . . . . . . . . . . . . . . . . . 179
5.3.2 Where To Go . . . . . . . . . . . . . . . . . . . . . . . . . . . 180
5.4 Conclusion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 182
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 183
A Ethics Approvals 189
B Copyright Releases 192
C Curriculum Vitae 195
xv
List of Tables
1.1 Physical factors that impact quantification . . . . . . . . . . . . . . . 21
1.2 Biological factors that impact quantification . . . . . . . . . . . . . . 29
1.3 Technical factors that impact quantification . . . . . . . . . . . . . . 32
1.4 Human factors that impact quantification . . . . . . . . . . . . . . . 40
1.5 Obtaining a µ-map without a transmission scan . . . . . . . . . . . . 49
1.6 Transmission scan geometries . . . . . . . . . . . . . . . . . . . . . . 51
1.7 Transmission scan energies . . . . . . . . . . . . . . . . . . . . . . . . 55
1.8 Future work . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 69
2.1 µ-coefficients assigned to materials . . . . . . . . . . . . . . . . . . . 101
2.2 Results of global error analysis on canines . . . . . . . . . . . . . . . 110
2.3 Results of global error analysis on phantom . . . . . . . . . . . . . . . 110
2.4 Results of local error analysis on canines . . . . . . . . . . . . . . . . 111
2.5 Results of local error analysis on phantom . . . . . . . . . . . . . . . 112
3.1 ANOVA results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 134
3.2 Results of local error analysis . . . . . . . . . . . . . . . . . . . . . . 140
4.1 Global error analysis two-way ANOVA results . . . . . . . . . . . . . 163
4.2 Global error analysis one-way ANOVA results . . . . . . . . . . . . . 164
4.3 Local error analysis one-way ANOVA results . . . . . . . . . . . . . . 165
xvi
List of Figures
1.1 PET/CT and PET/MRI . . . . . . . . . . . . . . . . . . . . . . . . . 3
1.2 Lines of response . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16
1.3 Dominant photon/matter interactions . . . . . . . . . . . . . . . . . . 19
1.4 Realistic line of response . . . . . . . . . . . . . . . . . . . . . . . . . 25
1.5 Impact of detector size on LOR localization . . . . . . . . . . . . . . 26
1.6 Ill-conditioned PET . . . . . . . . . . . . . . . . . . . . . . . . . . . . 35
1.7 Attenuation measurement . . . . . . . . . . . . . . . . . . . . . . . . 41
1.8 Components of µm over a range of energies . . . . . . . . . . . . . . . 44
1.9 Transmission scan geometries . . . . . . . . . . . . . . . . . . . . . . 53
1.10 Segmented MRI-based µ-map . . . . . . . . . . . . . . . . . . . . . . 62
1.11 Registered MRI-based µ-map . . . . . . . . . . . . . . . . . . . . . . 65
1.12 Mapped MRI-based µ-map . . . . . . . . . . . . . . . . . . . . . . . . 67
2.1 VOI placement . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 105
2.2 Example of an MRI-based µ-map . . . . . . . . . . . . . . . . . . . . 106
2.3 Comparison of canine SPECT and PET reconstructions . . . . . . . . 108
2.4 Comparison of phantom SPECT and PET reconstructions . . . . . . 109
2.5 Comparison of SPECT and PET scatter plots . . . . . . . . . . . . . 109
2.6 Example of PET sensitivity to MRI-based µ-map . . . . . . . . . . . 113
2.7 Example of SPECT sensitivity to MRI-based µ-map . . . . . . . . . . 114
xvii
2.8 Results of sensitivity analysis . . . . . . . . . . . . . . . . . . . . . . 114
3.1 VOI placement . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 131
3.2 T2* and proton density versus CT signal . . . . . . . . . . . . . . . . 133
3.3 Spatial correlation of lung signal in CT versus MRI . . . . . . . . . . 134
3.4 MRI to CT lung mappings . . . . . . . . . . . . . . . . . . . . . . . . 135
3.5 Pre-µ-maps of the lungs . . . . . . . . . . . . . . . . . . . . . . . . . 136
3.6 Results of global error analysis . . . . . . . . . . . . . . . . . . . . . . 137
3.7 Profiles through sample PET reconstructions . . . . . . . . . . . . . . 138
4.1 Sample µ-maps and associated errors . . . . . . . . . . . . . . . . . . 159
4.2 Results of global error analysis . . . . . . . . . . . . . . . . . . . . . . 160
4.3 Results of local error analysis . . . . . . . . . . . . . . . . . . . . . . 161
4.4 Joint histogram of lung signal in CT versus MRI . . . . . . . . . . . . 162
xviii
List of Appendices
Ethics Approvals 189
Copyright Releases 192
Curriculum Vitae 195
xix
Nomenclature
a Mean activity per unit time
~a Actual activity at each voxel of PET image
a¯e Mean estimated activity
a¯t Mean true activity
AC Attenuation correction
b Y-intercept of LOBF
c Speed of light
CT Computed tomography
CTclin Clinical quality CT
CTpre-µ CT precursor to µ-map
D Training data for SVM
df Degrees of freedom
E Energy or error, depending on context
F F -statistic
FDG 18F-fluorodeoxyglucose
FRC Functional residual capacity
I Photon beam intensity after attenuation
I0 Initial photon beam intensity
ITK Insight Segmentation and Registration Toolkit
k(xi,xj) Kernel function
L Length of material attenuating photon beam
LOBF Line of best fit
LOR Line of response
m Slope of LOBF or mass, depending on context
MIBI 99mTc-sestamibi
MRI Magnetic resonance imaging
MRIlung MRI of the lungs
MRIlungPD Proton density map of the lungs
MRIlungSTE Short echo time MRI of the lungs
MRIlungT∗2 T2* map of the lungs
MRIWB MRI of whole body
N Number of photons detected per unit time
xx
~n Number of observed counts along each LOR
n Number of voxels or training examples
P PET system matrix
p Probability of a type-1 error
p(·) Probability of ·
PET Positron emission tomography
PETCT PET via CT-based µ-map
PETglobal PET via MRI-based µ-map with global lung estimate
PETmap PET via mapped MRI-based µ-map
PETMRI PET via MRI-based µ-map
PETMRIdb PET via MRI-based µ-map with dilated body
PETMRIdl PET via MRI-based µ-map with eroded body
PETMRIeb PET via MRI-based µ-map with dilated lungs
PETMRIel PET via MRI-based µ-map with eroded lungs
PETMRI0 PET via unadulterated MRI-based µ-map
PETnone PET without AC
PETreg PET via registered MRI-based µ-map
PETset PET via segmented MRI-based µ-map
PETseg(number) PET via segmented MRI-based µ-map with bones assigned to (number)
PETslices PET via MRI-based µ-map with slice-by-slice lung estimate
PETvoxels PET via MRI-based µ-map with voxel-by-voxel lung estimate
PET(number) PET via MRI-based µ-map with lungs assigned to (number)
PIP Positive inspiratory pressure
q Dimension of SVM feature space
r Radial cylindrical coordinate
~r Position in 3D space
RF Radio frequency
R2 Pearson product-moment correlation coefficient
s Position along photon beam
SNR Signal-to-noise ratio
SPECT Single photon emission computed tomography
SPECTCT SPECT via CT-based µ-map
SPECTMRI SPECT via MRI-based µ-map
SPECTMRIdb SPECT via MRI-based µ-map with dilated body
SPECTMRIdl SPECT via MRI-based µ-map with eroded body
SPECTMRIeb SPECT via MRI-based µ-map with dilated lungs
SPECTMRIel SPECT via MRI-based µ-map with eroded lungs
SPECTMRI0 SPECT via unadulterated MRI-based µ-map
SPECTnone SPECT image without AC
SUV Standardized uptake value
SVM Support vector machine
TE Echo time
xxi
TR Repetition time
T1 Spin-lattice relaxation time
T2 Spin-spin relaxation time
T2* Spin-spin relaxation time with local magnetic field inhomogeneities
ui Class membership in SVM
UTE Ultrashort TE
VOI Volume of interest
xi True normalized PET activity
xi Feature vector for SVM
yi Estimated normalized PET activity
Z Atomic number
z Longitudinal cylindrical coordinate
α Maximal acceptable probability of type-1 error
β Standard deviation of Gaussian radial basis function
∆I Change in photon beam intensity
 Degree of sphericity
η Part of mass attenuation coefficient due to coherent scattering
θ Azimuthal cylindrical coordinate
κ Part of mass attenuation coefficient due to pair production
µ Linear attenuation coefficient
µm Mass attenuation coefficient
µ-coefficient Attenuation coefficient
µ-map Attenuation map
ρ Density
σ Part of mass attenuation coefficient due to Compton scattering
τ Part of mass attenuation coefficient due to photoelectric effect
φ(xi) Mapping implicitly applied by k
2D Two-dimensional
3D Three-dimensional
xxii
1Chapter 1
A Bird’s Eye Perspective of Attenuation
Correction in PET/MRI
1.1 Introduction
One of the most intriguing aspects of positron emission tomography (PET) is its
fundamentally quantitative nature. That is to say, given a patient with a radiophar-
maceutical on board, the activity distribution can be expressed in absolute terms, e.g.
MBq/mL. This capability, considering PET’s capacity to image a variety of molecular
biological processes, makes PET an extraordinarily powerful tool.
However, creating quantitatively accurate PET images is not trivial. Several
factors can adversely impact quantification and years of research have been devoted
to addressing them. The most important cause of quantification error is photon
attenuation, a phenomenon wherein γ-rays emitted from the radiopharmaceutical
interact with the patient’s body and thus remain undetected. One can compensate for
attenuation provided an attenuation map (µ-map) is available. A µ-map is an image
of the patient that is composed of attenuation coefficients (µ-coefficients), values that
indicate how likely a photon/matter interaction is to occur at a specified position.
For example, air has a low µ-coefficient as most photons pass though it undeterred.
2Conversely, cortical bone has a high µ-coefficient as it impedes many photons incident
upon it. The most straightforward way of obtaining a µ-map is to transmit photons
through the patient and record the fraction that makes it through to the other side. By
repeating this from different angles around the patient, a tomographic reconstruction
of the µ-map is generated. There are many variations on the theme, but the general
principle remains the same. For this reason, virtually every PET scanner has some
form of transmission imaging system built in, the most common today being X-ray
computed tomography (CT), i.e. PET/CT.
While combining PET and CT is useful from the point of view of attenuation
correction (AC), another major motivating factor is that the modalities yield com-
plimentary information: CT provides an anatomical context for the functional PET
images. A similar line of reasoning led to the conception of another hybrid modality
combining PET with magnetic resonance imaging (MRI), i.e. PET/MRI. Like CT,
MRI can produce anatomical images, but with improved soft tissue contrast (albeit
with poor delineation of bones). In addition, image contrast in MRI can be altered,
highlighting different structures and pathologies. MRI also boasts multiple functional
imaging options including blood oxygen level dependent effects, blood flow, perfusion,
diffusion, and chemical shift imaging [140]. What’s more, this is done without expos-
ing the patient to ionizing radiation. Researchers have been aware of these advantages
for some time, and accordingly, work began on PET/MRI in the late 1990s [162, 188]
preceding the completion of PET/CT [19]. That said, the first human simultaneous
PET/MRI images were not published until much later [182]. The delay was caused in
part by a temporary shift in interest away from PET/MRI owing to the remarkable
success of PET/CT, but also because of the technical difficulties associated with plac-
ing PET and MRI systems in close proximity without compromising the performance
of either modality. Several groups’ approaches to solving these problems are reviewed
3by Pichler et al [163]. It is thanks to their combined efforts that PET/MRI is now a
reality. Both a PET/CT and PET/MRI image are presented in Figure 1.1
Figure 1.1: (A) Whole-body PET scan displayed as a maximum intensity projection,
(B) PET/CT overlay (PET is in orange), and (C) PET/MRI overlay (PET is in
orange). All images are of the same patient and were acquired on the same day.
Oncologic lesions suspected of being malignant are visible in the PET scan in the
neck, chest, and lungs. Adapted from Drzezga et al [54].
There remains an unresolved issue, however: it is difficult to obtain a µ-map.
In simultaneous PET/MRI scanners physical space is limited and costs are high, so
including an integrated or attached transmission imaging system is not feasible [221].
Further, obtaining a transmission scan from a separate machine (e.g. a detached
CT) is not viable because the patient would have to move from the PET/MRI to the
transmission system, resulting in differences in positioning that may produce severe
AC errors [69, 90, 153]. How then is AC to be performed? The obvious recourse is to
4derive the µ-map from MRI images. But in MRI, signal is dictated primarily by proton
density and magnetic relaxation times, i.e. T1, T2, and T2* [140]. Unfortunately,
these parameters are not easily relatable to µ-coefficients. Thus, MRI-based AC of
PET images is an open and challenging problem that must be solved if PET/MRI is
ever to be a quantitative imaging modality.
In this chapter, I examine the issue of MRI-based AC in detail. First, I discuss
the value of quantitative PET with respect to PET/MRI. Next, I catalogue and
explain the major factors that impact quantification in PET images to provide a
broader context for the role that photon attenuation plays. I subsequently focus
on AC and how it has been conducted historically, complete with the advantages
and disadvantages of each method. I then explain how MRI-based AC is conducted,
describing three general approaches to the problem. Finally, I identify unresolved
problems and suggest avenues for further research.
1.2 The Value of Quantitative PET/MRI
1.2.1 Oncology
By far, the most common clinical application of PET is imaging cancers, altering
management in 36.5% of cases overall [84]. PET’s adoption in this arena owes to
one radiopharmaceutical, 2-deoxy-2-(18F)fluoro-D-glucose, commonly referred to as
18F-fluorodeoxyglucose or FDG. A glucose analog, FDG enters the glycolysis chem-
ical pathway as would regular glucose, but stalls after phosphorylation to FDG-6-
phosphate due to its absent 2’ hydroxyl group. Consequently, FDG preferentially
accumulates in cells exhibiting high metabolic activity. As glycolysis is upregulated
in most cancers [63], FDG PET may be used to visualize malignancies. An imme-
diate application of this capacity is staging, where PET has proved useful in several
5cancers [57, 97, 174, 213]. Indeed, staging is likely to play a part in the clinical role
of PET/MRI [5].
However, accurate quantification is generally not essential for staging; the appear-
ance of cancerous hot spots is sufficient to localize the disease. In fact, there is some
evidence that, with respect to lesion detection in FDG PET, there is no benefit to
performing AC at all [104]. In other words, AC is not always necessary for qualitative
aspects of PET image interpretation. However, oftentimes it is valuable to quantify a
tumour’s FDG uptake, an impossibility without AC. For example, the lesion’s degree
of FDG uptake has been associated with the cancer’s aggressiveness and the patient’s
prognosis [12, 15, 155]. Perhaps even more interesting, multiple studies indicate that
after the initiation of a chemotherapeutic regimen, declining levels of FDG uptake
from baseline correlate with the treatment’s efficacy [2, 175, 179]. This may have
tremendous implications for drug development, i.e. in deciding which candidate ther-
apies should be advanced to large-scale, phase III clinical trials [211]. Further, the
ability to predict an anti-cancer drug’s efficacy on a patient-by-patient basis yields
exciting possibilities for personalized medicine.
The rationale for accurate quantification in oncological PET imaging is well estab-
lished, but how does PET/MRI fit in? In particular, when is quantitative PET/MRI
more appropriate than quantitative PET/CT? One likely scenario is for brain tu-
mours. MRI is widely accepted as the modality of choice in neuro-oncology. This
is because of MRI’s excellent anatomical delineation of intracranial masses—often
correlating with histological features and clinical behaviour [81]—and its functional
imaging options. For instance, magnetic resonance spectroscopy (MRS) has demon-
strated utility in several applications such as grading [164], biopsy site selection [44],
and differentiating progressive disease from radiation necrosis [173] while both diffu-
sion tensor imaging and functional MRI (known as fMRI) can aid in neurosurgical
6planning [147, 185]. Like MRI, PET provides a wealth of information about brain
tumours. Interestingly, in neuro-oncology, FDG is not the radiopharmaceutical of
choice due to an inherently low contrast to noise ratio caused by strong uptake in
healthy gray matter [216]. But using alternate radiopharmaceuticals such as O-(2-
[18F]fluoroethyl)-L-tyrosine, the addition of PET to MRI has demonstrated potential,
including the determination of tumour extent [158] and in radiation treatment plan-
ning [148] amongst other applications [21]. With special pertinence to quantitative
PET, PET/MRI may prove a powerful tool for assessing treatment response [50, 94].
Although the field is young and there is still much speculation, the first clinical stud-
ies evaluating the use of simultaneous PET/MRI in neuro-oncology are beginning to
emerge, and the initial results are encouraging [26].
PET/MRI’s role in clinical oncology will not likely be confined to the brain, how-
ever. For example, CT does not play a major role in breast cancer imaging whereas
there is extensive interest in MRI as it is the most sensitive modality for identify-
ing local extent of the disease, although it suffers from low specificity [14]. Thus,
PET/MRI is a more natural fit for breast cancer than PET/CT, assuming of course
that PET adds value to the study. Indeed, PET has been shown to be useful for
predicting response to neoadjuvant chemotherapy [179, 187], which may be synergis-
tic to treatment response information provided by MRI [35, 100, 156, 165] and MRS
[137].
Another area that quantitative PET/MRI may find application outside the brain
is in imaging neoplasms that occur primarily during childhood. CT is a significant
source of radiation (about 15 mSv for an adult, whole-body, diagnostic quality scan),
often more so than the radiopharmaceutical itself (about 7 mSv) [28]. Further, ra-
diation exposure can be increased as CT scanners are pushed to image faster and
yield images of higher quality [146].This is highly undesirable in the paediatric pop-
7ulation [101]. If PET is indicated in a child with cancer, it would be better if both
the anatomical localization and AC was performed with MRI, provided of course the
CT is not serving an important clinical function. A good example would be in the
initial evaluation of soft tissue sarcomas, where MRI is often the modality of choice
for visualizing the primary lesion [48] and quantitative PET may be useful for grading
and predicting malignancy [12].
The preceding discussion is by no means comprehensive; many possible oncolog-
ical applications of quantitative PET/MRI have been omitted. Rather, the select
examples above should serve as an indication that PET/MRI may have an important
role to play in evaluating a significant subset of cancers.
1.2.2 Neurology
As mentioned earlier in the context of brain tumours, PET/MRI can generate a
wealth of information, both anatomical and functional, regarding the central nervous
system. Of course, diseases of the brain are not limited to neoplasms; in this section,
the prospect of using quantitative PET/MRI to improve the management of some
additional cerebral pathologies is explored. In particular, I touch on Alzheimer’s
disease, ischemic stroke, and epilepsy.
Alzheimer’s disease is an excellent example of a pathology that is well suited to
imaging with PET/MRI. In routine medical practice the diagnosis of Alzheimer’s is
essentially a clinical one, though anatomic MRI is often indicated as well, largely to
exclude other pathologies [116]. This is problematic in that a diagnosis cannot be
made until relatively severe and likely irreversible cortical damage has accrued. How-
ever, significant advances in the understanding of Alzheimer’s pathogenesis indicate
that a sequence of measurable changes begin well before dementia occurs. Further,
these changes follow a general temporal ordering: according to a recent hypothesis,
8the order is given by 1) β-amyloid accumulation in the cortex, 2) tau mediated neu-
ronal injury, 3) brain atrophy, 4) memory loss, and finally 5) impaired clinical function
[99]. Many of these biomarkers can be detected via imaging, which is important as
they follow characteristic spatial patterns. For instance, it is well established that
PET can be used to detect β-amyloid burden [96], while both PET and MRI can
indirectly measure neuronal damage via reduced metabolism [102, 172] and cerebral
atrophy [22], respectively. Making use of these techniques has the potential to permit
early diagnosis and accurate staging of Alzheimer’s [99], and there are ongoing ef-
forts to incorporate them into diagnostic criteria [55]. Indeed, PET and MRI provide
complimentary information in Alzheimer’s [98, 192], while their hybridization bears
technical benefits such as MRI-guided partial volume effect correction of the PET
images [202].
However, without quantification, PET’s ability to characterize Alzheimer’s disease
is limited to observing the presence or absence of biomarkers. With quantification,
PET can determine how much biomarker is present, compare concentrations between
different regions of the brain, and track changes over time, all of which are likely
clinically relevant [99, 192]. Furthermore, PET has shown promise for therapeutic
monitoring in Alzheimer’s [170], another application that demands proper quantifi-
cation.
In ischemic stroke, the concept of the penumbra is of great interest. Simply put,
the penumbra comprises a region of brain tissue surrounding the necrotic core that
exhibits impaired function owing to hypoxia induced by hypoperfusion, but remains
salvageable provided perfusion is restored quickly [7]. From a clinical standpoint,
“quickly” has been found to be within 4.5 hours of the ischemic insult, meaning that
thrombolytic therapy with tissue plasminogen activator is generally indicated prior to
the 4.5 hour mark [74]. But not all penumbras convert to infarcted tissue at the same
9rate; penumbral tissue has been documented even 16 hours post-insult in humans,
suggesting that in some cases the therapeutic window should be extended [11].
The penumbra can be visualized with MRI by collecting both diffusion weighted
and perfusion weighted images, the former identifying the necrotic core and the latter
localizing perfusion deficits [10]. The penumbra is seen as the mismatch between the
perfusion and diffusion lesions. Accordingly, several clinical trials have evaluated the
use of MRI in selecting patients eligible for tissue plasminogen activator administra-
tion beyond the traditional therapeutic window, but results have been disappointing
[53, 139]. One of the potential problems is that MRI exhibits inaccuracies identifying
the true penumbra and necrotic core [80]. PET, conversely, is recognized as the gold
standard for the detecting the penumbra and infarcted tissue [11], but is not used
in clinical practice because the exam is logistically complex. The immediate role for
PET/MRI in stroke is likely not in the management of individual patients, but in the
validation of improved MRI protocols to better delineate the penumbra [215]. This is
a situation wherein the simultaneity of data collection is pivotal considering the rela-
tively fast dynamics involved. Additionally, the PET images should be quantitative,
as they must enumerate the degree of hypoperfusion in the penumbra for the MRI to
be checked against.
In the future, PET/MRI may prove more directly useful in stroke, such as for
localizing thrombi with dual probes [207]. Also, given the potential neuroprotective
strategies [135] that have been proposed on the basis of the evolving concept of multi-
ple “molecular” penumbras [189], PET/MRI may play a major role in the evaluation
of novel stroke therapeutics.
Finally, PET/MRI might prove helpful in a subset of focal epilepsy cases that
remain uncontrolled despite the administration of antiepileptic drugs. Under these
circumstances, neurosurgical intervention often induces remission via resection of the
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epileptogenic focus [195]. Said focus is generally identified as a lesion on anatomical
MRI, the modality of choice for surgical planning in epilepsy [56]. However, a lesion is
not always apparent on MRI, and in such cases additional imaging with PET (which
visualizes the epileptic focus as an area of reduced cerebral metabolism using FDG)
is both helpful [125, 176, 214] and cost-effective [151]. Generally, one identifies an
area of reduced cerebral uptake by comparison to the contralateral side of the brain.
If the PET images are not quantitative, there is no guarantee of symmetry, especially
if the patient’s head is tilted with respect to the scanner. What’s more, without
quantification, the decreased uptake might itself be obscured.
PET appears especially useful for surgical planning if coregistered with MRI [125,
176], a task for which simultaneous PET/MRI is the gold standard. Beyond this
clinical application, sophisticated PET radiopharmaceuticals and MRI protocols make
PET/MRI well suited for exploring epilepsy’s pathophysiology [56, 121, 169].
There are numerous applications of PET/MRI to neurology and neuroscience that
are not mentioned above, several of which are reviewed elsewhere [21, 79, 83, 141].
1.2.3 Cardiology
There are already several modalities and protocols available to the clinician to eval-
uate cardiac function, so the addition of PET/MRI to the list of options may seem
superfluous. However, this hybrid platform has the potential to have a significant
clinical impact, as evidenced by the following example.
Coronary heart disease is responsible for approximately 1 of every 6 deaths in
the United States [127]. In coronary heart disease, plaques in the coronary arteries
restrict blood flow to regions of the heart, which, if severe enough, will lead to car-
diac dysfunction. One of the important clinical issues is to determine if dysfunctional
myocardium is irreversibly injured or dead, or if it remains viable but its function is
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compromised because of reduced blood flow. Myocardial cells can exhibit reduced or
absent contractility but remain viable; such cells are known as either “hibernating”
[167] or “stunned” [111] depending on the length of the ischemic insult, but appear
similarly dysfunctional. There is evidence from several retrospective studies that
patients with dysfunctional yet viable myocardium are more likely to benefit from
revascularization procedures such as percutaneous transluminal coronary angioplasty
or coronary artery bypass grafting than patients without salvageable myocardial tissue
[34, 181]. This observation motivated three prospective randomized controlled trials
assessing whether cardiac viability imaging for treatment selection improves patient
outcomes [13, 25, 38]. The results of all three trials were negative, but with some
major caveats. The outcome of a clinical trial studying a test for guiding therapy
depends not only on the accuracy of the test itself, but also upon clinicians’ adherence
to the test result and the efficacy of the treatments. Indeed, in the PET and Recov-
ery Following Revascularization-2 (PARR-2) trial, adherence to viability test-based
recommendations was only 75.4% [13]. It was found that in the subgroup of patients
where revascularization decisions were based on PET viability testing, imaging was
associated with improved outcomes (death, myocardial infarction, and heart failure).
Further, in some patients, medical management may provide comparable outcomes
as would be achieved with surgical intervention [160]. There is evidence that via-
bility imaging may be useful in optimizing treatment within the subpopulation of
sickest patients where surgical risk is highest [13]. So, despite the apparent negative
outcomes of the trials, there may be a place for viability assessment for treatment
selection in some patient groups. Further randomized trials are currently underway
that will adopt a more rigorous, test-guided approach to revascularization decisions
to try and confirm the results seen in the PARR-2 adherence patients. Regardless of
whether viability imaging is useful in therapeutic guidance, there is little doubt that
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it is an excellent prognostic indicator [25].
For the reasons discussed above, determining cardiac viability remains a key issue
in patients with coronary heart disease. Viability can be assessed with several imaging
modalities including single photon emission computed tomography (SPECT), dobu-
tamine echocardiography, PET, and MRI [203]. However, no single modality has
emerged as the most accurate test [181]. Since the tests assess viability through dif-
fering mechanisms, it may be that they are complimentary rather than competitive.
For instance, in PET, both cardiac perfusion and glucose metabolism scans are as-
sessed; areas of reduced perfusion and increased glycolysis are predictive of viable
tissue at risk of death [204] since the myocardium switches from primarily fatty acid
to glucose metabolism when ischemic [144]. Areas of altered perfusion and glycolysis
cannot be reliably identified unless the PET images are quantitative, nor can the
degree of aberration be assessed. MRI, in comparison to PET, can provide infor-
mation about viability in alternate ways [177]. For instance, several minutes after
injection with a contrast agent called Gadolinium diethylene triamine pentaacetic
acid (usually referred to as Gd-DTPA), infarcted tissue can be reliably identified as it
enhances (sequesters the tracer) more than viable tissue due to altered cellularity and
clearance kinetics [105, 203]. Therefore, MRI is assessing the extent of irreversibly
injured scar, with the inference that dysfunctional myocardium that is not scar is
viable. Another approach is to acquire MRI images of the beating heart at baseline
and after the administration of dobutamine, a sympathomimetic drug, to identify
wall motion abnormalities; this test is similar to dobutamine echocardiography but
provides a high-resolution volume dataset and can incorporate myocardial tagging
to improve wall motion assessment [120]. Viable myocardium will respond to the
inotropic stimulus of dobutamine with improved contractility whereas dead tissue
will remain dysfunctional. By combining the information obtained from PET and
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MRI, an unprecedentedly comprehensive picture of myocardial status should be at-
tainable. Further, a detailed anatomical context provided by MRI will be available to
facilitate the interpretation of PET. In fact, the resolution and signal-to-noise ratio
(SNR) of the PET images themselves can be improved by virtue of MRI’s ability to
correct for cardiac and respiratory motion [52, 72]. Considering all these advantages,
PET/MRI may well provide the most accurate means available to noninvasively assess
myocardial viability. However, it will need to be demonstrated that enhanced diag-
nostic accuracy translates into improved patient outcomes assessed in well designed
randomized clinical trials.
Beyond myocardial viability assessment, PET/MRI bears some exciting prospects
for cardiovascular imaging. Briefly, one of the most intriguing is the localization
and characterization of atherosclerotic plaques. Magnetic resonance angiography is
a popular method to identify luminal stenoses throughout the body (e.g. carotid
arteries, peripheral vasculature, and even coronary arteries), but it provides limited
information about the plaque itself. A means to examine the plaque could enable the
clinician to estimate the risk of rupture if it can identify an inflammatory component
which often precedes acute events such as myocardial infarction. Both MRI [205] and
PET [152] have demonstrated potential on this front, with numerous applications such
as stroke prevention [206], therapeutic monitoring and drug development [152], and
the early diagnosis of atherosclerosis [178]. There is a multitude of other possibilities
for PET/MRI in cardiovascular imaging, and the reader is referred elsewhere for
further discussion [118, 145].
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1.3 Factors Influencing Quantification
1.3.1 PET Physics Primer
The basic premise underlying PET image formation is relatively simple, but as with
most things, the devil is in the details. I will begin with a simplified explanation of
how PET works and subsequently catalogue the physical (§1.3.2), biological (§1.3.3),
technical (§1.3.4), and human (§1.3.5) factors that limit the system’s performance,
elaborating on salient details as required.
Essentially, PET’s purpose is to determine the location and magnitude of physi-
ological processes in the body. Given a process of interest (e.g. glucose metabolism
or perfusion), a chemical probe that targets said process is introduced into the body.
After a period known as the uptake time, the probe will have distributed itself within
the body in approximate proportion to the physiological process. PET is merely a
clever means of inferring where the probe went. The trick is that the probe is bound
to a radioactive element; PET uses the radiation to determine where the nucleus that
released it must have been. It is for this reason that the probe is generally referred
to as a radiopharmaceutical or radiotracer.
For PET to work, the radioactive nucleus must decay by a process known as
positron emission, wherein one of the radionuclide’s protons is converted to a neutron
via the expulsion of a positron and a neutrino. The neutrino is unimportant in PET,
but the positron is critical. Once released, it will collide with its antiparticle (the
electron) and annihilate, generating a pair of photons in the process. In order to
conserve a net zero momentum, the photons travel in opposite directions, tracing out
a straight line. In a PET system, the subject is surrounded by a cylindrical array of
detectors tuned to identify these photons.
Since photons travel at the speed of light, no matter where a photon pair originates
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the photons will strike the detectors within a few nanoseconds of each other. So if a
pair of detectors is activated nanoseconds apart, the PET system assumes that the
photons that struck them must have originated from the same positron annihilation.
This is known as a “coincidence”. Moreover, since the photons travel along a straight
line, the positron annihilation must have occurred somewhere in between the two
activated detectors. The imaginary line connecting a pair of activated detectors is
called the line of response, or LOR for short (Figure 1.2). Once many LORs have
been collected, they are input into a reconstruction algorithm, a mathematical model
that converts the raw data collected by the PET scanner into an image (details in
§1.3.4).
In theory, by computing the difference between the arrival times of the two photons
involved in a coincidence, one can determine where along the LOR the positron
annihilation occurred, improving the quality of data collected by the PET scanner.
This is termed time-of-flight, referring to the amount of time the photons travel for
prior to detection. In practice, time-of-flight requires that the PET system make
very accurate measurements of time, an ability characterized by a parameter called
timing resolution. No current PET system can localize annihilation events to a single
point (which requires a timing resolution of about 3 ps), but it is possible to localize
annihilations to a particular region along the LOR.
Unfortunately, whether using time-of-flight or not, sometimes the PET system
can detect false LORs, thereby deteriorating image quality. This can happen two
ways. First, suppose two positron annihilations occur within nanoseconds of each
other. Suppose further that one member of the photon pair from each annihilation
is lost somehow, for instance via attenuation (see §1.4.1) or passing through the
detector without stopping. If the two remaining photons are detected, a false LOR
is formed between them (Figure 1.2). Such LORs are termed “randoms”, since they
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Figure 1.2: Real and false LORs. The outer ring is a cylindrical array of PET
detectors. The light grey ellipse in the centre represents a patient’s body. Black
circles are positron annihilations and the solid black lines emanating from them are
photon trajectories. Trajectories terminating with an arrow denote photon detection,
while those terminating with an ‘X’ indicate that the photon was lost. The dashed
lines represent false LORs. There are three types of LOR: (A) true, (B) random, and
(C) scatter.
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arise from the chance detection of two unrelated photons. Second, suppose that one
(or both) of the photons emitted from an annihilation is deflected prior to detection.
The resulting LOR will be deflected as well (Figure 1.2). LORs formed in this way
are known as “scatter”, its name derived from Compton scattering, the physical
process that deflects photons. Incidentally, all true LORs (i.e. created by an actual,
undeflected photon pair) are unsurprisingly called “trues”.
There is an additional feature of photon pairs arising from positron annihilation
that warrants explanation. Recall that mass and energy are equivalent according
to Einstein’s famous equation, E = mc2, where E is energy, m is mass, and c is
the speed of light. Using this equation, one can show that the energy contained
in the mass of a positron is 511 keV. Similarly, as electrons have the same mass
as positrons, they also bear 511 keV of energy. Accordingly, when a positron and
electron collide and annihilate, the total energy released is 1022 keV. This is divided
equally between the photon pair, giving each 511 keV. Photons are the particles that
mediate electromagnetic radiation, and electromagnetic radiation with 511 keV of
energy falls into the γ-ray region. Hence, PET operates by detecting 511 keV γ-rays.
PET systems take advantage of the fact that photons derived from positron anni-
hilations have an initial energy of 511 keV. Recall that photons can be deflected prior
to detection giving rise to false LORs called scatter. The primary mechanism that
deflects photons at 511 keV is called Compton scattering, wherein the photon collides
with a bound electron and changes course. In the process, the photon transfers some
of its energy to the electron; the larger the angle of deflection, the more energy it
transfers. In short, deflected photons have energies below 511 keV. PET systems
capitalize on this phenomenon by measuring the energy of every photon they detect.
In principle, by rejecting coincidences wherein one or both photons have less than
511 keV of energy, scatter would be completely eliminated. However, PET systems
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cannot measure photon energy perfectly. Every measurement of energy is associated
with an error characterized by a parameter called energy resolution. Therefore, in
practice, PET systems will accept photons with energies in a predefined region around
511 keV, and reject those that fall outside this region. Said region is called the accep-
tance window. For reference, the acceptance window of most clinical PET scanners is
about 350 keV to 650 keV [92]. Thus, some scatter can be rejected, but a significant
proportion still falls within the acceptance window.
Finally, a word about photon attenuation. Attenuation and its correction are
discussed in detail in §1.4, but it for now, it will suffice to know how it arises. At-
tenuation describes the phenomenon that some photons are “lost” prior to detection,
and therefore fail to generate a LOR at all. Photons can be lost three ways: 1)
by being absorbed by a bound electron via a mechanism called the photoelectric ef-
fect, 2) by undergoing Compton scattering to such a degree that the photon’s energy
loss excludes it from the acceptance window, and 3) by colliding with a nucleus and
transforming into a positron and electron, a process called pair production. At PET’s
energy, 511 keV, the photoelectric effect is negligible and pair production impossible
(the photon would require at least 1022 keV of energy to generate the mass contained
in a positron and electron). Hence, attenuation in PET is due almost exclusively to
Compton scattering (Figure 1.3), creating an interesting relationship between atten-
uation and scatter. Specifically, all scattered photons should be deemed attenuated,
and thereby handled by attenuation correction algorithms. Unfortunately, due to
PET’s limited energy resolution, some scattered photons are able to generate false
LORs and must be accounted for by scatter correction algorithms.
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Figure 1.3: Dominant photon/matter interactions according to atomic number (Z)
and photon energy. Adapted from Yip [219].
20
1.3.2 Physical Factors
As described in §1.3.1, the goal in PET is to infer the underlying spatial distribution of
a positron emitting substance that gives rise to measured electromagnetic radiation.
In broad terms, there are three mechanisms that deteriorate the ideal distribution:
the statistical nature of radioactive decay, positional uncertainty concerning the site
of positron emission, and biases in the detected radiation. Each will be discussed
in turn and the associated impact on quantification will be assessed. A summary of
these factors is presented in Table 1.1
1.3.2.1 Photon Statistics
The inherently statistical nature of radioactive decay dictates that it is impossible
to recover the true underlying radiopharmaceutical distribution. Conceptually, the
problem can be illustrated with the following example. Imagine that there are two
identical radioactive sources resting inside two identical radiation detectors. The
detectors are both turned on for the same amount of time, and each records how
many photons are released from its radioactive source. Since radioactive decay is a
random process, the numbers will not be the same. There is therefore an inherent
uncertainty when attempting to determine “how radioactive” a source is.
This uncertainty can be described mathematically. Given a radioactive source
with mean activity per unit time a, the probability of recording N events (with a
perfect detector) in a unit time follows a Poisson distribution, P (N ; a) = (e−aaN)/N !.
The associated uncertainty of the measurement is 100%/
√
N . Thus, the fewer photons
one detects, i.e. the lower N , the more uncertain your estimate of the source’s activity.
In PET, there are numerous factors that limit N . Some obvious ones include finite
time available for the scan and the radiation safety limits dictating the maximum
allowable patient dose.
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Table 1.1: Physical factors that impact quantification.
Mechanism Factor Explanation
Statistical uncertainty of
measurements
Scan time More time allows for more
counts to be recorded
Administered
activity
More activity leads to more
counts per unit time
Geometric
efficiency
Extent of detectors’ spatial
coverage, proportional to counts
Intrinsic
efficiency
Proportion of photons that
interact with the detectors
Photofraction Proportion of detected trues
that are accepted
Attenuation Lost photons reduce trues
Deadtime
losses
High count rates cause pileup
and reduce recorded counts
Time-of-flight
capability
Improves “utility” of counts
Partial volume effect by
impacting spatial resolution
Positron
range
Positron emission and
annihilation sites different
Photon pair
noncolinearity
Actual LOR is “bent”, shifting
observed LOR
Detector size Cannot localize interaction site
Radiation not representative
of underlying distribution
Attenuation Photons passing through much
matter preferentially lost
Randoms False counts throughout image
Scatter Severely mislocalized LORs
Detector
imperfections
Generates image distortions
(nonlinearities, nonuniformities)
22
There are four additional factors that reduce N : these are geometric efficiency,
intrinsic efficiency, photofraction, and attenuation, and will be described in turn. As
the detectors do not completely surround the patient, only a fraction of total positron
annihilations will produce radiation incident on the detectors. This fraction is the ge-
ometric efficiency. Further, the detectors themselves are imperfect and only interact
with a fraction of the photons incident upon them, i.e. the intrinsic efficiency. Unfor-
tunately, even if a photon/detector interaction does occur, sometimes it still does not
register. This occurs if the photon does not deposit sufficient energy in the detector
to land in the acceptance window. Such events are indistinguishable from scatter
and are erroneously rejected. The proportion of trues interacting with the detectors
that do fall in the acceptance window is the photofraction. Finally, attenuated γ-rays
either never make it to the detectors or fall beneath the acceptance window, further
decreasing the number of available trues. Ultimately, the net sensitivity of the system
for trues can be expressed as the product of geometric efficiency, intrinsic efficiency,
photofraction, and a factor accounting for losses due to attenuation.
But beyond the PET system’s net sensitivity, an even greater proportion of trues
are lost when there is a high rate of coincidences (also called a high count rate). These
are called dead time losses, stemming from limitations in the PET photon counting
system. Specifically, every time a photon interacts with a detector, a pulse is created
in the associated electronics. If two photons interact with the same detector one
immediately after the other, the electronic pulses will overlap, summing to one big
pulse. This is aptly named pulse pileup, and will result in the loss of at least one
of the two photons since the PET system only “sees” one pulse. Worse, the height
of the pulse is used to infer the incident photon’s energy; the bigger the pulse, the
higher the energy. If the summed pulse borne of the two photons is large enough, it
will fall outside the acceptance window, resulting in the rejection of both photons.
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The shortest time between two pulses wherein the PET scanner can still resolve both
pulses is known as the dead time. A shorter deadtime results is less pileup and fewer
deadtime losses.
In short, considering all the factors the reduce N , only a relatively small, finite
number of positron decays are ever detected, fundamentally limiting the reliability of
quantification. Interestingly, typical PET scans generally have less than one coinci-
dence event per LOR in a three-dimensional (3D) acquisition. Incidentally, a 3D ac-
quisition is one where all possible LORs are recorded, compared to a two-dimensional
(2D) acquisition where only LORs parallel to the axial plane are recorded.
1.3.2.2 Spatial Resolution and the Partial Volume Effect
Positional uncertainty regarding the site of positron emission degrades spatial reso-
lution, which in turn can cause severe quantification errors (i.e. > 50%) through a
mechanism called the partial volume effect [194]. The partial volume effect impacts
small objects, in particular those more than two or three times smaller than the PET
system’s resolution. Essentially, since small objects cannot be properly resolved, their
activity is diffused over a larger area. Consequently, though the sum total activity
remains constant, the maximal activity is greatly reduced.
The ensuing commentary discusses the reasons that PET cannot perfectly localize
positron emissions, thereby limiting resolution and giving rise to quantification errors
via the partial volume effect. For simplicity, it is also assumed that only trues are
detected, ignoring false LORs (i.e. scatter and randoms).
Numerous issues prevent the precise localization of positron emissions. For one,
PET systems do not detect positron emission; they detect positron annihilation,
which occurs some distance away from the site of emission. This is because at emis-
sion, positrons have some kinetic energy as dictated by the nuclear energy levels and
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the proportion of kinetic energy given to the neutrino that is also produced in the
reaction. Since positron annihilation is more probable when the positron is moving
slowly (and hence has more time to interact with the electron), the positron generally
dissipates some of its initial kinetic energy in the form of a series of collisions prior
to annihilation. Thus, the positron effectively follows a random walk from the site of
emission prior to emitting the photon pair. The typical distance a positron travels
before it annihilates is called the positron range, and varies from one radionuclide to
another [37].
Further, the assumption that the coincident photons are emitted at 180◦ to one
another is false. The positron typically has a non-zero momentum at annihilation.
Therefore, according to the conservation of linear momentum, the two photons pro-
duced from the annihilation must have the same net momentum as the positron.
As velocity and momentum vectors are parallel, this implies the vector sum of the
photon velocities is nonzero. Of importance to PET imaging, this induces a slight
noncolinearity of 180◦± 0.25◦ thereby mislocalizing the LOR. The effects of positron
range and photon pair noncolinearity are illustrated in Figure 1.4.
More important than positron physics is the finite size of each detector, making
it impossible to know exactly where a given photon struck the device. There is
uncertainty with respect to LOR localization both in two directions parallel and the
one direction perpendicular the the detector face (Figure 1.5. The latter case is known
as the depth-of interaction effect [92], referring to at what depth the photon interacts
with the detector.
Finally, a few words about time-of-flight information are warranted as it behaves
differently than the other factors that degrade resolution. Time-of-flight is not nec-
essary to reconstruct PET images, nor does it improve spatial resolution. Rather, by
providing an estimate of the photon’s origin along the LOR, each photon becomes
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Figure 1.4: Realistic LOR affected by positron range and photon pair noncolinearity.
The outer ring is a cylindrical array of PET detectors. The light grey ellipse in the
centre represents a patient’s body. The star is the site of positron emission. The thin,
irregular line emanating from the site of positron emission represents the positron’s
path prior to annihilation at the black circle. The thick black lines originating from the
annihilation site are the photon trajectories. Note that they are at an (exaggerated)
angle to one another, preserving the initial momentum of the positron. The dashed
line is the observed LOR, which does not cross the positron emission site.
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Figure 1.5: Impact of detector size on LOR localization. The outer ring is a cylindri-
cal array of PET detectors. The light grey ellipse in the centre represents a patient’s
body. Activated detectors are marked with a white circle. (A) If there is a pho-
ton pair strikes two detectors directly opposite one another, the uncertainty of the
positron annihilation site is only as large as the detector face, as indicated by the
translucent grey rectangle. (B) If the photon pair strikes a pair of detectors that are
not directly opposite, there is additional uncertainty as to the positron annihilation
site as indicated by the larger translucent grey rectangle. This occurs because the
depth within the detector at which the interaction occurred is unknown, i.e. the
depth-of-interaction effect.
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more “useful” in determining the underlying distribution. Thus, a reconstruction
making use of time-of-flight can achieve the same image quality as one that does
not, but with fewer recorded counts [199]. In other words, time-of-flight boosts the
statistical power of a PET scan.
1.3.2.3 Observed Radiopharmaceutical Distribution
The last physical mechanism that undermines PET’s quantitative fidelity is that
detected radiation is not representative of the underlying radiopharmaceutical dis-
tribution. Attenuation [113], randoms [27], and scatter [223] are responsible for this
disconnect. Attenuation reduces the number of trues coming from the patient by
well over an order of magnitude, especially in regions where the photons must travel
through large amounts of matter to escape [113]. The result is a grossly inaccu-
rate image including, but not limited to, disproportionately low counts towards the
patient’s centre and seemingly “hot” lungs (since the lungs are mostly air and do
not interact with many photons). Randoms, in contrast, are detected by chance es-
sentially approximately uniformly over the entire field of view, posing as trues. In
whole-body imaging, randoms often exceed trues, resulting in substantial overesti-
mates of activity over the whole image in addition to deteriorating SNR with the
excess artifactual activity [27]. Finally, scatter neither removes trues nor adds fal-
lacious ones, but rather shifts the apparent LOR of a true to an incorrect location.
Typically, the result is a specious migration of activity from the edge of the patient
towards the centre. As with randoms, the amount of scatter can easily exceed the
number of trues in whole-body imaging with serious consequences for quantification
[223].
In addition to attenuation, randoms, and scatter, imperfections and geometrical
variation in the detectors can also alter the perceived radiopharmaceutical distribu-
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tion potentially causing image distortions. There are two characteristic distortions:
nonlinearities, wherein linear objects appear curved, and nonuniformities, wherein ob-
jects with uniform activity appear to have variable activity. These problems are often
detected via routine quality control and are rectified using normalization procedures.
In sum, a great number of physical factors preclude perfect quantification in PET
imaging. Each limitation can be categorized according to whether it adversely impacts
count statistics, degrades resolution, or alters the appearance of the radiopharmaceu-
tical distribution.
1.3.3 Biological Factors
When a radiopharmaceutical is administered, its distribution and behaviour is dic-
tated by the organism’s physiology. Consequently, multiple biological factors influence
quantification (Table 1.2).
In the most general terms, uptake is a function of how much radiotracer reaches
and attaches to a given tissue. This in turn is impacted by the route of tracer
administration, the blood perfusion of the tissue of interest, the rate and strength of
binding, and the availability of binding sites. A thorough discussion of these factors
is beyond the scope of this article, but there are reviews that delve into some of
these issues more deeply [154, 159]. Furthermore, radiotracer uptake is a dynamic
process, so quantification becomes a function of time. The allowed uptake period
not only impacts clinical interpretation of PET images [128], but is also a critical
consideration when comparing PET scans to one another [23].
Additionally, there are innumerable processes that can modify one or more of the
factors that directly determine a radiopharmaceutical’s biodistribution. For example,
a well-known confounder that impacts FDG uptake is blood glucose level [126]. In
tumours, glucose competes with FDG for uptake resulting in an inverse relationship
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Table 1.2: Biological factors that impact quantification.
Mechanism Factor Explanation
Directly impacts
biodistribution
Route of radiotracer
administration
May alter capacity to reach
different parts of the body
Perfusion Often mechanism by which
radiotracer is transported
Binding affinity Faster and stronger binding
increase uptake
Binding sites More sites implies more uptake
Uptake time Radiotracer uptake is dynamic
Modifies factors that
impact biodistribution
Blood glucose Competitive binding with FDG
in certain tissues
Physical activity /
patient discomfort
Stimulates FDG uptake in
muscles
Hypoxia Affects cell membrane
transporters that import FDG
Medications Huge range of effects
Alters perceived
biodistribution
Patient motion Blurs image and causes
emission / transmission
mismatch
Superposition of
activity
Multiple sources of uptake may
occur within one voxel
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between glucose level and activity, whereas in muscles the association is reversed with
glucose stimulating additional FDG uptake. (Incidentally, FDG uptake in muscles
is also stimulated by physical activity and patient discomfort [60].) Correction algo-
rithms have been proposed to account for blood glucose, but their benefit is not clear
[142] and they remain a matter of debate [23]. Another example is hypoxia, which
impacts cell membrane transporters that handle FDG [159]. A third is medication
status, and depending on what medication is being taken and what radiopharmaceuti-
cal is being used, the potential effects are practically infinite. This list is by no means
comprehensive, as essentially anything that alters the body’s chemical environment
could influence radiotracer uptake.
Quantification errors also arise if a biological process alters the perceived biodis-
tribution. One example is patient motion. The motion can be physiological (e.g.
respiration, cardiac activity, peristalsis, etc.) or gross (e.g. shifting weight). Part of
motion-induced error stems from a blurring of the emission data, creating a pseudo-
partial volume effect. A more subtle aspect of the error, with particular relevance
to CT-based attenuation correction, is that motion creates a fundamental mismatch
between emission and transmission data. Emission data is collected over a relatively
long period of time, during which the patient moves. In contrast, the CT scan is
acquired quickly, representing the patient at an instant in time. The mismatch can
lead to substantial quantification and lesion localization errors [61, 69]. Correction of
motion artifact is an arena in which PET/MRI is likely to excel because MRI can be
used to collect movies (or more properly, “cines”) of patient motion without exposing
them to any ionizing radiation. The cines can then be used to guide PET image
reconstruction [52, 72]. In contrast, motion correction via CT is usually not practical
because of the associated radiation burden.
Another factor that alters perceived radiotracer uptake is the complexity of biolog-
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ical systems. Many physiological processes alter the pattern of radiopharmaceutical
distribution, potentially misleading the observer. For instance, if multiple sources of
radiotracer uptake are superimposed in the same spatial location, separating them
becomes challenging if not impossible. Inflammation surrounding a tumour in FDG
PET is a good example. In this case, uptake in the tumour is likely the property of
interest, but its quantification is confounded by uptake owing to the inflammatory
response. A number of additional examples are reviewed by Gorospe et al [68]. A
familiarity with typical patterns of tracer uptake is helpful in identifying this type of
mistake [60].
1.3.4 Technical Factors
The operator has many options in PET imaging. There are multiple ways to re-
construct the images, multiple approaches to extract quantitative data, and multiple
image acquisition protocols. The choices the operator makes on each of these fronts
influences quantification; I refer to this type of quantitative variation as technical
error, the sources of which are summarized in Table 1.3.
1.3.4.1 Image Reconstruction
Before delving into how image reconstruction algorithms impact quantification, some
background is necessary. PET systems do not collect images. Rather, they collect
LORs (and sometimes time-of-flight information) that serve as inputs for a recon-
struction algorithm that creates the image. To do so, every reconstruction algorithm
models the photon detection process and the associated noise; the better the model,
the better the output image.
Reconstruction methods can be classified as either analytic or iterative. Roughly
speaking, analytic methods generate an image by solving a mathematical equation.
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Table 1.3: Technical factors that impact quantification. (SUV = standardized uptake
value.)
Mechanism Factor Explanation
Alters raw data to image
conversion
Reconstruction
algorithm
Huge selection, each with
different assumptions
Free
parameters
Reconstruction algorithms can
usually be tuned
Alters the information
extracted from the image
Model Many kinetic models and
simple measures like SUV
Free
parameters
Tune kinetic models, variable
SUV interpretation
Alters raw data 2D v.s. 3D
acquisition
3D mode increases trues,
randoms, and scatter
Transmission
scan
Choice dictates attenuation
map’s form
Contrast
agents
Creates artifacts in CT-based
attenuation maps
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This is called a closed-form solution. In contrast, iterative methods start with a crude
guess of the image, compare it to the data collected by the scanner, and update the
guess in such a way that it better matches the observed data. This process is repeated
(i.e. the algorithm iterates) until some stopping criterion is reached. For instance, the
algorithm might continue until the guess stops changing or until a predefined number
of iterations is reached.
All iterative algorithms possess an “objective function”. This is an equation that
compares the current guess to the observed data. For the purposes of this discussion,
the better the guess, the bigger the number the objective function calculates. (In
actuality, in some objective functions smaller numbers equate with better guesses,
but this is a triviality that is easily reversed by introducing a negative sign.) Thus,
the objective function is what guides the guessing: the iterative algorithm seeks
the guess that maximizes the objective function. In many ways, the shape of the
objective function dictates how well the iterative algorithm will work. For example,
if the function looks like a hill, with only one maximum surrounded by a smooth
descent, finding the peak is relatively easy. However, if the function looks more like
the sea during a storm, there are multiple peaks, and it becomes very difficult to find
the largest. This type of function is undesirable because it becomes possible for the
guess to converge on the wrong peak.
Let us now return to how reconstruction methods influence quantification, starting
with analytic methods. Analytic reconstruction methods—the most common one
known as filtered backprojection—were borne of the notion that the number of trues
for any detector pair is directly proportional to the activity between them. The
3D closed-form solutions of this model have long been know [40] and modified to
accommodate the practical reality of truncated datasets [114], that is, situations
where the patient is not completely surrounded by detectors. (Recall the discussion
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of geometric efficiency in §1.3.2.)
Analytic methods are fast and relatively easy to implement, so they unsurpris-
ingly served as the workhorse of PET reconstruction for many years. However, the
model upon which analytic methods are based is flawed, failing to account for phys-
ical phenomena such as positron range and photon pair noncolinearity. It also does
not account for the fact that detector sensitivity changes depending on where the
annihilation event happened. Further, the statistical nature of radioactive decay is
not considered. Ergo, images reconstructed with analytic techniques do not make
optimal use of the acquired data and suffer from degraded resolution and noise char-
acteristics. For these reasons, analytic reconstruction methods are increasingly falling
out of favour and are certainly not ideal for accurate quantification.
Iterative reconstruction algorithms, which are reviewed by Qi and Leahy [166],
are an excellent alternative. Popularized in the 1980s [122, 190] iterative algorithms
can elegantly incorporate the physics of the photon detection process and radioactive
decay statistics into a probabilistic model. However, depending on the specific algo-
rithmic choice, four main problems may become manifest: i) it can take a long time,
ii) it can produce the wrong answer, iii) it may never reach an answer, and iv) the
problem may be ill-conditioned, i.e. the answer may be sensitive to small changes in
the acquired data. For instance, the first iterative algorithm (i.e. the maximum like-
lihood expectation maximization algorithm) [190] converges to a definitive answer,
but is slow and ill-conditioned. In practice, it has been supplanted by the ordered
subset expectation maximization algorithm [91], which is much faster but may not in
fact converge on a single answer.
Ill-conditioning is a very common problem for reconstruction algorithms. In prac-
tice, its effect is to create a checkerboard pattern on the image after many iterations.
Thus, ill-conditioning is often approached by either terminating the iterations early
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[210] or filtering the images [191] to get rid of the checkerboard effect. Alternatively,
ill-conditioning can be abetted by modifying the objective function such that it pro-
motes image smoothness (i.e. penalizes sharp changes in intensity) [62]. This can be
accomplished equivalently by incorporating into the algorithm a prior notion of what
the reconstructed image should look like; this is the so-called Bayesian approach
[70] (Figure 1.6). Unfortunately, both these workarounds complicate the objective
function by introducing multiple peaks [166]. They also make implementation more
difficult and can increase computational burden.
Figure 1.6: Two reconstructions of simulated data from the Shepp-Logan phantom.
(A) No compensation for ill-conditioning. (B) Bayesian approach. Note the former
appears noisy compared to the latter. Adapted from Teng et al [201].
In short, there is no perfect reconstruction algorithm; quantification is a function
of not only which algorithm is chosen, but also the values assigned to the chosen
algorithm’s free parameters [1].
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1.3.4.2 Quantitative Model
Once a PET image is reconstructed, the quantitative information of interest must be
extracted. If precise physiologic measurements in absolute terms are required, such
as the rate of glucose uptake from the blood into cells, a kinetic model will likely
be needed. These are techniques that model the radiotracer concentration in various
body compartments (e.g. blood and intracellular) and its transfer between them.
However, multiple kinetic models are available [93, 95, 157, 193], and as with image
reconstruction, the results one gets depend on model selection and the choice of free
parameters.
Though kinetic modeling techniques provide detailed quantitative information,
they are often laborious and impractical, requiring, for example, arterial blood sam-
pling and a constant patient bed position in the PET scanner. For this reason, the
most popular approach to extract numeric data from PET images is via the stan-
dardized uptake value (SUV). This semi-quantitative parameter is free from many
of the restrictions imposed by kinetic models but nonetheless correlates well with
gold standard measures [58, 88]. The idea is to measure the radioactivity within a
user defined region called a volume of interest (VOI), and to somehow normalize this
measurement across patients. Thus, the SUV is defined as:
SUV =
(measure of activity in a volume of interest)× (normalization factor)
administered dose corrected for decay
The preceding definition is left intentionally broad because variations in its inter-
pretation lead to technical errors. Let us first focus on what is meant by a “measure
of activity”. The most common method to measure activity in the SUV is to use the
maximal activity in the VOI [211]. Since the maximal activity is solely determined by
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a single voxel, this method is resistant to the partial volume effect and VOI selection.
By the same token, it is highly susceptible to image noise [24]. Alternatively, one can
compute the mean activity in the VOI, an approach that is less susceptible to noise
but sensitive to the partial volume effect and VOI structure [24]. Thus, VOI selection
can dramatically affect the SUV, and the choices abound with respect to both shape
and placement.
Clearly, much variation can be introduced in the “measure of activity in a VOI”
term of SUV’s definition. Let us now turn to the “normalization factor” term. Tra-
ditionally, this is the subject’s body weight. However, as FDG exhibits low uptake
in white fat, normalizing by body weight in obese patients results in overestimations
[198]. Therefore, alternate normalization factors including lean body mass and body
surface area have been developed that largely eliminate the SUV’s dependence on
body weight [198]. Of course, the SUV will vary depending upon which normaliza-
tion factor is selected.
Regarding the “administered dose corrected for decay” term, the errors impacting
it are human in nature and are covered in §1.3.5. The variation in SUV measurements
induced by alternate formulations points to an urgent need for standardization [23,
211], without which comparisons of SUVs across sites and PET systems become
meaningless [180].
1.3.4.3 Data Acquisition
A final mechanism giving rise to technical error is via the image acquisition pro-
tocol. For instance, many PET systems have the option of acquiring in 2D or 3D
mode. Recall that this amounts to whether only LORs parallel to the axial plane are
recorded or whether all LORs are recorded, respectively. The characteristics of the
acquired data vary significantly based on this choice; in particular, though sensitivity
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to trues is vastly greater in 3D mode than in 2D mode, the proportion of coincidence
events attributable to scatter and randoms increases markedly as does deadtime [92].
This in turn impacts quantification [124, 208]. Issues also arise with respect to the
transmission scan for attenuation correction. The PET reconstruction is strongly
dependent on the transmission method be it a positron source, gamma ray source, or
x-ray source (see §1.4.3) [113]. Further, if x-ray CT is used, oftentimes intravenous
and/or oral contrast is administered for diagnostic purposes [6], a practice that will
bias the attenuation map and hence, the PET image. That said, this phenomenon
may not be clinically significant [71, 218].
It should now be clear that quantification in PET is not only impacted by physics
and biology, but by the operator’s choices with respect to image reconstruction, meth-
ods of analysis, and image acquisition protocol.
1.3.5 Human Factors
Human errors can compromise the quantitative fidelity of PET acquisitions (Table
1.4). Errors of this sort generally have to do with incorrectly measuring the amount
of radioactivity in the patient’s body at a given time. With respect to the SUV, the
“administered dose calibrated for decay” term is affected. For instance, this term
will be overestimated if the residual radiation left in the syringe after an injection is
not subtracted from the injected dose, producing an underestimated SUV. This also
occurs in the event of a paravenous injection, wherein much of the radiopharmaceuti-
cal never actually makes it into the blood stream. Additionally, as the administered
dose must be corrected for radioactive decay, the operator must accurately record
when the dose was drawn up, injected, and assessed for residual activity. This in-
formation is typically entered into the PET system, which automatically applies the
appropriate corrections using predicted exponential decay based on the radionuclide’s
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half life. However, the reliability of these corrections hinges on the synchronization
of the operator’s and PET system’s clocks. Finally, the PET system must be prop-
erly calibrated; that is to say, the relationship between count rate per unit volume
and true activity concentration must be established. Further, the PET system must
be cross-calibrated with the well counter (measures the radioactivity of samples, like
urine or blood) and dose calibrator (measures the radioactivity administered to the
patient). Incorrect calibrations are a real-world problem, posing particular difficulties
for multi-centre studies [64].
1.4 Attenuation Correction
1.4.1 Definition of Attenuation
Attenuation is defined as the reduction in intensity of electromagnetic radiation as
it travels through a medium and interacts with matter. To better understand atten-
uation, let us consider an experiment. Imagine there is a beam of photons. Each
photon has the same energy, E. In other words, the beam is monoenergetic. The
intensity of the beam, that is the number of photons passing through a unit area per
unit time, is I0. This beam is directed through a homogenous element of thickness
L, atomic number Z, and density ρ. An ideal detector is positioned directly opposite
the incident beam, only identifying photons with unaltered trajectories and energies,
i.e. those that did not interact with the material. The intensity of the recorded beam
is denoted I. The experimental setup is shown in Figure 1.7.
Let us define the change in beam intensity, i.e. I0 − I, as ∆I. Note that I0 ≥ I,
since as the beam passes through the homogenous element, it can lose photons but
not gain them. Therefore, ∆I ≥ 0. The fraction of photons that interacted with the
element is given by the change in beam intensity divided by the initial intensity, i.e.
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Table 1.4: Human factors that impact quantification.
Mechanism Factor Explanation
Alters perceived
radiation in
patient’s body
Not accounting
for residual
activity in syringe
Overestimates activity in body
Paravenous
injection
Radiopharmaceutical not distributed
throughout body, so activity effectively
overestimated
Not accounting
for radioactive
decay
Overestimates activity in body
Inaccurate
recording of
important times
Time dose drawn up, injected, and
checked for residual activity needed for
radioactive decay correction
Operator and
PET clock not
synchronized
Biases time measurements, as PET
system applies corrections
PET calibration
to real activity
Without calibration, PET measurements
are not quantitatively accurate
PET
cross-calibration
with other
instruments
Well counter, dose calibrator, and PET
must give the same readings or
quantification will be biased
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Figure 1.7: Experiment to measure attenuation. A radioactive source is positioned at
the far left, with photon trajectories indicated by the lines emanating from it. Since
it emits radiation in all directions, a source collimator is needed to create the photon
beam. As the beam passes through a homogenous element, some photons reach the
detector undeterred, while others interact with matter and are scattered. A detector
collimator prevents scattered radiation from reaching the detector.
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∆I/I0. It is observed that this fraction is directly proportional to L, the element’s
thickness. To convert the proportionality to an equality, we define µ, the so-called
linear attenuation coefficient, giving us the following key relationship:
∆I
I0
= −µL (1.1)
The negative sign simply indicates that the beam intensity has decreased. µ has units
of inverse length, typically cm−1.
Let us examine µ in more detail. It essentially characterizes how effectively the
element in our experiment interacted with the photon beam. The bigger it is, the
more photons interact. But clearly different elements will have different propensities
to interact with photons, so µ must depend on the atomic number, Z. Furthermore,
it serves to reason that the denser the material, the more photons it will affect.
This intuition is true, and it turns out µ and density, ρ, are directly proportional.
Oftentimes it is desirable to remove this density dependence, and to do so one must
simply divide µ by ρ, leading to the definition of the “mass attenuation coefficient”:
µm ≡ µ/ρ. (The three horizontal lines simply mean “defined as”.) Finally, the energy
of the photon beam influences the probability of photon/matter interactions, so µ
depends on E as well. In summary, for the mathematically inclined, µ and µm are
both multivariate functions, related as follows:
µ(Z, ρ, E)
ρ
= µm(Z,E) (1.2)
Incidentally, µm of composite materials (i.e. made of multiple elements) is easily
calculated as the weighted average of its constituents’ µms.
But recall from §1.3.1 that there are multiple ways photons and matter can inter-
act. In particular, the photoelectric effect, Compton scattering, and pair production
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were described. There is also an additional interaction called coherent (Rayleigh)
scattering that is similar to Compton scattering but is not associated with a loss of
photon energy. So which of these interactions does µ characterize? All of them; µ
accounts for photons that interact with matter via any mechanism. In fact, µ can be
decomposed into the individual mechanisms of photon interaction. This is generally
expressed in terms of the mass attenuation coefficient: µm = η + τ + σ + κ, where
η is the part of µm due to coherent scattering, τ is the part due to the photoelec-
tric effect, σ is the part due to Compton scattering, and κ is the part due to pair
production. Figure 1.8 illustrates the relationship between µm, η , τ , σ, and κ over
a range of photon energies in water, a good approximation for much of the human
body. Note that at PET’s energy of 511 keV, µm is composed virtually entirely of
Compton scattering, in agreement with our earlier discussion (Figure 1.3).
Now, let us return to the photon beam experiment outlined above but use a new
material where µ varies along its length. We will reference what position we are at
in the element with a new variable, s. Since µ depends on s, we can write it as a
function, µ(s). Such a material can be thought of as several homogenous materials,
each with its own µ, glued end to end. Suppose that each of these segments is very
thin (infinitesimally so, actually), and has a length ds. Each segment will cause the
beam intensity to change (infinitesimally) by dI. Thus, for any arbitrary segment, we
can use Equation (1.1) to relate the fraction of photons that make it through, dI/I0,
to its particular linear µ-coefficient, µ(s), and its length, ds:
dI
I0
= −µ(s)ds (1.3)
By summing up the contributions from each segment, one can determine the to-
tal amount of attenuation that occurs. When summing infinitesimal quantities in
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Figure 1.8: Component photon/matter interactions that sum to µm over a range of
energies. These include coherent scattering (η), the photoelectric effect (τ), Compton
scattering (σ), and pair production (κ). Adapted from Yip [219].
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mathematics, the operation is called integration, denoted by
∫
. When both sides of
Equation (1.3) integrated and rearranged, we find that:
I
I0
= e−
∫
photon beam path µ(s) ds (1.4)
The summation is carried out over the entire path of the beam, through all objects
that it might interact with.
Equation (1.4) is important; given any material with arbitrarily varying (and
known) µ-coefficients along its length, we are able to compute the proportion of
photons that will make it through. Importantly, the expression on the right side
of the equation can be interpreted as the probability that a given photon will pass
through the material unimpeded.
This result can be adapted to PET by applying Equation (1.4) to both photons
that make up a photon pair released from a positron annihilation. In particular, the
probability that each photon will reach the ring of detectors is exp
(− ∫
half of LOR
µ(~r) ds
)
.
The summation runs over the half of the LOR that one of the two photons traverses.
The term ~r is simply shorthand for the three coordinates that describe the photon’s
position in 3D space. In order to generate a coincidence event, both photons must
be detected. These events are independent: one photon’s fate does not influence the
other’s. Thus, the probability of a coincidence is simply the product of the prob-
abilities that each photon will be detected. When computed, the following result
emerges:
p(coincidence) = e−
∫
LOR µ(~r) ds (1.5)
This is a remarkably simple result. It says that if one knows the spatial distribution
of attenuation coefficients, i.e. µ(~r), or in other words the attenuation map (µ-map),
one can calculate the probability that a photon pair will reach the detector along any
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LOR. Moreover, the answer only depends on the µ-coefficients along the LOR under
consideration.
1.4.2 How Attenuation Is Corrected
Assuming the µ-map, i.e. µ(~r), is available (the acquisition of which is the subject
of §1.4.3), attenuation correction (AC) is quite straightforward. Generally speaking,
there are two ways to carry out AC.
One approach is to pre-correct the PET data prior to reconstruction. Suppose
that a dataset of coincidence events has been acquired and that all corrections aside
from attenuation have already been applied. (AC is often last to be completed in
clinical PET systems.) The acquired coincidences can be binned according to which
detector pair recorded them, or in other words, which LOR they came from. Suppose
that n trues were recorded along a particular LOR. The actual number of positron
decays along the LOR, n0, is easily calculated by appealing to (1.5). One must simply
divide the number of observed trues by the probability that any given photon pair
emitted along the LOR would be detected. Put another way, to figure out how many
trues along a given LOR would have been recorded if there was no attenuation, one
must multiply the observed number of trues by the following “attenuation correction
factor”:
attenuation correction factor = e
∫
LOR µ(~r) ds (1.6)
This simple modification of the observed data effectively erases the effects of attenu-
ation.
Alternatively, AC can be carried out during the reconstruction process. Iterative
reconstruction methods depend on an object known as the system matrix, P. A given
element, Pij, represents the probability that a photon pair emitted from the jth pixel
47
will be detected by the ith detector pair. Each detector pair has an associated LOR.
Using P, one can state the PET reconstruction problem quite elegantly. To do so, let
us define two vectors. Let ~a be the actual radioactivity in each image voxel, which is
what we wish to find. Let ~n be observed counts along each LOR, which is what the
PET scanner measures. The relationship between P, ~a, and ~n is simply:
~n = P~a (1.7)
All the physics of how ~a gives rise to ~n is modelled in P. Accordingly, the effect of
attenuation can be directly incorporated into P. This is done by dividing each row
by the ith attenuation correction factor [78]. In this way, reconstruction is carried
out without modifying the acquired data itself. This technique has some advantages
in terms of preserving the Poisson nature of the data when rebinning a 3D acquisition
to 2D slices [41].
1.4.3 How the µ-Map Is Obtained
1.4.3.1 Transmission Scan Primer
The crux of AC is in finding µ(~r), and doing so is the subject of multiple reviews [8,
113, 222, 224]. Finding µ(~r) is greatly simplified by a process known as transmission
scanning. Up to this point, we have been focusing on PET which is an emission scan,
i.e. image formation relies on detecting radiation emitted from within the patient.
In contrast, in transmission scanning, radiation is produced by a source external to
the patient and transmitted through the patient’s body. The fraction of photons
that make it through the patient are recorded, much like the experiment described
in §1.4.1. This is repeated from several different angles around the patient; the data
collected at each angle is referred to as a “projection”. Each projection can be loosely
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thought of as a planar image like that produced via standard x-ray radiography. Image
reconstruction algorithms are able to convert the planar projections into a 3D volume
of µ-coefficients, i.e. µ(~r)!
Transmission scans can take many forms. The most widely known is x-ray CT, but
it is by no means the only example. One can categorize transmission scans according
to two parameters: 1) the shape of the radioactive source and 2) the energy of the
transmitted radiation. These are discussed in detail in §1.4.3.3 and §1.4.3.4, respec-
tively. First, however, I will explain how µ(~r) can be formed without a transmission
scan at all.
1.4.3.2 Without a Transmission Scan
There are ways to acquire µ(~r) without a transmission scan, summarized in Table 1.5.
This is appealing as transmission scans can take several minutes to acquire, require
additional instrumentation and maintenance, and deliver an additional radioactive
dose to the patient, though the dose can vary widely depending on the type of trans-
mission scan acquired. Unfortunately, as will become evident, obtaining a reliable
µ-map is challenging if depending only on emission data.
The simplest approach for generating µ(~r) is to draw it manually based on a
reconstruction of the uncorrected emission data [123]. Although this method is easy to
implement, it induces a dramatic tradeoff between µ(~r)’s accuracy and the time spent
creating it. Further, it is subject to inter-operator variability. A more sophisticated
approach is to automate the µ-map drawing process. For example, an early algorithm
developed by Bergstro¨m et al [16] used the derivatives of the emission projections to
infer the boundary of the patient’s head, assigning a constant linear µ-coefficient
therein. Techniques like this eliminate human labour and inter-operator variability,
but are inherently limited in their capacity to generate detailed µ-maps.
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Table 1.5: Benefits and drawbacks of the approaches to obtain µ(~r) without a trans-
mission scan.
Method Advantages Disadvantages
Manual
drawing
Easy implementation Accuracy/effort tradeoff
Automated
drawing
Little or no human
effort, repeatable
Limited accuracy
Image
registration
Arbitrary accuracy Template µ-map may not reflect
patient, registration nontrivial
Reconstruct Arbitrary accuracy Image/µ-map crosstalk, complicated
objective function
Consistency
conditions
No image/µ-map
crosstalk
Limited accuracy
One tactic to add detail to the µ-map is to make use of an atlas consisting of
both a nuclear medicine scan and a paired µ-map. First, the former is aligned to
the uncorrected reconstructed emission data. The transform used to achieve the
alignment is applied to the µ-map, which then serves as µ(~r). This idea was initially
applied in SPECT [197]. Though this approach allows for an arbitrarily detailed
µ-map, its reliability depends on how well µ(~r) represents the patient, a function of
both the alignment accuracy and morphological discrepancies between the atlas and
patient.
An alternate scheme is to treat µ(~r) as an unknown and incorporate its discov-
ery into the reconstruction algorithm. This notion was conceived by Censor et al
[33], and has since been incorporated into modern iterative reconstruction algorithms
[149]. This provides more flexibility in µ(~r)’s construction than do automated drawing
procedures, but framing the reconstruction in this manner results in a complicated
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objective function with many peaks. Thus, convergence to the correct µ-map is in no
way guaranteed. This is because the reconstructed PET image and µ(~r) affect one
another, a phenomenon called cross-talk. However, by modifying the reconstruction
algorithm such that image smoothness is encouraged, the amount of cross-talk can
be reduced [149]. (Recall that ill-conditioning is also rectified in such a manner.)
Another interesting means to estimate µ(~r) during image reconstruction is via the
use of “consistency conditions”, or more formally, the Helgason-Ludwig conditions.
Described in the context of emission tomography by Natterer [143], the premise hinges
on the fact that an ideal set of emission data demonstrates internal consistency. In
particular, the zeroth condition stipulates that the activity recorded in each projec-
tion is equal while the first condition states that the first moments of the projections
should trace out a sine wave. This is because the first moment is a stationary point
in image space and therefore manifests as a sine wave in the sinogram. Higher order
conditions involve the characteristic tracings (sums of sines with different periods) of
higher order moments. The µ-map that best satisfies these constraints when applied
to the emission data is chosen. The problem is that the Helgason-Ludwig conditions
alone are not sufficient to compute an arbitrary µ(~r). However, if a template µ-map
is parameterized, the consistency conditions may be used to find the optimal param-
eters. For example, an early application to PET used a generic 2D torso phantom
parameterized by an affine transformation [212] (i.e. it could be rotated, translated,
scaled, and sheared). Unfortunately, though this methodology eliminates the cross-
talk between the emission image and µ-map, it comes at the cost of greatly limiting
µ(~r)’s form since the template µ-map can only be transformed certain ways.
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Table 1.6: Benefits and drawbacks of various transmission scan geometries.
Radioac-
tive source
geometry
Advantages Disadvantages
Ring
source
Collect all projection angles
simultaneously
Cannot separate transmission
from emission data, must use
coincidence detection
Line
source
Can separate transmission from
emission data, can use
coincidence or singles detection
Only one projection angle at a
time, deadtime losses with
coincidence detection
Point
source
Same as rotating line source, but
can also be used in 3D mode
Same as line source, but also
not a standard implementation
1.4.3.3 Geometric Considerations for Transmission Scans
Calculating µ(~r) is simplified via transmission scanning. The first examples of images
formed by γ-ray transmission were described in 1952 by Mayneord [134]. These were
planar projection images, similar in appearance to those obtained via conventional ra-
diography. Fourteen years later, the first transmission images acquired in conjunction
with emission images were collected for the purposes of anatomic localization [119].
This preceded the development of PET and SPECT, and again, the images were sim-
ply projections. Nineteen seventy-five marked the birth of transmission scanning for
AC in PET [49, 161].
Transmission scans can take multiple forms. A key defining characteristic of a
transmission scan is its acquisition geometry. Geometry refers both to the shape of
the photon source and whether the radioactive source is a single photon emitter or
photon pair (i.e. positron) emitter. Important geometric features are summarized in
Table 1.6.
52
The most common photon source shapes are a ring, a rotating rod, or a rotating
point (Figure 1.9). For transmission scanning to work, one must know where each
detected photon originated, otherwise there is no way of knowing what part of body
it passed through. With this in mind, consider the ring source. If the radioactive
material in the ring was a single photon emitter, that is each radioactive decay released
one photon rather than a photon pair, there would be no way to tell which part of
the ring any detected photons came from. However, if the radioactive material was a
positron emitter, thereby releasing a photon pair with each decay, each coincidence
defines a LOR, and its intersection with the ring is where the transmitted photon
originated. A problem with this geometry is that there is no reliable method to
exclude scatter and randoms. More importantly, the transmission scan cannot be
conducted during the emission scan as there is no way to distinguish between emitted
and transmitted coincidences; therefore, the transmission scan must be carried out
prior to radiopharmaceutical administration, significantly lengthening the patient’s
exam.
These problems are addressed by the rotating rod source with a positron emitter.
By only accepting LORs collinear with the rod (a process called windowing), scatter
and randoms are greatly reduced and the transmitted photons can be separated from
emitted ones. Accordingly, transmission scanning can be accomplished during the
radiotracer uptake period [30] or even during emission data collection [136]. Unfor-
tunately, a great deal of radiation strikes the detectors adjacent to the rod, leading
to significant deadtime effects that compromise the count rate.
Herein lies the value of using a single photon emitter (or singles triggering of a
positron emitter) with a line source. Since the concept of coincidence detection is
meaningless for single photon emitters, the detectors nearby the rod source can be
shielded, mitigating the deadtime problem and substantially increasing count rate.
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Figure 1.9: Various transmission scan geometries. The radioactive source is shown
in red. (A) Ring photon pair source. Positron annihilations are represented by the
black circles. Note that the origin of the transmitted photon can be inferred via
coincidence detection; the LOR crosses the ring at two points and either can be
selected as the origin. This would not be possible with a single photon emitter as
they do not generate a LOR. (B) Rotating line (or point) photon pair source. In
this circumstance, scatter and randoms can be largely eliminated by only accepting
LORs collinear with the source. However, there are large deadtime losses adjacent
to the source. (C) Rotating line (or point) single photon source. Though windowing
is no longer possible, the deadtime losses adjacent to the source are eliminated by
shielding.
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However, windowing becomes impossible as it depended on coincidence detection.
Also, as with the ring, the origin of any detected photons is unknown; it could be
anywhere along the rod. To circumvent this problem, this approach must be combined
with shields called inter-slice septa that block any photons that are not perpendicular
to the rod. If this is done, the photon’s path may be computed using the rod’s position
and the point of detection within any given axial slice.
The first description of a single photon emitting line source actually used singles
triggering of a positron emitter and reported greatly improved statistics compared to a
line source with coincidence counting, but deteriorated axial resolution due to the need
for inter-slice collimation, eliminating cross plane acquisitions [45]. Later incarnations
used 137Cs as the emitter, an isotope that releases 662 keV photons [108, 220]. Not
only does 137Cs cost less and have a much longer half-life than 68Ga/68Ge generator
systems (the positron emitters of choice for transmission scanning), its altered photon
energy enables transmitted photons to be distinguished from emission data given
sufficient energy resolution [108]. However, for many systems (e.g. with bismuth
germinate scintillator crystal detectors) this is not feasible [220].
Finally, If one wishes to conduct a fully 3D transmission scan with a single photon
emitter, one must use a rotating point source since the photon origin is always known
in that case [9, 108].
1.4.3.4 Energy Considerations for Transmission Scans
A second key feature of transmission scans is what photon energy is selected. Recall
that µ-coeffecients are dependent on photon energy (§1.4.1). Thus, only 511 keV will
provide the correct values for µ(~r) since that is the energy of the radiopharmaceutical.
If any transmission photon energy is used, the measured µ-coefficients will be biased.
(Incidentally, the presence of scatter and randoms has a similar effect.)
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Table 1.7: Benefits and drawbacks of various transmission scan energies.
Radioactive
source type
Advantages Disadvantages
Positron emitter
(511 keV)
µ-coefficients unbiased Severe transmission
time/statistics tradeoff
Single photon
emitter
(monochromatic
energy, 100s of
keV)
Relatively fast scans with
good statistics
µ-coefficients slightly
biased (depending on
energy), requiring mapping
or segmentation
X-ray CT
(polychromatic
energy, 40–140
keV)
Very fast scans with excellent
statistics, doubles as
anatomical localization with
diagnostic quality
µ-coefficients highly
biased, requiring mapping
or segmentation, high
radiation dose
However, as alluded to in §1.4.3.3, oftentimes using energies aside from 511 keV
can accelerate the transmission scan, and/or improve its signal to-noise-ratio. This
was the impetus for using single photon emitters. Even greater accelerations can be
obtained by using an x-ray source, i.e.PET/CT [115]. The photon flux attainable in
CT scans is much greater than that of γ-ray sources, yielding high SNR transmission
scans in a matter of seconds. If acquired after radiotracer administration, the CT
scan remains uncontaminated by 511 keV emission photons due to their relatively
minuscule number in comparison to the x-ray photons.
If the transmission scan is obtained at an energy other than 511 keV, µ(~r) must
be mapped to the correct 511 keV, linear µ-coefficients. One method of accomplish-
ing said mapping is via a mathematical function. When compensating for photon
energy differences, the function becomes more complicated the further from 511 keV
the transmission photon energy is. For example, as Compton scatter is the dominant
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interaction in human tissue for both 511 keV and 662 keV photons (Figure 1.8), atten-
uation correction factors derived from 137Cs imaging can be scaled to the appropriate
values using a simple exponential relation [220]. However, at x-ray energies, both
the photoelectric effect and Compton scatter contribute to attenuation, and further-
more, they contribute to different extents in soft tissue versus bone; this necessitates
a bilinear mapping function, often with the lines meeting at 0 HU [29, 115].
More generally, the mapping is a function of both atomic number and density. A
means to identify the correct mapping for any materials is by dual-energy CT, which
allows the relative contributions of the photoelectric effect and Compton scatter to
be inferred over a wide range of energies [4]. This principle has been applied for AC
in PET [73, 112], but as it complicates the transmission scanning protocol and can
expose the patient to additional ionizing radiation, it is not used routinely.
With respect to CT specifically, there is an additional complication concerning
photon energy. The x-rays are not monoenergetic, but rather range from about 40
keV to around 140 keV, depending on the acquisition protocol. The lower energy
photons are preferentially attenuated, shifting mean photon energy upwards, a phe-
nomenon known as beam-hardening. The degree of beam-hardening is a function
of the patient’s geometry, composition, and photon path, resulting in local intensity
variations in the reconstructed image that are not representative of the actual CT
number. The problem is exacerbated when highly attenuating materials such as dental
implants [107], pacemakers or defibrillator leads [51], and joint replacements [65] are
present. (These high atomic number materials also reduce image quality by virtue of
increased noise, partial voluming, scatter, and exceeding the image’s dynamic range,
i.e. clipping.) All CT scanners apply routine beam-hardening corrections, but they
are imperfect and research in the field remains active [209].
A convenient method of correcting biases in µ(~r, t), be they from photon energies
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other than 511 keV, scatter, or beam hardening, is via image segmentation. In par-
ticular, if one can divide µ(~r) into its component tissues, the appropriate µ-coefficient
can simply be assigned to each region. Segmentation also has the advantage of elimi-
nating noise from the transmission scan. First proposed in 1981 by Huang et al [89],
a rich body of research has emerged on the subject [17, 115, 138, 217].
Segmenting the µ-map does bear some disadvantages, though. The segmentation
can be quite challenging, and the quality of the AC is only as good as the robustness
of the segmentation algorithm. Further, by its very nature, segmentation compresses
a continuum of values (or, more correctly, a large number of discrete values) to a few
numbers, one per tissue type. This is acceptable for relatively uniform tissues, but not
for ones with variable µ-coefficients like the lungs [82, 106] and bones [129]. Similarly,
if the µ-coefficient distribution in a given tissue varies between individuals, as is the
case in the lungs [82] and bones [129], it is invalid to assign the same µ-coefficient to
that tissue type in every patient. Additionally, segmentation may impose practical
limitations such as the computational time required to post-process the transmission
image.
1.4.3.5 Problems Specific to X-ray CT Transmission Scans
Aside from beam hardening (§1.4.3.4), there are other issues that arise only in PET/CT
[224]. For example, in many PET/CT systems, the PET field of view is often larger
than that of the CT. If the object of interest extends beyond the CT field of view, the
CT projections are truncated and the resulting µ-map will not only be missing parts,
but display characteristic artifacts near the periphery. Without correction algorithms,
the impact on the PET images can be severe [18, 133].
Additionally, patient motion can induce misalignments between the CT-derived
µ-map and the emission data as they are collected over different temporal scales.
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In essence, the PET scan is collected over several minutes and blurs patient motion
together, whereas a CT scan is captured in seconds and is akin to a snapshot in time.
The best solution is to acquire a dynamic µ-map, making it a function of time (t),
i.e. µ(~r, t). The emission data can be binned according to t and corrected using
the corresponding µ(~r, t). In principle, such an approach could account for arbitrary
motion induced transmission/emission mismatch, but in practice radiation constraints
limit the approach to cyclical motions such as respiration or the cardiac cycle. In this
case, µ(~r, t) need only be computed for one cycle, rather than necessitate continuous
acquisition during the entire emission scan. Many authors have implemented cine-
CT acquisitions for AC and have characterized the errors induced by using various
time-independent µ-maps [3, 36, 42].
1.5 MRI-Based Attenuation Correction
1.5.1 Relation to Transmission Scans
In many ways, anatomic MRI is disparate from transmission scanning. In particular,
the mechanism of signal acquisition is completely different. Simplistically, the former
measures voltages induced by precessing magnetization whereas the latter measures
the flux of a photon beam passing through the object. Unsurprisingly, the resulting
images have dissimilar contrasts. Beyond this, depending on the pulse sequence and
characteristic timing parameters such as the repetition time (TR) and echo time (TE),
the contrast of MRI images can be drastically altered. Conversely, the contrast of
transmission images cannot be changed very much: the more attenuating the material,
the brighter it will appear.
In other respects, however, anatomic MRI and transmission scans are not so dif-
ferent. Specifically, they can both generate anatomical images of the body. Yes, the
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images do not look the same, but the major components of the body can be visual-
ized in either case. The beauty of this observation is that it suggests, with respect to
µ-map generation, that the approaches historically employed on transmission scans
might be applicable to MRI as well. This intuition is, in fact, correct.
Clearly, an MRI requires post-processing to yield a valid µ-map. We have seen
this concept applied to transmission scans to correct their deficiencies. For instance,
recall that image segmentation can be used to eliminate noise and map the component
tissues to the appropriate 511 keV µ-coefficients [17, 89, 115, 138, 217]. The same
principle can be used to convert MRIs to segmented µ-maps. Also, remember that one
approach of inferring the µ-map from emission data is to align a generic transmission
scan with the uncorrected reconstruction [197]. Again, this methodology is trans-
ferrable to MRI-based AC by using the MRI as the registration target as opposed to
a preliminary emission tomography image. Finally, mathematical functions played a
major role in mapping µ-coefficients acquired at photon energies other than 511 keV
to the correct values [29, 115, 220]. Generally, these were single variable, one-to-one
functions. Though such relations are too simple to model the mapping between MRIs
and µ-maps, more sophisticated functions—especially those originating from the field
of machine learning [85, 87, 103]—have achieved impressive results on this front.
All things considered, there is nothing fundamentally new about MRI-based AC:
the three principle approaches for inferring an µ-map from MRI, namely segmenta-
tion, registration, and mapping, have been present in the AC literature for decades.
In §1.5.2, I describe their application with respect to PET/MRI, building on the
previous review by Hofmann et al [86].
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1.5.2 MRI to µ-Map Conversion
1.5.2.1 By Segmentation
The first MRI-based AC algorithm was proposed—rather ahead of its time—in 1994
by Le Goff et al [67]. It was designed for cranial PET and generated the µ-map
via segmentation into three tissue classes, namely air, soft tissue, and bone. The
segmentation algorithm was based on thresholding and mathematical morphology
(i.e. geometric manipulations applied to sets of voxels). It neglected the sinuses
and, according to the authors, did not perform well in the slices containing the eyes.
Despite this, initial results were encouraging: the relative error in several expertly
placed VOIs did not exceed 12% (avoiding slices where the algorithm failed). No
global error analysis was reported. Zaidi et al [225] improved upon this approach
by using a more robust fuzzy clustering segmentation algorithm that could identify
the sinuses. Although it had a tendency to overestimate activity, its performance
was good compared to multiple other AC algorithms [226]. In particular, statistical
testing showed that absolute quantification in most regions of the brain was not
significantly different from AC based on 137Cs transmission scanning. Globally, the
correlation between the MRI-corrected and transmission-corrected volume of interest
(VOI) activities was high, with a squared Pearson correlation coefficient (R2) of 0.91.
A problem with both Le Goff’s and Zaidi’s approaches is that they may not be
robust to abnormal anatomy. After all, both air and bone appear dark in MRI,
so both AC methods implicitly utilize normal anatomy to differentiate between the
two. This motivated both Keereman et al [109] and Catana et al [32] to design an
alternate segmentation scheme based on ultrashort TE (UTE) pulse sequences [171].
Unlike standard pulse sequences, UTE sequences yield signal from bone, theoretically
enabling it to be discriminated from air based solely on voxel intensity. In practice, the
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problem is complicated and involves several post-processing steps, but both groups
overcame these issues and demonstrated its promise. That said, both studies were
proofs-of-principle focussing on developing the algorithm rather than assessing the
errors in the resulting PET images. Notably, no statistical analyses were conducted.
This is a necessary step to compare it to other AC methods and to ascertain where
improvement is needed. It would also be interesting to see whether the UTE AC
algorithms do indeed produce better results than alternate approaches when imaging
patients with abnormal anatomy.
Segmentation has also been used in whole-body MRI-based AC. Two groups have
reported algorithms identifying air, lung, and soft tissue in MRI images [186, 196].
One study was conducted using humans [186] (Figure 1.11) whereas the other used
dogs [196], but the algorithms were similar, both involving thresholding and other
simple image processing techniques guided by assumptions about normal anatomy.
Different means of local error analysis were employed in the studies: SUVs of lesions
[186] versus VOIs spanning entire organs [196]. A common observation was that,
within bony structures, the activity was systematically underestimated as bone was
not included in the segmentation. Conversely, the human study described a system-
atic overestimate of activity in the abdomen owing to the absence of a tissue class
for fat [186] . This was not apparent in the canine study, likely because canines tend
to be lean, reducing the importance of fat segmentation. Despite neglecting fat in
humans, the global voxel-by-voxel correlation was excellent (R2 = 0.985) [186].
Martinez-Mo¨ller et al [132] proposed that fat could be included in an AC segmen-
tation model with the aid of the 2-point Dixon pulse sequence [43]. This sequence
can partially distinguish between fat and water based on phase differences between
their respective nuclei. Though they used 35 patient PET/CT scans to demonstrate
the potential merit of a segmented CT-derived µ-map comprised of air, lung, fat,
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Figure 1.10: Example of a whole-body µ-map generated via segmentation of an MRI.
(A) Coronal slice through original MRI and (B) corresponding segmented µ-map
comprised of air, lung, and soft tissue classes. Adapted from Schulz et al [186].
and muscle, they did not consider a segmented CT-derived µ-map without fat, mak-
ing comparison impossible. Further, their method was only used to generate two
MRI-based µ-maps as a proof-of-principle, precluding a meaningful error analysis.
Fortunately, a followup study evaluating the methodology in 35 patients was con-
ducted by Eiber et al [59], demonstrating an exceptional correlation between lesion
SUVs in MRI-based AC versus CT-based AC PET images (R2 = 0.995).
Ideally, one might think that bones would also be included in the segmentation
model. Unfortunately, they are very challenging to identify on whole-body MRI, and
though effective in the head, UTE methods are ill-suited for large field of view ac-
quisitions. Thus, bone segmentation remains an open problem in MRI-based AC.
However, Schlyer et al [183] used PET/CT scans to demonstrate some pitfalls that
arise when using bone segmentation. The dilemma is twofold: 1) can the bones be
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segmented accurately and 2) what µ-coefficient should be assigned to them? Regard-
ing the second point, it was found that the best result was produced when patient
specific, mean bone µ-coefficients were employed. This information, of course, is not
necessarily going to be available for patients receiving a PET/MRI, so it is likely that
a fixed µ-coefficient will be required. Interestingly, Schyler et al found that concern-
ing quantification in the chest, a bone µ-coefficient (0.13 cm−1) yielded worse results
than the µ-coefficient of soft tissue (0.95 cm−1), a problem that worsened when the
bones were oversegmented. That is not to say bone segmentation is futile. Perhaps
the most appropriate µ-coefficient in this region is somewhere between 0.95 cm−1 and
0.13 cm−1. Admittedly, the optimal µ-coefficient is likely different in other parts of
the body, such as the skull or pelvis. Ultimately, the problem is that segmentation
collapses the µ-coefficient distribution to a single value that is bound to be subop-
timal in some areas. Though very effective for relatively uniform materials such as
air, fat, and muscle, segmentation is simply not the best choice for tissues that can
assume a wide range of µ-coefficients.
A possible means to improve bone segmentation is to divide it into two classes:
cortical and cancellous, thereby quantizing the continuum of µ-coefficients to two
values rather than one. Using a digital whole-body phantom, Keereman et al [110]
found that doing so reduced the relative error in spine lesions from over 10% to under
5%. Interestingly, they also found that quantification in these lesions was relatively
insensitive to the µ-coefficient assigned to cortical bone. In lungs, however, another
tissue with highly variable µ-coefficients [82, 106], this was not the case. Though
shedding some light on the effects of segmentation error, Keereman’s findings must
be verified in patients. Further, this study used CT to determine the segmentations,
yielding near perfect results. This will be much more challenging using MRI. For
example, differentiating cortical from cancellous bone may prove difficult since they
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are in close proximity and tend not to be easily visualized in MRI.
1.5.2.2 By Registration
An alternate MRI-based AC method relies on image registration, that is, aligning
medical images to one another. In particular, one can infer µ(~r) by taking a generic
µ-map and forcing it into alignment with the patient’s MRI, thereby simulating the
true µ-map. Unlike segmentation, AC techniques based on image registration do
not need to collapse µ-coefficient distributions down to single numbers. The generic
µ-map can be arbitrarily detailed. The problem is that the µ-coefficients in the
generic µ-map may not correspond to the patient’s. Further, the registration itself
can be exceptionally challenging, especially in whole-body applications. In fact, the
registration may not even be sensible if there are anatomic differences between the
generic µ-map and the patient. Many of these issues are assuaged if only the head
is considered as it exhibits less variance than the rest of the body; accordingly, the
application of MRI-based AC exclusively via registration has only been reported in
cranial PET. The first study of its kind was too small to make definitive conclusions
(n = 4), but a VOI analysis suggested its performance was similar to a segmentation-
based approach [117].
Another group proposed a deformable registration algorithm and quantified its
ability to approximate the true µ-map, but only presented PET data for one patient
[184]. Despite promising surrogate measures of their approach’s quality, its actual
performance in terms of reconstructing PET data remains to be seen.
In an interesting study by Malone et al [130], two generic µ-maps were registered
to the patient MRI: one was a segmented µ-map based on the BrainWeb phantom
[39] while the other was an atlas derived from 10 68Ge transmission scans. In both
global and local analyses, the latter approach demonstrated less error, a conclusion
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Figure 1.11: Example of a cranial µ-map generated via registration of a template to an
MRI. (A) Axial slice through original MRI, (B) template µ-map before registration to
MRI, and (C) template µ-map after registration to MRI. Adapted from Schreibmann
et al [184].
that remained valid irrespective of what µ-coefficient was assigned to bone in the
segmented µ-map. A possible confounder, however, is that the registration error was
likely different between the two approaches; the moving image used to derive the
transform was a segmented pseudo-MRI for the segmented µ-map and a real atlas
MRI for the atlas transmission scan. The latter may have resulted in more realistic
transforms than the former. Nonetheless, the results suggest that generic µ-maps
based on transmission scans are superior to those based on phantoms.
1.5.2.3 By Mapping
The final MRI-based AC method is mapping the MRI directly to a µ-map. This gen-
erally involves constructing some mathematical function that analyzes the MRI one
voxel at a time, converting each one into an estimated µ-coefficient. In some ways,
mapping combines the strengths of segmentation and registration; like segmentation,
mapping can theoretically cope with anatomical anomalies, but like registration, dis-
tributions of µ-coefficients need not be collapsed to a single value. Beyer et al [20]
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were the first to describe a map between MRI and µ-maps. Specifically, using aligned
MRI / CT pairs, they applied histogram matching to the MRI to scale its values to
CT numbers. The function produced by histogram matching is necessarily monoton-
ically increasing, and therefore one-to-one. Hence, for histogram matching to be a
truly effective approach, increasing MRI signal intensity would have to correspond to
increasing µ-coefficients. This is obviously not so (e.g. air versus bone), and therefore
histogram matching is fundamentally limited as a mapping technique for MRI-based
AC. Beyer et al [20] characterize the method as a toolbox to study pitfalls in MRI to
CT mapping rather than as a solution to the problem.
It was Hofmann et al [85, 87] who proposed the first realistic MRI to CT map-
ping, both in the head [87] (Figure 1.12) and in the whole-body [85]. Their mapping
function is called a Gaussian process, which is used in the field of machine learning.
For each voxel in the MRI, the Gaussian process accepts a number of inputs and
calculates a CT number. A large contributor to the function’s success lies in choos-
ing appropriate inputs, a process known as feature selection. Hoffman et al use two
types of features: one type consisted of the voxel intensities in a patch centred upon
voxel of interest, while the other type constituted the voxel’s coordinates. Intuitively,
the concept is that by examining the MRI voxel’s intensity, its surroundings, and its
location, one should be able to do a relatively good job of predicting the CT number.
In Hofmann et al ’s implementation, the Gaussian process inferred the relationship
between the inputs and outputs by exposure to labeled examples drawn from seven-
teen aligned MRI/CT pairs. This training paradigm is known as supervised learning.
In the head, Hoffman et al ’s [87] approach generated stunningly detailed pseudo-CT
images from MRI images. A global analysis revealed an R2 of 0.968 between the
voxel-wise estimated and true PET activities. In the whole-body, the quantitative
analysis was based on SUVs both in standard anatomic positions and over lesions
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[85]. Compared to a segmentation-based approach that, importantly, did not include
bone, the Gaussian process method provided superior quantification primarily within
or nearby bony structures.
Figure 1.12: Example of a cranial µ-map generated via mapping from an MRI. From
left to right are the MRI, mapped pseudo-CT, and real CT . Adapted from Hofmann
et al [87].
Of the inputs used in Hoffman et al ’s implementation of the Gaussian process,
the most troublesome are the coordinates. To be meaningful, they must somehow be
normalized across the training MRI/CT pairs and the patient under consideration.
To accomplish this, Hoffman et al registered each MRI/CT pair to the patient in
question, and carried out patient specific supervised learning using standard Cartesian
coordinates. That means every time a new patient MRI needs to be converted to a
µ-map, not only must a new model be built, but also multiple registrations need to
be executed. A more efficient method may involve utilizing a coordinate system that
can naturally represent positions in the human body without requiring every subject
to be in an identical reference frame. Another option is to avoid using coordinates
altogether. This premise is consistent with an approach for cranial PET proposed by
Johansson et al [103] wherein voxel intensities from both anatomic and UTE MRI
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sequences serve as inputs to a Gaussian mixture model (another machine-learning
technique). Similarly to some segmentation schemes [32, 109], the incorporation of
UTE sequences permit discrimination between bone and air independent of position.
Additionally, it may provide information about bone density [168]. Unfortunately,
though their pseudo-CTs look excellent and the predicted CT numbers correlated
well with truth, Johansson et al [103] did not provide any PET data to evaluate their
methodology.
1.5.3 Ongoing Problems and Future Work
MRI-based AC is still a young field, and hence, there remain multiple un- or partially
resolved issues. In the following section, I outline some ongoing problems and propose
directions for future research, including those that are explored in the coming chapters
of this thesis (Table 1.8).
Recall that in CT-based AC, truncation artifacts were problematic due to CT’s
reduced field of view compared to PET. Regrettably, MRI’s field of view is even
smaller, often cropping substantial parts of the patient’s body (especially the arms
and shoulders), leading to average and maximum biases of about 15% and 50% in the
PET images, respectively [47]. Delso et al [47] proposed a method based on active
contours to infer the missing portions of the µ-map; their method reduced the average
bias to well under 10%, but the maximum bias still exceeded 20% in areas where their
algorithm erroneously induced attenuating material. Another approach involving the
reconstruction of truncated regions based on the emission data has been proposed by
Nuyts et al [150]; the initial results are promising, but the algorithm requires more
extensive testing. Truncation of MRI-based µ-maps remains an open problem ripe
for further research.
A problem specific to MRI-based AC is that, unlike CT, many attenuating objects
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Table 1.8: Future work in MRI-based AC.
Problem Addressed
in thesis?
Explanation
Truncation of
MRI
No MRI field of view too small to acquire complete
µ-map
MRI invisible
objects
No Difficult to incorporate such objects into the µ-map
Metal
artifacts
No Create signal voids in MRI, which consequently
deteriorate the µ-map
MRI-based
AC in
SPECT
Chapter 2 Quantitative reliability of MRI-based AC applied
to SPECT has yet to be determined
Lung
µ-coefficients
Chapter 3 Lungs yield little signal in MRI, so extracting their
µ-coefficients is challenging
Algorithmic
framework
Chapter 4 Understanding the capabilities and limitations of
segmentation, registration, and mapping is key
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such as RF coils [46, 200], patient positioning aids [131], and medical probes [46], do
not appear in standard MRI images. Under some circumstances, this may not be of
much importance. For example, foam positioning aids induced relatively little error
(≈ 5%) when imaging the extremities [131], as did surface coils in a phantom study
of thoracic imaging [200], while medical probes only caused local artifacts in the PET
image [46]. However, more substantial hardware such as head and neck RF coils
have been found to induce errors of up to 20% [46, 200]. Further, patient positioning
aids contributed to errors over 10% in cranial PET [131]. Only one study proposed a
means of correcting some of these problems [46], and much more work is required both
to characterize and correct errors induced by MRI invisible objects. Some possible
directions include the use of UTE sequences to produce signal from otherwise MRI
invisible materials and the emission based inference of missing parts of the µ-map as
described in the paragraph on truncation [150].
A related problem occurs when the patient has metal in their body. Metal induces
a blooming artifact in MRI which can appear as a signal void, depending on the pulse
sequence. This artifact has been shown to seriously disrupt otherwise effective MRI-
based AC schemes [85]. As of yet, no studies have been published systematically
evaluating the resulting AC errors, nor have any solutions been proposed.
Though truncation, MRI invisible objects, and metal artifacts are important con-
siderations in MRI-based AC, these topics are not explored further in this thesis.
The following paragraphs outline the problems that are addressed in the following
chapters.
Thus far, I have discussed MRI-based AC in the context of PET, exclusively.
However, efforts are already underway to develop SPECT/MRI systems [66, 75].
SPECT/MRI, like PET/MRI, requires MRI-based AC, but virtually no present lit-
erature examines the application of MRI-derived µ-maps to SPECT data. However,
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as detailed in §1.5.2, numerous MRI-based AC algorithms have been validated using
PET. One therefore might ask whether existing MRI-based AC algorithms that have
been validated in the context of PET can be expected to perform similarly well when
applied to SPECT. The problem is interesting in that SPECT requires “less” atten-
uation correction that PET (i.e. has smaller attenuation correction factors), but is
much more challenging to implement, making it hard to know in which modality (if
any) MRI-based AC would be better suited. In Chapter 2, I examine this problem
by implementing a simple MRI-based AC algorithm (in particular, a 3 tissue class
segmentation model) and apply it to both PET and SPECT canine data. The analy-
sis is focussed on identifying differences in the quantitative fidelity between these two
modalities.
After exploring the application of MRI-based AC in PET versus SPECT, I elected
to attempt to improve existing MRI-based AC algorithms. The problem I chose to
investigate is that there is currently no means to accurately predict the µ-coefficients
in the lungs, which as mentioned earlier, are highly variable [82, 106]. This, unsur-
prisingly, adversely impacts quantification in the lungs [85, 110], and quite likely, in
surrounding structures as well. The problem is not trivial as the lungs tend to appear
black on MRI regardless of their µ-coefficient distribution. This is in part because
lung parenchyma has about a third the proton density as soft tissues [77], but more
importantly because of its very short T2* caused by susceptibility effects from the
numerous air/tissue interfaces [31, 76]. Additionally, motion and flow artifacts are
abundant and further compromise image quality [77]. In Chapter 3, using a pulse
sequence capable of yielding signal from the lungs, I propose a means to map MRI
lung signal to CT numbers, which in turn can be converted to µ-coefficients. The
approach is tested in healthy canines using PET data.
Finally, after having been exposed to a great variety of MRI-based AC algorithms,
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it occurred to me that there was no unified framework for classifying the multitude
of techniques. In particular, as explained in §1.5.2, every approach relied on either
segmentation, registration, mapping, or some combination thereof, but nowhere were
these categories explicitly stated, precluding their direct comparison. Therefore, for
my final research project (Chapter 4), I chose to implement a version of each algo-
rithmic class and compare them head-to-head-to-head, seeking to formally identify
their strengths and weaknesses. I am of the opinion that without an understanding
of the capabilities and limitations of segmentation, registration, and mapping, the
development of novel MRI-based AC algorithms will be impeded.
Incidentally, an additional novelty arose from the work in Chapter 4. Bones
present a challenge in MRI-based AC. They are not easy to identify using standard
pulse sequences, and UTE sequences can become unreliable if the FOV is large,
as is the case for whole-body imaging. To date, only one whole-body MRI-based
AC method incorporates bones [85]. The authors concluded that their methodology
(which uses mapping) is superior to a segmentation approach, but the latter did not
include a bone category, making the comparison somewhat unfair. This is addressed
in Chapter 4, as the segmentation model includes a bone category, which to the best
of my knowledge has not been published.
1.6 Conclusions
PET and MRI are exceptionally powerful technologies. By combining these modalities
together in a PET/MRI system, we now have the capability to examine a wide range of
physiological and pathological processes with both modalities in spatial and temporal
register. But without reliable MRI-based AC, the vast potential of PET/MRI is
unattainable.
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In this chapter, I have attempted to put MRI-based AC in a broader context.
I began by exemplifying the importance of quantitative PET/MRI in three medical
fields, namely oncology, neurology, and cardiology. Next, a relatively comprehensive
picture of the factors that influence quantification in PET was provided, helping
the reader to understand how attenuation fits in. I subsequently focused specifically
on attenuation: what it is, how it is corrected, and how to obtain the µ-map from
emission or transmission data. Ultimately, I discussed MRI-based AC, emphasizing
its relationship to existing AC techniques. I went on to discuss some directions for
future research, highlighting research covered in the subsequent chapters of this thesis.
In particular, the overarching objective of my thesis is to improve quantification in
PET and SPECT images that are attenuation corrected with an MRI-based µ-map.
I begin by comparing MRI-based AC in PET versus SPECT to see which modality is
more quantitatively accurate. I subsequently focus on a particular issue in MRI-based
AC: i.e. assigning reliable µ-coefficients to the lungs. I finish by comparing the three
approaches to making an MRI-based µ-map, namely segmentation, registration, and
mapping, to establish the circumstances that dictate good versus poor performance.
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Chapter 2
A Comparison of MRI-Based Attenuation
Correction in PET Versus SPECT∗
2.1 Introduction
The idea of combining positron emission tomography (PET) and magnetic resonance
imaging (MRI) systems is not a new one. In fact, early work on hybrid PET/MRI
[18, 24] preceded the completion of PET/CT [1]. Although it took several years
to overcome the technical challenges that constrained PET/MRI to the pre-clinical
arena [28], the combined efforts of several groups have made human PET/MRI a
reality. Several commercial vendors have recently unveiled whole-body platforms.
PET/MRI’s unprecedented capacity to combine anatomical, functional, and molecu-
lar information has implications across multiple fields including neurology [9], oncol-
ogy [21], and cardiology [17].
Like PET, single photon emission computed tomography (SPECT) has been com-
bined with MRI [7, 8]. Research on SPECT/MRI has lagged behind PET/MRI, pos-
∗The contents of this chapter have been published as: H.R. Marshall, R.Z. Stodilka, J. Theberge,
E. Sabondjian, A. Legros, L. Deans, J.M. Sykes, R.T. Thompson, and F.S. Prato. A comparison of
MR-based attenuation correction in PET versus SPECT. Phys Med Biol, 56:4613–4629, 2011. It is
reproduced with the permission of the publishers.
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sibly due to challenges associated with moving parts and MRI-compatible collimator
design [5]. Nevertheless, the potential applications of SPECT/MRI are exciting, espe-
cially given SPECT’s ability to simultaneously image multiple radiopharmaceuticals.
Accordingly, it is probable that human SPECT/MRI systems will come to fruition
within the foreseeable future.
Of the multiple corrections that must be applied to reliably reconstruct PET and
SPECT images, attenuation correction (AC) is among the most important. Without
AC, gross deviations from the true radiopharmaceutical distribution are observed and
accurate quantification is impossible. Traditional methods of obtaining attenuation
maps (µ-maps) such as radionuclide transmission imaging or x-ray computed tomog-
raphy (CT) are generally not possible in PET/MRI or SPECT/MRI due to space and
cost restrictions. The obvious alternative is to use MRI images for AC, but this is
non-trivial since the signal in MRI arises from proton density, whereas photon atten-
uation is dictated by electron density. In spite of this, multiple innovative MRI-based
AC algorithms have been proposed for application in the brain [4, 10, 13, 22] and
body [6, 15, 23, 25]. Although the details of the approaches differ, they share a com-
mon feature: they were all validated for PET reconstructions. This is unsurprising
given the relatively advanced state of PET/MRI compared to SPECT/MRI, but it
does give rise to a natural question. Can an MRI-based AC algorithm that has been
designed for PET/MRI be successfully applied to SPECT/MRI as well? The answer
depends on several fundamental differences between PET and SPECT, including the
amount of attenuation that takes place and the complexity of applying a correction.
In the present work, this question is investigated in detail. A whole-body, MRI-
based AC algorithm representative of trends in the literature is described and used to
reconstruct both phantom and in vivo canine PET and SPECT images. The deviation
of these reconstructions from the truth (obtained via “silver standard” CT-based AC)
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is compared between PET and SPECT. The comparisons are done both globally and
locally to capture differences in the PET and SPECT reconstruction quality over a
wide range of physical scales. Finally, a sensitivity analysis is conducted to assess the
impact of variations in the µ-map on the reconstructions’ fidelity.
2.2 Imaging Protocol
2.2.1 Animals
Eight adult female mongrel canines (mass 22 – 24 kg) were included in this study using
a protocol approved by The University of Western Ontario animal care committee.
Each canine received either PET/CT and MRI imaging (n = 4) or SPECT/CT
and MRI imaging (n = 4). Particular members of the former experimental group
will be referred to as canines P1 through P4, and the latter as canines S1 through
S4. The canines in both groups were essentially identical in terms of body size and
weight. No canines exhibited any indication of lung pathology which, if present, could
compromise the MRI-based AC as discussed in §2.6.
Anesthesia was initiated with propofol and maintained with 2.0%–2.5% isofluo-
rane. After anesthesia and subsequent intubation, artificial ventilation was conducted
with a Veterinary ADS 1000 system (Engler Engineering Co., Florida, USA).
To facilitate registration of the MRI to PET/CT or SPECT/CT images, the
canines were immobilized on a rigid board for the duration of the experiment. The
field of view was from the neck to the lower abdomen for all modalities.
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2.2.2 Phantom
In addition to the animal data, imaging of an anthropomorphic torso phantom (model
ECT/TOR/P) with a cardiac insert (model ECT/CAR/I) produced by Data Spec-
trum Co. (North Carolina, USA) was carried out. This phantom simulates several
anatomical structures including the lungs, heart, liver, and spine. Further, it accu-
rately simulates the attenuating properties of the human body. When imaged with
MRI, the phantom approximates the signals generated by tissues in vivo, but cer-
tain effects are not reproduced (e.g. very short T2* in the lungs owing to magnetic
susceptibility).
Imaging was done with PET/CT, SPECT/CT, and MRI using the same protocol
as the canine experiments, although the radioisotopes were not bound to biologically
active molecules. The concentration of radioactivity was varied according to anatom-
ical compartment in a ratio of 1:3:12:12 for the lungs, soft tissue, heart, and liver
respectively. A total of 400 MBq 99mTc was used for the SPECT/CT and 800 MBq
18F for the PET/CT.
2.2.3 PET/CT
The PET/CT imaging was conducted on a Discovery VCT system (GE Healthcare).
For the canine studies, 18F-fluorodeoxyglucose (FDG) was selected as the radiotracer.
Following an eight hour fast and an intervenous (IV) glucose infusion to promote
cardiac uptake, approximately 250 MBq of FDG was administered. One hour was
allotted for uptake to occur. During the 3D PET acquisition, coincidence rates were
generally around 400 kcps prior to applying any corrections. Each table position
was maintained for 5 minutes. The PET reconstruction was performed using ordered
subset expectation maximization (OSEM) with 3 iterations and 8 groups. The re-
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constructed volumes’ in-plane resolution was 5.47 mm × 5.47 mm (matrix size 128
× 128) with a slice thickness of 3.27 mm.
The CT acquisition was collected on exhalation with 140 kVp and 30 mAs. The
in-plane resolution was 1.37 mm × 1.37 mm (matrix size 512 × 512) with a slice
thickness of 3.75 mm.
2.2.4 SPECT/CT
The SPECT/CT imaging was conducted on a Symbia T6 system (Siemens Medical).
For the canine studies, 99mTc-sestamibi (MIBI) was selected as the radiotracer. Fol-
lowing an eight hour fast, approximately 300 MBq of MIBI was administered. Three
hours were allotted for uptake to occur. The time per SPECT projection was 30 s and
a total of 180 projections were collected. The SPECT reconstruction was performed
in the same manner as the PET reconstruction, i.e., OSEM with 3 iterations and 8
groups. The reconstructed volume had an isotropic resolution of 4.8 mm (in-plane
matrix size 128 × 128).
The CT acquisition was collected on exhalation with 130 kVp and 20 mAs. The
in-plane resolution was 0.98 mm × 0.98 mm with a slice thickness of 5 mm.
2.2.5 MRI
The MRI was conducted on a Verio 3 Tesla system (Siemens Medical). Data collec-
tion was carried out using a rapid acquisition with refocused echoes (RARE) pulse
sequence (TE = 13 ms, TR = 1910 ms) with end-expiration respiratory gating for
the canine experiments via a respiratory bellows. RF transmission was through the
whole-body coil while both the spine array and body matrix coils were used for recep-
tion. The MRI images had an in-plane resolution of 3.13 mm × 3.13 mm with a slice
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thickness of 5 mm. The FoV was 400 mm in each dimension (matrix size 128 × 128
× 80). The flip angle was 150◦, the bandwidth per pixel was 130 Hz, the echo train
length was 9, and averages = 1. Total imaging time was approximately 5 minutes.
2.3 Image Processing
2.3.1 µ-Map Generation
2.3.1.1 CT-Based
The CT images from both the PET/CT and SPECT/CT were resampled to match the
voxel size of the PET and SPECT reconstructions, respectively. The voxel intensities
were subsequently converted from Hounsfield units to attenuation coefficients (µ-
coefficients) via a bilinear scaling approach [2, 3]. The CT associated with the SPECT
scan was mapped to µ-coefficients at 140 keV, while the CT associated with the PET
scan was mapped to µ-coefficients at 511 keV. The slopes and y-intercept used in the
mappings were calibrated specifically for each scanner.
2.3.1.2 MRI-Based
A simple MRI-based AC method designed to produce similar µ-maps as multiple
approaches described in the literature [15, 23, 25] was developed and implemented
in Matlab v7.4.0 (The MathWorks, Massachusetts, USA). This algorithm was used
for both the phantom and animal experiments, which was only possible because the
phantom was anthropomorphic. The algorithm was based on image segmentation,
and in particular, classified each voxel in the MRI image as either air, lung, or soft
tissue. Subsequently, each material was assigned a constant µ-coefficient (Table 2.1).
Image segmentation commenced by separating foreground from background air
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Table 2.1: µ-coefficients assigned to materials by MRI-based AC algorithm.
Attenuation coefficient (cm−1)
Energy (keV) Air Lung Soft tissue
140 0 0.031 0.149
511 0 0.026 0.096
using a single, empirically derived threshold of 25% the mean slice intensity, excluding
the darkest 5% of pixels. “Holes” in the foreground mask (e.g. from air in the
lungs falling below the threshold) were automatically filled in. All voxels outside
the foreground mask were classified as air. The MRI image then was normalized by
setting the mean foreground signal intensity of each axial slice to 1.
The lungs were identified using a level set algorithm implemented in ITK-SNAP
[30], a free open-source segmentation software. The seed voxels used to initiate the
level set were automatically extracted in Matlab. In particular, regions of low signal
intensity within the subject were identified by applying a second empirically derived
threshold to MRI voxels within the foreground mask. Low signal regions residing
outside the lungs were excluded using connected-component analysis. Specifically,
only the largest 3D, 26-connected region was retained for use as seed voxels for the
level set.
To complete the lung segmentation, the MRI image and lung seed voxels were
exported to ITK-SNAP. The MRI image was preprocessed using an intensity region
filter that mapped low-signal regions to a value of 1 and high-signal regions to a value
of 0 with a sigmoidal transition centred at 0.6. Following pre-processing, the sparse
field level set algorithm was initiated. The propagation and curvature terms were set
to 1 and 0.2, respectively. The level set was run until convergence was achieved, and
the resulting lung segmentation was imported back into Matlab.
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The last step in the segmentation was soft tissue identification. All voxels con-
tained in the foreground mask that had not been designated as lung were deemed to
be soft tissue.
Finally, the MRI-based µ-map (MRI µ-map) was registered to the CT-based µ-
map (CT µ-map). The registration procedure is described in §2.3.2. Once the µ-maps
were aligned, the patient bed present in the CT µ-map was added to the MRI µ-map.
2.3.2 Registration
Although the purpose of the image registration was to align the MRI µ-map with
the CT µ-map, the spatial transform relating the two was obtained by registering the
original MRI image to the CT µ-map. This prevented the registration algorithm from
inadvertently “correcting” segmentation errors in the MRI µ-map by forcing poorly
segmented regions into alignment with the silver standard.
The registration algorithm was implemented using the Insight Segmentation and
Registration Toolkit (ITK) [12], an open source software available at www.itk.org.
Since the registration was intermodality in nature, Mattes mutual information [16]
(a quantity measuring the mutual dependence of two random variables) was selected
as the similarity measure. For the phantom, a rigid transformation model was used.
However, for the canine studies the transformation model was hierarchical, evolving
sequentially from rigid to affine to non-rigid. The non-rigid transformation model
was originally described by Rueckert et al [20]. Each transform model was iteratively
optimized using a gradient descent scheme prior to evolution to the next model. The
final deformation field was applied to the MRI µ-map, and the registration’s fidelity
was assessed visually.
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2.4 Assessment of MRI-Based AC Quality
2.4.1 Error Analysis
2.4.1.1 Global
The SPECT and PET projections were reconstructed twice, once with the CT µ-
map, and once with the derived MRI µ-map. These nuclear medicine images will be
denoted SPECTCT, SPECTMRI, PETCT, and PETMRI. This notation is extended in
§2.4.2. For reference, reconstructions without any AC were also created and will be
denoted SPECTnone and PETnone.
Global errors in the SPECTMRI and PETMRI images were assessed in a tissue
specific fashion. By manually thresholding the CT µ-maps, lung, soft tissue, and bone
voxels were extracted. For the phantom and each subject, three voxel-by-voxel scatter
plots of approximate versus true activities were created, one per tissue type. The
activities were normalized by expressing them as a fraction of the maximal tissue and
subject specific true activity (after AC as per the CT-based µ-map). Linear regression
was performed on each scatter plot to obtain a line of best fit (LOBF). Systematic
bias of the SPECTMRI and PETMRI images was reflected in the LOBF’s slope (m)
and y-intercept (b), while precision was reflected in the correlation coefficient (R2).
In the animal experiments, m, b, and R2 were compared statistically between
the SPECT and PET scatter plots. In total, 9 comparisons were conducted (3 tissue
types × 3 LOBF parameters). The comparisons were conducted using two-tailed, two
sample t-tests. The variances of the samples being compared were not assumed to be
equal. The level of statistical significance was set at α = 0.05, which was adjusted to
α = 0.0055 by the Bonferroni correction for multiple comparisons.
104
2.4.1.2 Local
An approach based on volumes of interest (VOIs) was used to analyze errors localized
to particular spatial positions. Five 3D VOIs (3 voxels × 3 voxels × 3 voxels) were
defined for the phantom and fourteen VOIs were defined for each canine using the CT
µ-map to determine position (Figure 2.1). A complete list of the VOIs can be found
in Tables 2.4 and 2.5. The mean activity in each VOI was calculated for each nuclear
medicine reconstruction. The error in each SPECTMRI or PETMRI VOI was calculated
and expressed as a percentage of the true activity in the corresponding SPECTCT
or PETCT VOI. These percent errors were compared, one VOI at a time, between
the SPECTMRI and PETMRI images using the same statistical technique described in
§2.4.1.1. Since 14 comparisons were made, α = 0.0035 with the Bonferroni correction.
2.4.2 Sensitivity Analysis
Since multiple MRI-based AC methods are available, each one yielding different MRI
µ-maps, it is valuable to ascertain the sensitivity of SPECTMRI and PETMRI re-
constructions to slight variations in the MRI µ-maps used to create them. To this
end, four variants of the original canine MRI µ-maps were created (the phantom was
not included in this portion of the analysis). This was done by enlarging (dilating)
or shrinking (eroding) the lungs or outer body surface via morphological operations.
The erosion/dilation structuring element was composed of a centre voxel with a single
voxel extending from each face. Five SPECTMRI or PETMRI images were generated
per subject, one for the original MRI µ-map and one for each of the four derivative
MRI µ-maps. To refer to reconstructions made by particular variants of the MRI
µ-map, the SPECTMRI/PETMRI notation is extended by allowing the MRI subscript
to have the following secondary subscripts: MRI0, MRIdl, MRIel, MRIdb, and MRIeb
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Figure 2.1: Sample placement of several VOIs superimposed on CT µ-map (canine
S2). Only 11 of the 14 VOIs are shown. (a) Lungs, humeri, and adjacent to humeri.
(b) Thoracic spine and adjacent soft tissue. (c) Myocardium. (d) Liver.
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representing the original, dilated lung, eroded lung, dilated body, and eroded body
MRI µ-maps, respectively.
Error images expressed as a percentage of true activity were derived from each
reconstruction. The standard deviation of the errors was computed voxel-by-voxel as
a metric of sensitivity to variations in the MRI µ-map. This metric was averaged over
three tissue types (lung, soft tissue, and bone) for each subject. The tissue specific
mean standard deviations of the error were compared between the SPECTMRI and
PETMRI reconstructions using the statistical technique described in §2.4.1.1. One
comparison was made for each tissue type, so α = 0.016 with the Bonferroni correc-
tion.
2.5 Results
Visual inspection of each registered MRI µ-map confirmed the absence of major seg-
mentation or registration errors that could interfere with subsequent analysis. A
typical canine MRI image, MRI µ-map, and CT µ-map are shown in Figure 2.2.
Figure 2.2: Example of an MRI µ-map after image registration. The images are
derived from canine S1. (a) Coronal slice through MRI image. (b) Corresponding
slice through the MRI µ-map. (c) Corresponding slice through the silver standard
CT µ-map. (d) MRI prior to registration for reference.
Each µ-map was applied to projection data which was then processed by the
OSEM reconstruction algorithm to yield a nuclear medicine image. Examples (drawn
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from the canine experiments) of each class of reconstruction (SPECTCT, SPECTMRI0 ,
PETCT, and PETMRI0) are presented in Figure 2.3, as are reconstructions without
AC for comparison (SPECTnone and PETnone). For a more quantitative perspective,
profiles through the images are also provided. SPECTCT and PETCT reconstructions
of the phantom are provided in Figure 2.4.
The global error analysis was based on scatter plots and properties of their LOBFs.
Representative scatter plots are displayed in Figure 2.5, one for SPECT and one for
PET. Both are specific to voxels in soft tissue.
The results of the global analysis are tabulated in Tables 2.2 and 2.3 for the
animal and phantom experiments, respectively. In the animal experiments, R2 was
significantly higher for SPECT than PET in both lung and soft tissue. The trend
was similar in bone, but did not reach statistical significance (p = 0.03). For both
modalities, m tended to be less than its ideal value of 1, excepting soft tissue in
SPECT. However, there was a trend for m to be closer to 1 in SPECT than PET for
each tissue type, with p < 0.025 in all cases. Finally, b was generally very close to
0, except for lung tissue in PET. The results in the phantom were similar, with the
exception that PET demonstrated a notably higher R2 in bone than did SPECT.
To inspect errors on a smaller scale and within particular structures, a local error
analysis based on VOIs was conducted. The results are presented in Tables 2.4 and
2.5 for the canines and phantom, respectively. In the animal experiments, only one
comparison reached statistical significance. However, the mean magnitude of the
error was less for SPECT than PET in twelve of the fourteen VOIs. The errors were
generally acceptable in soft tissue structures, sometimes even if the VOI was adjacent
to bone. Large errors were observed in VOIs within bony anatomy and the lungs,
especially in PET. Similarly, the errors in the phantom were smallest in the soft tissue,
larger in the lungs, and largest in bone. The absolute value of the errors in SPECT
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Figure 2.3: Comparison of SPECT and PET reconstructions. The data presented
are typical. The top row corresponds to SPECT (canine S4) and the middle row
to PET (canine P1). The slices are axial and pass through the heart, which is the
source of the high activity regions. Profiles through the reconstructions are presented
in the bottom row. (a) CT µ-map corresponding to slices in the top row. The red
line indicates the position of the profiles in (i). (b) SPECTnone. (c) SPECTCT. (d)
SPECTMRI0 . (e) CT µ-map corresponding to the slices in the middle row. The
red line indicates the position of the profiles in (j). (f) PETnone. (g) PETCT. (h)
PETMRI0 . (i) Profiles through the SPECT reconstructions. (j) Profiles through the
PET reconstructions. For both (i) and (j), the solid line is through the reconstruction
with CT-based AC, the dashed line is through the reconstruction with MRI-based
AC, and the dotted line is through the reconstruction without AC.
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Figure 2.4: Coronal slices of (a) SPECTCT and (b) PETCT phantom reconstructions.
The lungs, liver, and heart are all visible amongst the background soft tissue.
Figure 2.5: Scatter plots comparing the “true” activities in soft tissue voxels to those
obtained with MRI-based AC. Each scatter plot comes from a single canine. All
the activities have been normalized by expressing them as a fraction of the maximal
tissue and subject specific true activity. Note that although the normalized activities
can assume any value between 0 and 1, the plots focus on regions where most of the
data resides, although insets showing the complete datasets are provided in the top
left corner of each plot. In particular, the axes of the SPECT plot run from 0 to
0.05, while the axes of the PET plot run from 0 to 0.3, the discrepancy owing to the
different uptake characteristics of MIBI and FDG. The LOBF is superimposed on each
scatter plot. (a) Soft tissue scatter plot for a SPECT reconstruction (canine S3). The
equation of the LOBF (calculated using all the data, not just that in the truncated
plots) is y = 1.02x− 1× 10−4 with R2 = 0.998. (b) Soft tissue scatter plot for a PET
reconstruction (canine P2). The equation of the LOBF is y = 0.92x+ 5× 10−3 with
R2 = 0.985.
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Table 2.2: Results from global error analysis. The (dimensionless) LOBF metrics
averaged across all canines are displayed for both SPECT (n = 4) and PET (n = 4)
for three tissue types. Mean values are presented ± standard deviation. Statistically
significant differences between SPECT and PET are bolded. p-values are provided.
Mean ± SD
Tissue Metric SPECT PET p
Lung R2 0.90 ± 0.10 0.21 ± 0.19 0.0019
Lung m 0.90 ± 0.09 0.30 ± 0.23 0.0094
Lung b 0.01 ± 0.01 0.15 ± 0.09 0.0577
Soft tissue R2 0.998 ± 0.001 0.979 ± 0.005 0.0043
Soft tissue m 1.01 ± 0.04 0.93 ± 0.03 0.025
Soft tissue b −5× 10−5 ± 8× 10−5 0.008 ± 0.004 0.032
Bone R2 0.96 ± 0.02 0.87 ± 0.05 0.030
Bone m 0.91 ± 0.01 0.83 ± 0.04 0.021
Bone b −0.004± 0.002 −0.03± 0.03 0.17
Table 2.3: Results from global error analysis on phantom. The (dimensionless) LOBF
metrics are displayed for both SPECT and PET for three tissue types.
Tissue Metric SPECT PET
Lung R2 0.917 0.840
Lung m 1.114 1.027
Lung b −0.027 0.032
Soft tissue R2 0.999 0.995
Soft tissue m 0.998 0.959
Soft tissue b −0.001 0.003
Bone R2 0.751 0.915
Bone m 0.751 0.726
Bone b −0.122 −0.068
111
Table 2.4: Results from local error analysis. The mean percent errors in fourteen VOIs
are presented ± standard deviation for both SPECT and PET images. Statistically
significant differences between SPECT and PET are bolded. p-values are provided.
Mean error ± SD (%)
VOI SPECT PET p
Left lung −5.1± 17.5 −25.7± 11.6 0.10
Right lung −8.9± 14.3 −45.2± 25.7 0.060
Rostral liver 0.1± 9.6 −6.8± 1.5 0.25
Caudal liver −3.2± 2.6 −5.6± 0.9 0.17
Medial left ventricle −3.6± 5.3 −4.1± 1.4 0.88
Lateral left ventricle 2.6± 4.2 −10.6± 11.4 0.099
Thoracic vertebra −8.9± 2.6 −16.9± 6.0 0.069
Lumbar vertebra −28.3± 7.6 −23.4± 5.8 0.35
Left humerus −9.2± 1.9 −14.5± 5.8 0.17
Right humerus −13.4± 1.6 −19.6± 6.0 0.13
Near thoracic vertebra −5.7 ± 1.5 −10.7 ± 1.1 0.0022
Near lumbar vertebra −21.8± 7.0 −13.8± 7.3 0.16
Near left humerus −4.3± 5.4 −8.0± 2.5 0.28
Near right humerus −4.3± 0.9 −5.0± 2.4 0.063
were smaller than those in PET in three VOIs, approximately the same in one (the
myocardium), and larger in the remaining VOI (the spine).
To assess the sensitivity of reconstructions to variations in the MRI µ-map, mul-
tiple reconstructions were generated using the original canine MRI µ-map and four
derivatives. Referring to Figure 2.6, one can see both how the MRI µ-map was mod-
ified and how the PET reconstructions were influenced as a result. Figure 2.7 is
analogous, but presents data from a SPECT scan. The reconstructed activity at a
voxel is linearly related to its error, and thus Figure 2.6 parts (d) and (e) provide
some insight into the origin of the metric used in the sensitivity analysis. In particu-
lar, a pronounced dependence of activity on the MRI µ-map implies the same of the
error, and consequently a high standard deviation of the error taken across all five
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Table 2.5: Results from local error analysis on phantom. The percent errors in five
VOIs are presented for both SPECT and PET images.
VOI SPECT PET
Left lung 12.8 17.0
Right lung 5.3 10.4
Liver −0.1 −3.6
Myocardium 1.7 −1.4
Spine −51.8 −44.4
reconstructions.
The results of the sensitivity analysis, broken down by tissue type, are presented
in Figure 2.8. In both lung and soft tissue, PET was more sensitive to changes in the
MRI µ-map than was SPECT. For both modalities, the lung was the most sensitive
tissue while bone was the least.
2.6 Discussion
The goal of the present study was to compare the fidelity of MRI-based AC in SPECT
versus PET. The issue was investigated using a three part analysis identifying global
quality, local quality, and a sensitivity to MRI µ-map variations. Each component of
the analysis points towards the same conclusion: SPECTMRI approximates SPECTCT
better than PETMRI approximates PETCT.
A suggestion of SPECTMRI’s superiority over PETMRI can be readily observed in
Figure 2.3. Visually, it is difficult to identify any differences between the SPECTMRI0
and SPECTCT images. In contrast, although the PETMRI0 image does closely re-
semble its PETCT counterpart, some discrepancies are obvious. Notably, PETMRI0
exhibits reduced activity in parts of the lungs and both humeri. Further, deviations
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Figure 2.6: Example of the variations induced in a PET reconstruction (canine P3) by
alterations in the MRI µ-map. (a) and (b) are visual depictions of how the MRI µ-map
was modified. Either the lung (a) or the body contour (b) segmentation was altered.
The colours indicate the border of the structure when it was eroded (yellow), left
unchanged (green), or dilated (blue). The PET reconstruction corresponding to the
unchanged MRI µ-map is presented in (c). Profiles were taken through the blue line.
(d) Profiles from reconstructions produced by altering the lungs (i.e. PETMRIel and
PETMRIdl , with PETMRI0 for reference). (e) Profiles from reconstructions produced by
altering the body contour (i.e. PETMRIeb and PETMRIdb , with PETMRI0 for reference).
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Figure 2.7: Example of the variations induced in a SPECT reconstruction (canine S1)
by alterations in the MRI µ-map. The SPECT reconstruction corresponding to the
unchanged MRI µ-map is presented in (a). Profiles were taken through the blue line.
(b) Profiles from reconstructions produced by altering the lungs (i.e. SPECTMRIel
and SPECTMRIdl , with SPECTMRI0 for reference). (c) Profiles from reconstructions
produced by altering the body contour (i.e. SPECTMRIeb and SPECTMRIdb , with
SPECTMRI0 for reference).
Figure 2.8: Results of the sensitivity analysis broken down by tissue type. The dark
bars correspond to SPECT and the white bars to PET. Asterisks denote statistically
significant differences. Error bars represent the standard deviation of the sample.
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are present in soft tissue. These are made most apparent by examining the profiles
through the PET reconstructions from −120 mm to −40 mm and from 60 mm to 75
mm. In both regions, PETMRI0 overestimates the true activity. In comparison, the
profile through the SPECTMRI0 image is a near perfect match with SPECTCT.
Another comparison of SPECTMRI and PETMRI’s performance in soft tissue is
presented in Figure 2.5. These are scatter plots of estimated versus true activity in
every soft tissue voxel, a more comprehensive point of view than profiles, but still
limited to individual canines. The main point to note is that the spread of points
about the LOBF in PET is much wider than in SPECT. This implies that given a
particular true activity at a voxel, PETMRI is less able to make a consistent estimate
(good or bad) of the truth than SPECTMRI. In other words, SPECTMRI has greater
precision than PETMRI. This trait was quantified by computing R
2 of the LOBF.
Tables 2.2 and 2.3 summarize the findings of the global analysis. With respect to
R2, it was confirmed that SPECTMRI is more precise than PETMRI within lung and
soft tissue. The same trend appeared within bone in the animal experiments but was
reversed in the phantom. In the canine studies, the correlation coefficient computed
for soft tissue in PET (R2 = 0.979 ± 0.005) agrees closely with values reported by
other groups that validated MRI-based AC algorithms for PET images of the whole
body (R2 = 0.985 ± 0.006) [23] and brain (R2 = 0.968 ± 0.011) [10]. However, the
results reported here are the first time that R2 has been computed within different
tissue types as opposed to over the entire image.
In both the animal and phantom experiments, precision is better in soft tissue
than in bone or lung. One aspect of the explanation relates to the variation of µ-
coefficients within each tissue type. Although soft tissue does exhibit some variability,
it is not as pronounced as the other two tissues. For instance, not only do the at-
tenuating properties of bone depend on whether the bone is cortical or cancellous,
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but on the subject as there are large differences in bone density between individuals
[14]. The situation is equally complicated in the lungs because in addition to wide
inter-subject variability, the observed µ-coefficient is a function of inflation and grav-
itational dependency [27]. Further, the presence of pathology affecting the bones or
lungs can cause each tissue’s µ-coefficient distribution to deviate significantly from
healthy population norms. MRI-based AC would benefit greatly from a means to
measure patient specific µ-coefficients. A potential approach to this end is to utilize
ultrashort echo time (UTE) pulse sequences. UTE sequences have already been used
to aid in bone segmentation for MRI-based AC [4, 13], and have shown promise infer-
ring the density of both bone [19, 29] and lung [26] tissue. However, if UTE (which
can take well over ten minutes) is to be used in addition to conventional sequences,
imaging time for attenuation correction is lengthened which is undesirable from a
clinical standpoint.
Admittedly, physiological variation within the µ-coefficient distribution cannot
adequately explain why R2 was reduced in the phantom’s simulated bone, which is
a homogenous material. Of importance, there was no true activity in the simulated
bone, so activity localized to this region was due to scatter and the partial volume
effect. It is therefore likely that the reduced R2 is related to these phenomena rather
than AC. Indeed, the simulated spine having a relatively small diameter is susceptible
to partial voluming and presents challenges for scatter correction which struggles at
high spatial frequencies.
The other two metrics in the global analysis, m and b, measured systematic bias
of the MRI-based reconstructions. Generally, b was approximately nil, indicating that
the activity in SPECTMRI/PETMRI reconstructions was not over- or underestimated
by an additive constant. With regards to m, the ideal value is 1, and deviations from
this value imply a consistent over- or underestimation of true activity by a constant
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multiplicative factor. In all cases save one, m was closer to 1 in SPECTMRI than
PETMRI, indicating SPECTMRI has less systematic error. Although the results were
not statistically significant, the trend was strong with p < 0.025 for each compari-
son. Generally m < 1, suggesting activity was systematically underestimated. One
contributor to this bias is that bone was neglected in the MRI µ-maps, leading to
underestimated activity both within and in proximity to bony anatomy (Table 2.4).
Similar findings have been reported by several groups [15, 23, 25].
Another factor leading to systematic underestimates of activity was a mismatch
between the predefined µ-coefficient assigned to lung parenchyma (Table 2.1) and
the actual mean lung µ-coefficient of the canines in the experiment. The numbers
used in this work were were taken from published values [2, 11], but as previously
mentioned, there is a great deal of variation of µ-coefficients in lungs. The 511 keV
µ-coefficients assigned to lung tissue in other MRI-based AC algorithms are diverse,
including 0.018 cm−1 [15], 0.024 cm−1 [23], and 0.03 cm−1 [25]. The choice of optimal
µ-coefficients for segmented MRI µ-maps is non-trivial, depending on the population
under investigation and the efficacy of scatter correction (narrow-beam versus broad-
beam geometry). This will remain an important issue in MRI-based AC and warrants
further study.
The primary result from the local analysis was that the magnitude of the observed
errors were smaller in SPECTMRI than PETMRI for twelve of the fourteen canine VOIs
and three of the five phantom VOIs. Admittedly, only one comparison between the
canine groups reached statistical significance. This is best understood by recognizing
that distribution of errors at a single VOI across several canines can be quite wide,
owing to differences in local MRI µ-map quality. Likely, the statistical power required
to reach significance when comparing these broad distributions was not met with four
canines in each group. Nevertheless, the pattern remains clear.
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The final component of the analysis was the assessment of the sensitivity of
SPECTMRI/PETMRI reconstructions to variations in the MRI µ-map. As exhibited
in Figure 2.8, PETMRI was more sensitive than was SPECTMRI within lung and soft
tissue, although no difference was seen in bone. When combined with the findings
of the global and local analyses, this result indicates that not only is SPECTMRI
more quantitatively accurate than PETMRI, the accuracy is less dependent on the
characteristics of the MRI µ-map itself.
The sensitivity metric (plotted on the y-axis of Figure 2.8) has an interesting
interpretation: increasing or decreasing the segmented size of the lungs or body by
one voxel will change the estimated activity, on average, by the value of the sensitivity
metric. With this in mind, the results of the sensitivity analysis signify the importance
of accurate segmentation in this class of MRI µ-map. Further, they provide some
insight into the magnitude of quantification errors due to misregistration of the CT
µ-map and MRI µ-map since misregistration makes it appear that the MRI µ-map
was segmented erroneously.
With all three components of the analysis indicating that MRI-based AC is more
reliable in SPECT than PET, it is natural to seek an explanation. Indeed, the re-
sult is counterintuitive in that the mechanics of attenuation correction in SPECT are
more complicated than in PET; the former generally relies on iterative algorithms
with embedded attenuation correction while the latter reduces to pixel-by-pixel mul-
tiplication of two sinograms prior to reconstruction. That said, AC relies on entities
called AC factors derived from line integrals through the µ-map. In SPECT, since one
photon is emitted per radioactive decay, the line integrals traverse from the decay site
to the site of detection. In PET, each decay produces a positron which subsequently
annihilates, generating a pair of photons emitted at 180◦ to one another. As both
photons must be detected to register the decay event, the line integrals pass between
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the two detectors involved. In short, the line integrals in SPECT are shorter than
those in PET, and thus tend to generate smaller AC factors. However, SPECT is
typically done at lower photon energies than PET and therefore its µ-maps are com-
prised of higher µ-coefficients, tending to generate larger AC factors. Of these two
phenomena, the line integral length generally has more influence, and consequently
SPECT has lower AC factors than PET. (As an illustration, in the profiles presented
in Figure 2.3, notice that there is a larger difference between PETnone and PETCT
than SPECTnone and SPECTCT.) Consequently, differences between the MRI µ-map
and CT µ-map are not magnified in SPECT to the extent that they are in PET.
Thus, MRI-based AC is more forgiving in SPECT than in PET.
The present study contains some inherent limitations. For instance, there are
several varieties of MRI-based AC algorithms, of which only one is investigated. Al-
though it is plausible that the results of this experiment hold for related algorithms,
this may not be so for other techniques. Further, the segmentation used to generate
MRI-based µ-maps was rather simple, only comprising three tissue types; notably,
bone was excluded. However, to the best of our knowledge no group has successfully
implemented a whole-body MRI-based AC algorithm accounting for bone, and such
an endeavour is beyond the scope of this paper.
Another limitation is that, due to practical considerations (excessive length of
anaesthesia and concurrent use of two radiotracers thereby interfering with photon
detection), different cohorts of canines were used for SPECT and PET imaging. Imag-
ing the same animals with both modalities would remove a source of variation in the
data and potentially improve the statistical power of the study. Such an experimental
design would be useful to pursue in future work.
Finally, due to cardiac and respiratory motion, there was a fundamental mismatch
between both the CT- and MRI-based µ-maps and the emission data. The µ-maps
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were acquired at expiration whereas the emission data was ungated. The emission
data and corresponding reconstructions were therefore blurred over the respiratory
cycle, a phenomenon that was not reflected in the µ-maps which are more akin to
snapshots in time. However, as this effect was present for both nuclear imaging
modalities, it is unlikely that it would significantly alter the conclusions described in
this work.
In summary, we have demonstrated that MRI-based AC in SPECT performs bet-
ter than PET. Specifically, it is more precise, more accurate, and less sensitive to
the particulars of the MRI µ-map. The implication is that if an MRI-based AC algo-
rithm has been adequately validated for application to PET, it can it be appropriately
applied to SPECT as well.
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Chapter 3
Variable Lung Density Consideration in
Attenuation Correction of Whole-Body
PET/MRI∗
3.1 Introduction
After a decade and a half of development, human whole-body PET/MRI systems are
now a reality [12]. It has been widely speculated that PET/MRI will prove useful
in several clinical disciplines [10, 23, 26], a prediction that is in the nascent stages of
realization [1, 34]. However, without a means of attenuation correction (AC), accurate
quantification in PET is not possible.
Multiple approaches have been proposed to create MRI-based attenuation maps
(µ-maps) [3, 13, 14, 18, 22, 25, 29, 31, 32]. However, none measure the attenuation
coefficients (µ-coefficients) of the lungs, which vary both between individuals [11]
and within a given individual [6, 17] and are influenced by inflation [11, 17, 35],
gravitational dependency [6, 35], and pathology [7, 17, 19].
∗The contents of this chapter have been published as: H.R. Marshall, F.S. Prato, L. Deans, J.
The´berge, R.T. Thompson, and R.Z. Stodilka. Variable lung density consideration in attenuation
correction of whole-body PET/MRI. J Nucl Med, 2012. Epub ahead of print.
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Visualizing lung parenchyma with MRI is challenging. The lungs have a low
proton density [9] and short transverse relaxation time (T2*) [2, 8], compromising
available MRI signal. Also, the lungs are mobile and highly vascular, generating
motion and flow artifacts, respectively [9].
In this work, an MRI-based AC method that incorporates patient specific mea-
sures of lung µ-coefficients is developed. First, a standard MRI pulse sequence capable
of visualizing lung tissue is described. Next, the relationship between MRI signal and
CT signal in the lungs is evaluated. Said relationship was used to create µ-maps with
patient specific µ-coefficients. The quantitative fidelity of PET reconstructions pro-
duced using these µ-maps was compared to reconstructions done with µ-maps that
assumed a constant µ-coefficient in the lungs across all subjects.
3.2 Materials and Methods
3.2.1 Experimental Protocol
Five canines were imaged with PET/CT and MRI. One set of PET emission data
was collected per canine, but CT scans were acquired at three respiratory states (via
a ventilator) to simulate different lung densities. The CT scans yielded a clinical
quality CT (CTclin) and a pre-µ-map for AC (CTpre-µ). Two types of MR image were
acquired: one of the whole body (MRIWB) and one of the lungs (MRIlung). As with
CT, MRI was acquired at three respiratory states. Further, MRIlung was acquired at
four TEs enabling the computation of a lung T2* map (MRIlungT∗2) and extrapolated
proton density map (MRIlungPD). The MRIlung image with the shortest TE was given
the name MRIlungSTE, where STE stands for short TE.
The MRI signal was related to CTclin signal in the lungs rather than 511 keV
µ-maps because the latter exhibited severe partial volume effects. First, MRIlungSTE
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was registered to CTclin. Three scatter plots of CTclin lung signal versus MRIlungSTE
signal were produced: one relating signal intensities at individual voxels, one relating
mean signal intensities of coronal slices—coronal slices were chosen to preserve the
dorsal/ventral lung density gradient that arises in supine subjects [6, 17], and the last
relating mean signal intensities of the lungs in their entirety. Linear regression was
carried out on each scatter plot, and the resulting mappings were termed voxel-by-
voxel, slice-by-slice, and global, respectively. The process was repeated for MRIlungT∗2
and MRIlungPD, but for reasons discussed in the results, only MRIlungSTE was used to
create µ-maps.
Next, multiple MRI-derived pre-µ-maps (CT-like objects that the PET/CT scan-
ner converts to µ-maps) were formed. First, MRIWB was segmented into air, lung,
and soft tissue. Air and soft tissue were assigned values of −1000 HU and 0 HU, re-
spectively. Three pre-µ-maps were formed by registering MRIlungSTE to MRIWB, and
applying either the voxel-by-voxel, slice-by-slice, or global mappings to the lungs.
PET reconstructions using these pre-µ-maps are denoted PETvoxels, PETslices, and
PETglobal, respectively. Eleven pre-µ-maps were formed by assigning the lungs a con-
stant CT number ranging from −900 HU to −400 HU in 50 HU increments. PET
reconstructions using these pre-µ-maps are referred to by subscripting the CT num-
ber assigned to the lungs, e.g. PET−650. Reconstruction using any MRI- or CT-based
µ-map, are termed PETMRI and PETCT, respectively.
The quality of the PETMRI reconstructions was assessed by comparison to PETCT.
The analysis included both global and local components. Statistical testing was done
with ANOVAs and Tukey’s tests.
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3.2.2 Subjects
This work was conducted on five female beagles (mass 8-12 kg). The protocol was
approved by The University of Western Ontario’s animal care committee.
Anesthesia was initiated with propofol and maintained with 2.0-2.5% isofluorane.
After intubation, artificial ventilation was conducted with a Veterinary ADS 1000 sys-
tem (Engler Engineering Co., FL, USA). To facilitate coregistration of the PET/CT
and MRI images, the canines were immobilized on a rigid board during the experi-
ment.
3.2.3 Imaging
Imaging consisted of an 18F-FDG PET/CT on a Discovery VCT (GE Healthcare) and
an MRI on a Verio 3 T (Siemens Medical). Following an overnight fast (mimicking
the clinical protocol for whole-body PET/CT), the 18F-FDG was administered intra-
venously one hour prior to the PET/CT. The injected activity was approximately 10
MBq/kg. The acquisition was 3D with 5 minutes/table stop. Reconstructions were
done with ordered subset expectation maximization (2 iterations, 28 subsets). The
PET images had in-plane pixel size of 5.47 mm × 5.47 mm (128 × 128 matrix size)
with 3.27 mm slice thickness. The acquisition was ungated.
CTs were acquired at three respiratory states: functional residual capacity (FRC)
was attained by halting ventilation and two levels of inspiration were achieved by
applying a positive inspiratory pressure (PIP) of 8 cm H2O and 16 cm H2O.
All CT scans had a kVp of 140, a mAs of 110, and were reconstructed with filtered
back projection. CTclin had an in-plane pixel size of 0.98 mm × 0.98 mm, a matrix
size of 512 × 512, and slice thickness of 3.27 mm. CTpre-µ had a larger in-plane
pixel size (1.37 mm × 1.37 mm). The scanner converted CTpre-µ into a µ-map by
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downsampling via voxel averaging to a 128 × 128 matrix size, smoothing with a
Gaussian filter (full-width half-maximum 10 mm), and then applying a lookup table.
The MRI protocol was repeated for each respiratory state. MRIWB was a 2D
Turbo-FLASH with a TR of 392 ms, TE of 1.3 ms, 1 signal average, in-plane pixel size
of 1.95 mm × 1.95 mm, matrix size of 128 × 128, axial slice thickness of 5 mm without
gaps, flip angle of 10◦, pixel bandwidth of 630 Hz/pixel, and anterior/posterior phase
encode direction. The acquisition was spread over four table positions aligned with
the isocentre, each consisting of 36 slices acquired in 15 s. MRIlung was also acquired
with Turbo-FLASH, but with some altered parameters: a TR of 121 ms, TE of 0.75
ms (shortest allowable TE given the other parameters), in-plane pixel size of 1.87
mm × 1.87 mm, coronal slice thickness of 10 mm without gaps, pixel bandwidth of
1532 Hz/pixel, and right/left phase encode direction. The acquisition was acquired
in one table position and consisted of 18 slices. MRIlung was cardiac gated in diastole
via three lead ECG. Imaging time was approximately 10 s. MRIlung was repeated
three more times with three different TEs of 0.85 ms, 0.95 ms, and 1.03 ms (longest
allowable TE given the other parameters) to compute MRIlungT∗2 via a voxel-by-voxel
exponential fit as a function of TE.
MRIlungSTE was normalized to the signal from a reference vial of saline placed
next to the canine’s neck. MRIlungPD was computed by voxel-by-voxel extrapolation
of MRIlungSTE to TE = 0 ms via MRIlungT∗2 .
Radio frequency (RF) transmission was via the body coil and signal reception was
through elements of the spine array, body matrix, and large flex RF coils adjacent
to the field of view. The body matrix was secured loosely to avoid obstructing chest
wall expansion. Prescan normalization was carried out prior to each acquisition to
reduce RF shading.
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3.2.4 Image Registration
MRIlungSTE, MRIlungT∗2 , and MRIlungPD were registered to CTclin in order to generate
the mappings. Resolution was matched by voxel averaging. Registration was car-
ried out using the Insight Segmentation and Registration Toolkit (ITK) [16]. Mattes
mutual information was chosen as the similarity measure since it is suitable for inter-
modality registrations. At FRC, there was excellent anatomical agreement between
CTclin and MRIlung so a rigid transform was used. For the other two respiratory states,
the diaphragm’s position oscillated slightly. To accommodate the minor discrepan-
cies in lung inflation, a hierarchical transform model was chosen, evolving sequentially
from rigid to affine to non-rigid [24]. Evolution of the transform type was initiated
when the previous transform converged on a solution.
Similarly, MRIlungSTE was registered to MRIWB and completed MRI-based pre-µ-
maps were rigidly registered to the CT-based pre-µ-maps. Once aligned, the back-
ground of the CT-based pre-µ-map (patient bed, rigid board securing the canines’
positioning, etc.) was added to the MRI-based pre-µ-map.
3.2.5 Image Segmentation
MRIWB was segmented into air, lung, and soft tissue using a semi-automated algo-
rithm developed in-house and implemented on Matlab v7.9.0.529 (The MathWorks,
MA, USA). The details of the segmentation algorithm have been described previously
[21]. Briefly, the subject’s body was identified using an empirical threshold. Voxels
outside the body were deemed air. The lungs were segmented by applying a level
set algorithm implemented in ITK-SNAP [36] to seed voxels identified with a second
empirical threshold. The air in the trachea was segmented by hand, and segmentation
errors were corrected manually. All remaining voxels were classified as soft tissue.
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3.2.6 Quantitative Analysis
The global quality of PETMRI images was assessed in lung, soft tissue, and bone.
Masks of these tissues were generated by thresholding the CT-based pre-µ-map (−950
HU < lung −150 HU < soft tissue 100 HU < bone). Only axial slices containing
lung were included in the analysis. For each PETMRI reconstruction, a voxel-by-voxel
scatter plot of PETMRI activity versus PETCT activity was created in lung, soft tissue,
and bone. The scatter plots were normalized to the maximum PETCT activity. Three
metrics were computed on each scatter plot: (1) the integral from 0 to 1 of the squared
difference between the line of best fit (LOBF) computed via linear regression and the
line of identity, D2y=x, (2) the squared Pearson product-moment correlation coefficient,
R2, and (3) the root mean squared error, E, defined as
√∑n
i=1 (yi − xi)2 /n where
yi and xi are the (normalized) estimated and true activities, respectively, at voxel i,
and n is the number of voxels. D2y=x measures the proximity of the LOBF to the
line of identity, i.e. accuracy. R2 measures the spread of points about the LOBF, i.e.
precision. E is impacted by both accuracy and precision; in particular, E approaches
zero if and only if D2y=x approaches zero and R
2 approaches one.
Each metric was analyzed statistically using a three-way AVOVA (α = 0.05) with
respiratory state, tissue type, and µ-map as factors. Significant results were followed
by Tukey’s test.
Local magnitude of relative error (%) was assessed in eight 1.094 cm × 1.094 cm ×
0.981 cm rectangular volumes of interest (VOIs) (Figure 3.1). Statistical analysis was
the same as above, except the tissue type factor was changed to VOI in the ANOVA.
Steps were also taken to identify experimental errors. Lung segmentation error in
MRIWB was computed as the percent difference in lung volume at FRC as compared
to CTclin. To see whether these errors were dependent on lung inflation, this was
repeated for the other respiratory states and the means and standard deviations were
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Figure 3.1: VOI placement on canine 1 at PIP = 16 cm H2O for local analysis. (A)
Axial CTclin slice with VOIs superimposed. Red = right lung, green = left lung, blue
= peripheral left ventricle, yellow = central left ventricle, purple = vertebral body,
orange = chest wall. (B) The same VOIs superimposed on PETCT. (C) Coronal
CTclin slice with the remaining VOIs. Cyan = vena cava, beige = dome of liver. (D)
These two VOIs superimposed on PETCT.
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compared statistically with a one-way ANOVA and Bartlett’s test for equal variances,
respectively.
The effect of misregistration between MRIlung and CTclin on the voxel-by-voxel
mapping (most sensitive to registration error) was inferred by shifting the registered
MRIlung by −1 cm to +1 cm in 0.5 mm increments along each of the X, Y, and Z
axes, and recalculating R2 as a function of the shift.
3.3 Results
Of MRIlungSTE, MRIlungT∗2 , and MRIlungPD, only MRIlungSTE could be used to predict
CT signal; thus neither MRIlungT∗2 nor MRIlungPD were included in the subsequent
analysis (Figure 3.2). Good agreement between the spatial distribution of lung signal
in CT and MRIlungSTE can be observed in Figure 3.3. The mappings from MRIlungSTE
to CT number are presented in Figure 3.4. A linear relationship was demonstrated
between the modalities.
The MRI-based pre-µ-maps that incorporate lung information are contrasted with
a CT-based pre-µ-map in Figure 3.5. The global mapping retains the least spatial
information, whereas the voxel-by-voxel mapping retains the most.
The results of the tissue-specific analysis are presented in Figure 3.6 and the
ANOVAs are found in Table 3.1. The results of the post hoc test are best visualized
in Figure 3.6; points without overlapping error bars are significantly different. The
µ-map class had little influence on the metrics in soft tissue and bone, but a marked
impact in the lungs. Within the lungs, PETvoxels exhibited the best accuracy, as
reflected by D2y=x. PETslices and PETvoxels were the most precise, as reflected by R
2.
The lowest E was achieved by PETvoxels, followed by PETslices.
The VOI analysis (Table 3.2) revealed that the minimum error in the lungs, heart,
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Figure 3.2: Voxel-by-voxel relationship between (A) MRIlungT∗2 and CT number and
(B) MRIlungPD and CT number. The data from all five canines is plotted on each
scatter plot. Each point’s colour represents the canine’s respiratory state, where dark
blue is FRC, red is PIP = 8 cm H2O, and light blue is PIP = 16 cm H2O. The T2*
estimates were too noisy to make either of these correlations useful.
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Figure 3.3: Spatial correlation between lung signal in CT (left) and MRIlungSTE
(right). A coronal slice from canine 1 at FRC is shown. The MRI is registered
to the CT. The CT image display ranges from −1000 to −700 HU, and the MRI from
0 to 180 arbitrary units.
Table 3.1: Results of ANOVAs on canine PETMRI metrics of overall quantitative
fidelity and quantification error in the myocardium.
Metric Factor F p
D2y=x Respiratory state 4.45 0.01
Tissue 271.41 < 0.0001
µ-map class 11.45 < 0.0001
R2 Respiratory state 13.72 < 0.0001
Tissue 899.97 < 0.0001
µ-map class 3.10 0.0001
E Respiratory state 0.13 0.88
Tissue 570.71 < 0.0001
µ-map class 9.35 < 0.0001
Magnitude of relative Respiratory state 44.65 < 0.0001
error in VOIs VOI 109.21 < 0.0001
µ-map class 25.63 < 0.0001
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Figure 3.4: Relationship between MRIlungSTE signal and CT number. Points on the
scatter plots represent (A) voxels, (B) coronal slices, and (C) all lung tissue. The
LOBF equations are y = 1116x − 916, y = 1223x − 932, and y = 1251x − 937,
respectively. The data from all five canines is plotted on each scatter plot. Each
point’s colour represents the canine’s respiratory state, where dark blue is FRC, red
is PIP = 8 cm H2O, and light blue is PIP = 16 cm H2O. As expected, an increased
volume of air in the lungs reduces both the MRI and CT signals.
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Figure 3.5: Axial slice through four pre-µ-maps obtained from canine 5 at PIP = 16
cm H2O. (A) CT-based. The others are MRI based and incorporate information from
MRIlungSTE via the (B) global, (C) slice-by-slice, and (D) voxel-by-voxel mappings.
The window and level are identical for all images and set to emphasize the lungs.
and liver was achieved by PETvoxels, PETglobal, and PETslices, respectively. Error was
minimized in the chest wall, vena cava, and vertebral bodies by PET−900, PET−700,
and PET−400, respectively. However, in many VOIs the differences were not statisti-
cally significant.
Representative profiles through the PET images are presented in Figure 3.7. The
effect of altering the lungs’ µ-coefficients is propagated into nearby soft tissues, in-
cluding the myocardium, diminishing as the distance from the lungs increases. In this
example PETvoxels is the most representative of the profile through PETCT.
The lungs were undersegmented at FRC by 16% ± 8%, at PIP = 8 cm H2O by
14% ± 12%, and at PIP = 16 cm H2O by 18% ± 11%. Neither the means (p =
0.82) nor the standard deviations (p = 0.81) were significantly different between the
respiratory states.
Regarding the effect of misregistration on the voxel-by-voxel mapping, R2 was
found to be an approximately Gaussian function of shift, peaking at 0.8 when no
shift was applied. To maintain R2 within 10% of its optimum, the maximum allow-
able shift was ±1.25 mm left/right and ±2.75 mm anteriorly/posteriorly or superi-
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Figure 3.6: Three metrics of PETMRIs quantitative fidelity broken down by tissue
type and µ-map class. The metrics include (A) D2y=x, (B) R
2, and (C) E. The
leftmost blocks of data are from within the lungs, the middle blocks from soft tissue,
and the rightmost blocks from bone. Each point within a given block corresponds to
a different PETMRI reconstruction. Error bars indicate 95% confidence intervals.
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Figure 3.7: Sample profiles through PET reconstructions of a canine at FRC. (A)
Transaxial slice through CT-based µ-map for anatomical reference. Profiles were
taken through the cyan line that can be seen to pass through the humeri, lungs,
and heart. (B) Corresponding slice through the PETCT image. (C) Profiles through
PET−900 and PET−400. Profiles through all other PETMRI images are bounded by
these curves. The solid line represents the truth as obtained via PETCT. (D) Profiles
through PETglobal, PETslices, and PETvoxels. Again, the black line represents the truth.
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orly/inferiorly.
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3.4 Discussion
In this work, a means of using MRI to infer the spatial µ-coefficient distribution in
the lungs was developed and tested on five canines. The evidence suggests doing so
improves quantification in PET images.
In Figure 3.6, observe that in lung tissue the µ-map class influences each of the
three metrics of quantitative fidelity; this was statistically significant in all cases
(Table 3.1). Moreover, PETvoxels performed the best according to all three metrics.
Additionally, PETvoxels had the least error in the lung VOIs (Table 3.2). These results
suggest that PETvoxels is the best choice for quantification in the lung.
Though µ-map choice did not influence quantification in soft tissue or bone when
averaged over the whole thorax (Figure 3.6), it did affect structures near the lungs
(Figure 3.7), notably the vena cava and peripheral left ventricle (Table 3.2). In the
latter, there was a benefit to estimating the lung’s µ-coefficients, which is potentially
of clinical significance as even subtle alterations in viability or perfusion PET imag-
ing can impact clinical impression [27]. However, in the vena cava (which crudely
simulated a pulmonary lesion), PET−700 performed the best. This may have been
due to limitation of MRI-based AC algorithms relying on segmentation. Notice in
Figure 3.5A that in the CT-based µ-map the vena cava was subject to the partial
volume effect. Segmentation cannot reproduce this phenomenon as each voxel must
be classified as air, lung, or soft tissue. In the MRI-based µ-maps (Figure 3.5B-D),
the voxels about the vena cava were preferentially deemed soft tissue. The MRI-based
estimates of activity were therefore inflated relative to PETCT. One means of com-
pensating is to underestimate the lung’s µ-coefficients. As the mean lung CT number
across all subjects and respiratory states was −600 HU, PET−700’s apparent success
was probably attributable to undervaluing the true mean by 100 HU. Further, notice
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that PETvoxels achieved the lowest standard deviation in the vena cava, suggesting
that albeit biased, it is the most precise, and therefore amenable to correction with
a scaling factor. In sum, accurate quantification of lung lesions in PET/MRI may
prove challenging even with patient specific estimates of the lungs’ µ-coefficients.
As the amount of adjacent lung tissue near the VOI decreases, so does the lung’s
impact on quantification. For instance, in the central left ventricle, vertebral body,
liver’s dome, and chest wall, the error was never changed by more than 9% based on
µ-map selection, and no statistically significant differences emerged. In these regions,
what µ-coefficients are assigned to the lungs is therefore less important.
The importance of reliable quantification in the heart and lung lesions is clear,
but several potential applications of PET/MRI depend on accurate PET images of
the lung parenchyma itself. For instance, while PET has demonstrated utility in
identifying lung inflammation and infection in cystic fibrosis [20], CT-based AC is
undesirable considering the predominantly paediatric patient population and ionizing
radiation that accompanies CT scans; MRI-based AC could provide a convenient
alternative, consistent with the “image gently” campaign. PET/MRI may also prove
useful in understanding the inflammatory response in acute lung injury; pulmonary
models of 18F-FDG kinetics [30] might be complemented by functional measures such
as perfusion via MRI [15]. There are several other instances where PET/MRI may
be useful for lung imaging [4], all of which will require accurate MRI-based AC of the
lungs.
To the authors’ knowledge, no other approach has been able to measure the lungs’
µ-coefficients. Some assign a constant µ-coefficient to the lungs [21, 22, 31, 32] while
others permit µ-coefficient distributions [13], but none are patient specific. One
method allows patient specific µ-coefficients to be estimated by an iterative recon-
struction algorithm [25], but correct convergence is not guaranteed. Ours is the first
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approach to directly link MRI to CT signal in the lungs, but is subject to several
limitations.
First, there remains a great deal of variance in Figure 3.4A unexplained by the
regression. One source is that the MRI signal is dependent on magnetic timing
parameters (notably T2*), which are location and subject specific [8]. Pure proton
density images would avoid this problem, but our measures of T2* proved too noisy to
reliably extrapolate the signal at TE = 0 µs. Eliminating T2* dependence may prove
even more important if pathology is present, but in this work the impact of disease
on the relationship between MRI and CT lung signal was not assessed. Exploring
how disease affects the connection between MRI and CT signal in the lungs should
be a priority for future work in this area, since ultimately, the method is intended for
patients with pathologies.
Another contributor to the unexplained variance in the scatterplots in Figure 3.4
is registration error. By exploring the impact of misregistration via translation on
R2, it was found that there exists a 1.25 mm to 2.75 buffer (depending on direction)
before the correlation deteriorates beyond 10%. It is difficult to quantify registration
error, especially for non-rigid transformations; however, given the precautions taken
to immobilize the dogs, the visual agreement between the registered images, and the
misregistration buffer, registration error likely had a limited impact on the results.
B1 inhomogeneity also adds to the scatterplots’ variance by making lung MRI
signal a function of spatial position. However, prescan normalization reduced this
problem. Retrospectively, it was found that the prescan normalization was also suffi-
cient to standardize the MRI signal across subjects, rendering the additional step of
normalizing to the signal from a saline vial unnecessary. This, however, may depend
on the manufacturer.
Apart from the assignment of erroneous µ-coefficients in the lungs, a major con-
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tributor to the observed errors in the PETMRI images was missegmentation. The
improper classification of air, lung, and soft tissue can alter quantification, even in
remote regions [21]. Indeed, our analysis found that the lungs were systematically
undersegmented by about 15% in all respiratory states. This problem might be as-
suaged with higher resolution MRI images to better delineate the lung boundaries.
Also, bone was ignored, explaining bone’s higherD2y=x and E than soft tissue’s (Figure
3.6A,C). Neglecting bone propagates underestimates of activity into adjacent tissues,
but this effect is localized and relatively small [28]. Accounting for bone remains a
challenge in MRI-based AC, with only one group doing so for whole-body PET [13].
Another complication is that respiration occurs throughout the PET acquisition
while a single phase of respiration was used to create the µ-maps in this experiment,
a problem referred to as transmission/emission mismatch. Thus, the PETCT image
is not a true gold standard; it may contain errors of considerable magnitude [5].
Nevertheless, these errors are separate from those induced by assigning erroneous µ-
coefficients to the lungs and do not alter the conclusions of this study. On the contrary,
without a means to account for the changing lung µ-coefficients with respiration
[11, 17, 35], optimal correction of the transmission/emission mismatch (via a time-
varying µ-map) would be flawed.
The principle reason that this study was carried out using a large animal model
was that it allowed for precise control of their ventilation; the lungs could be held
at the same respiratory state during the CT and MRI. A means of controlling res-
piratory state in humans would be helpful to extend MRI-based estimates of lung
µ-coefficients to patients. An impediment to translating the methodology described
here to humans is that people necessitate a larger field of view. Accordingly, if reso-
lution were to be maintained, scan time and consequently breath hold duration may
increase. One solution is to eliminate cardiac gating, accelerating the acquisition.
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Gating was employed in this study to facilitate image registration, but was likely
over-conservative. However, eliminating cardiac gating is not a panacea. Additional
problems will inevitably arise when modifying the pulse sequence for humans (e.g. al-
tered signal-to-noise ratio, unanticipated artifacts, etc.), for which different solutions
will be necessary. It should also be noted that this method is not fully automated; if
this approach is to be used clinically, automation is pivotal.
Most of the challenges associated with AC of the lungs in PET/MRI result from
MRI’s difficulty in reliably acquiring signal from lung parenchyma. An exciting
prospect is to use ultrashort TE pulse sequences to overcome lung tissue’s short T2*.
This method has been used to successfully demonstrate a correlation between signal
intensity and lung inflation in mice [33]. However, ultrashort TE pulse sequences are
harder to implement for large fields of view and the acquisition generally takes several
minutes. In the immediate future, standard gradient echo and turbo spin sequences
with relatively short TEs are more tenable [8, 9].
3.5 Conclusion
Until now, MRI-based AC algorithms have treated the µ-coefficients of the lungs as
unknown, undermining quantification in PET images. We have demonstrated that
MRI can be used to infer µ-coefficients and applied this principle to MRI-based AC.
As a result, quantification is clearly improved in the lungs, and is likely improved in
the surrounding tissues.
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Chapter 4
To Segment, Register, or Map? A
Comparison of Three MRI-Based
Attenuation Correction Methods for
Whole-Body PET
4.1 Introduction
There are a several avenues through which PET/MRI technology can be advanced
[26]. One of the most important is the development of robust MRI-based attenuation
correction (AC) strategies [7]. Though the particulars of converting MRI images into
attenuation maps (µ-maps) can vary immensely [1, 3, 6, 8, 12, 14, 15, 16, 17, 21, 22,
24, 27], the majority of approaches can be classified according to three categories:
segmentation, registration, and mapping.
MRI-based AC methods relying on segmentation [3, 12, 15, 16, 17, 22, 24, 27]
divide an MRI image into regions according to composition. Each region is assigned
a representative attenuation coefficient (µ-coefficient). Problems arise in tissues that
are not adequately characterized by a single µ-coefficient, such as the lungs [13, 15].
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Errors also arise from erroneous segmentation [13, 16, 20].
An alternate approach is to align a template µ-map with the patient’s MRI via
image registration [14, 21]. The template may be arbitrarily spatially complex and
offer a continuum of µ-coefficients. However, as the template µ-map is generic, its µ-
coefficients may not accurately reflect the patient’s. Moreover, finding the transform
relating the template µ-map with the patient’s MRI can be challenging. In fact, if
there are anatomical differences between the two, a sensible transform may not even
exist.
Finally, in techniques relying on mapping, one constructs a function that maps
MRI image voxels to µ-coefficients [1, 6, 8, 15]. It places no restrictions on µ-map
complexity and the µ-map is derived directly from the patient. The challenge lies in
finding an appropriate mapping function and input data.
In this work, we implemented three MRI-based AC algorithms employing segmen-
tation, registration, and mapping. We compared their performances quantitatively on
whole-body PET scans of cancer patients. PET scans reconstructed with CT-based
µ-maps were used as the silver-standard. Our aim was to identify some strengths and
weaknesses of each method and, in so doing, determine how they might be combined
synergistically.
4.2 Materials and Methods
4.2.1 Data Acquisition
Twelve oncologic patients (10 male, 2 female, mean age ± SD of 60 ± 10 y) were
imaged from head to pelvis with FDG PET/CT (Discovery VCT, GE Healthcare)
and MRI (Verio, Siemens Medical). The experiment was approved by The University
of Western Ontario’s human research ethics board.
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Following an overnight fast, 5 MBq/kg of FDG was administered intravenously
one hour prior to the PET/CT. During uptake, the patients rested supine in a dark
room. The acquisition was 3D with 210 s/table stop. Reconstructions were done with
ordered subset expectation maximization (2 iterations, 28 subsets). The PET images
had an in-plane pixel size of 5.47 mm × 5.47 mm (128 × 128 matrix size) with 3.27
mm slice thickness. The acquisition was ungated.
The CT scan, acquired during free but shallow breathing, had kVp of 140, mAs
of 110, and was reconstructed via filtered back projection with in-plane pixel size of
1.37 mm × 1.37 mm, matrix size of 512 × 512, and slice thickness of 3.27 mm. The
scanner converted the CT into a µ-map by downsampling, smoothing , and applying
a lookup table.
Following the PET/CT, the patient received an MRI within twenty minutes. The
whole-body MRI (MRIWB) was acquired at functional residual capacity (breath-hold)
with a 2D Turbo-FLASH sequence. The sequence parameters included TR of 786 ms,
TE of 1.32 ms, in-plane pixel size of 1.95 mm × 1.95 mm, matrix size of 256 × 256,
axial slice thickness of 5 mm without gaps, flip angle of 10◦, pixel bandwidth of
630 Hz/pixel, and anterior/posterior phase encode direction. Five table positions,
each with 36 slices and lasting 15 s, were acquired to form the whole-body image. A
separate 2D Turbo-FLASH sequence was also acquired to infer lung density (MRIlung)
[15]. It had TR of 121 ms, TE of 0.75 ms, in-plane pixel size of 3.125 mm × 3.125
mm, matrix size of 128 × 128, coronal slices with thickness of 10 mm (no gaps), flip
angle of 10◦, pixel bandwidth of 1532 Hz/pixel, and right/left phase encoding.
RF transmission was via the body coil and signal reception was through elements
of the spine array, body matrix, and large flex RF coils adjacent to the field of view.
Prescan normalization was carried out prior to each acquisition to reduce RF shading.
The algorithm is proprietary, but achieves similar ends as the N3 correction [23] (a
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well known post processing method to remove low frequency intensity variation).
4.2.2 MRI-Based µ-Maps from Segmentation
MRIWB was segmented into air, lung, soft tissue, and bone using a semi-automated al-
gorithm developed in-house and implemented on Matlab v7.9.0.529 (The MathWorks,
MA, USA). The details of the air, lung, and soft tissue identification have been de-
scribed previously [16], involving empirical thresholding, mathematical morphology,
and level set techniques [25]. However, the addition of a bone class is new, and re-
lied on a support vector machine (SVM) implemented in the open source software
SVMlight [10].
SVMs are supervised learning methods often used for classification or regression
problems, image segmentation being of the former type. The SVM is trained with a
set of data, D = {(xi, ui) |xi ∈ Rq, ui ∈ {−1,+1}}ni=1, where each xi is a vector of q
inputs called features, and ui is a binary variable indicating class membership. If the
xi are plotted in q-dimensional space, two point clouds are defined by the two values of
yi. Provided the point clouds are separated, a “decision boundary” can be constructed
between them and the membership of unseen examples is dictated according to which
side of the boundary they reside. Ideally, the point clouds are linearly separable; that
is, the decision boundary is a hyperplane. In the native q-dimensional space, this is
often not so. Thus, the SVM maps D to a higher (or even infinite) dimensional space
such that the modified D is linearly separable. Subsequently, the SVM computes
the hyperplane that “maximally” separates the point clouds in the high dimensional
space.
Conveniently, the high dimensional mapping is not computed explicitly. The SVM
only relies on inner products of vectors in the high dimensional space, which are
computed by the “kernel function”, k(xi,xj) = φ(xi) ·φ(xj), where φ is the mapping.
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Therefore, φ is implicitly defined by the choice of kernel.
We used a leave-one-out cross-validation approach to train our SVM. That is,
for each patient, D was drawn from all the other patients. For training purposes,
rather than manually segment the bone in MRIWB, we registered each patient’s CT
to their MRIWB and deemed voxels with a CT number greater than 300 HU cortical
bone. Voxels used for training were randomly selected and approximately equally
distributed between “bone” and “not bone” classes.
Each xi comprised 79 features. Three features were cylindrical coordinates (r, θ, z)
normalized in a patient specific fashion. In particular, the z axis ran in the supe-
rior/inferior direction and passed through the patient’s centre of mass as computed
on a binary, thresholded image. The r coordinate was divided by the lungs’ maximal
left/right width, θ was arbitrarily defined to be zero when pointing anteriorly, and z
was set to 0 at the most superior slice and 1 at the most inferior slice, varying linearly
in between. One feature was a measure of body size, computed as the fraction of the
field of view occupied by the patient. Finally, the remaining 75 features were the
intensities of a 5 × 5 × 3 voxel patch surrounding the voxel of interest.
Our kernel was the Gaussian radial basis function defined as:
k(xi,xj) = exp
[‖xi − xj‖2 / (2β2)]
with free parameter β chosen by cross-validation. The induced mapping is to an
infinite dimensional Hilbert space.
Once the four tissue classes were identified, they were each assigned CT numbers:
air was set to −1000 HU, lung to −750 HU, and soft tissue to 0 HU. To further
examine the impact of including bone in the segmentation, bone was set to either 0,
300, 600, or 900 HU; one µ-map was made for each of these values. The segmentation
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of air, lung, and soft tissue took a few minutes, but the bone segmentation lasted
several hours.
4.2.3 MRI-Based µ-Maps from Registration
For a given target MRIWB, the template to be registered was the CT scan of another
patient included in this study. Specifically, the gender-matched individual with the
closest body volume as a fraction of the field of view was designated the template.
This was a crude way to ensure the template and target had similar physiques.
Rather than register the template CT directly to the target MRIWB, a potentially
challenging inter-patient, inter-modality registration, we started by registering the
template patient’s MRIWB to their CT (inter-modality but intra-patient), yielding
an MRI/CT pair. We then registered the MRI component of this pair to the target
MRIWB (inter-patient but intra-modality), carrying the CT along by applying the
same transform.
These registrations, as well as all the others reported in this manuscript, were
accomplished using the BRAINSFit module of 3D Slicer [18]. Briefly, the registration
utilized a hierarchical transform model, evolving sequentially from rigid to affine
to non-rigid [19], with a mutual information similarity metric. The registrations
generally took a few minutes.
4.2.4 MRI-Based µ-Maps from Mapping
To define a mapping between MRI and CT signal, we used a simple modification of the
SVM approach described above. The sampling procedure, features, and kernel were
identical, however the SVM was instructed that it was to solve a regression problem
rather than a classification one. Thus, the labels ui on the training examples were
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actual CT numbers rather than merely +1 or −1. In this case, the SVM was charged
with the task of finding the hyperplane that optimally fit the data, as opposed to the
hyperplane that best divided the data into two clusters. Predictions were made by
computing the value of the hyperplane for the given xi.
There is one caveat, however. The lungs exhibit virtually no signal in most MRI
images, including MRIWB, making it difficult to predict CT number. This is why
MRIlung was collected. In dogs, we have demonstrated that not only does MRIlung
show signal from lung parenchyma, but this signal can be linearly mapped voxel-by-
voxel to CT numbers [15]. Accordingly, we determined a linear mapping between
MRIlung and Hounsfield units in humans; this relationship was used to map the lungs
to CT numbers. The rest of the body was mapped using the regression SVM, which,
like the bone segmentation, took several hours.
4.2.5 Processing the MRI-Based µ-Maps
Each MRI-based µ-map precursor had to be aligned with the PET projection data.
This was done by registering them to the patient’s CT scan. The MRI-based µ-map
precursor derived from segmentation was registered first, and the resulting transform
was applied to the other µ-map precursors, thereby eliminating registration differences
between them.
Once aligned, the background of the CT (patient bed, positioning aids, etc.)
was added to the MRI-based µ-map precursors. They were then imported into the
PET/CT system, and were converted to 511 keV µ-maps using the native software.
To refer to PET images reconstructed using a particular µ-map, a subscript nota-
tion is used. PETCT denotes the image created with the CT-based µ-map (the silver
standard). As for the images created by the MRI-based µ-maps, PETseg0, PETseg300,
PETseg600, and PETseg900 denote those derived from segmentation (the number indi-
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cating the CT number assigned to bone), PETreg that derived from registration, and
PETmap that derived from mapping.
4.2.6 Data Analysis
The data were analyzed two ways: globally in specific tissues and locally in volumes
of interest (VOIs).
The global analysis was conducted in lung, fat, “water” (e.g. muscles and organs),
and bone. Masks of these tissues were generated by thresholding the CT scan (−990
HU < lung ≤ −600 HU, −150 HU < fat ≤ −25 HU < water ≤ 100 HU < bone).
Within each tissue, a voxel-by-voxel scatter plot of estimated activity versus true
activity was created, normalized to the maximum PETCT activity. Three metrics
were computed: 1) D2y=x equal to the integral from 0 to 1 of the squared difference
between the line of best fit (LOBF) computed via linear regression and the line of
identity, 2) R2 which is the squared Pearson product-moment correlation coefficient,
and 3) E = 100(a¯e − a¯t)/a¯t where a¯e is the mean estimated activity and a¯t is the
mean true activity. D2y=x measures the proximity of the LOBF to the line of identity,
i.e. accuracy. R2 measures the spread of points about the LOBF, i.e. precision. E is
the relative error expressed as a percent.
The statistics on the global analysis commenced with a 4 (tissue) × 6 (µ-map)
repeated measures MANOVA (dependent variables =D2y=x, R
2, E). Significant effects
were followed up with 4 × 6 repeated measures ANOVAs applied to each dependent
variable in isolation. When the interaction term was significant, one-way (factor
= µ-map) repeated measures ANOVAs were carried out. Post-hoc testing was via
paired t-tests corrected for multiple comparisons via the Holm procedure [9]. The
significance level was set to 0.05 for all statistical testing. Further, the Greenhouse-
Geisser correction for violated sphericity was applied for all ANOVAs used in this
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study.
For the local analysis, spherical VOIs with a radius of 1 cm were placed in fourteen
standard positions and about pathological lesions in the thorax (n = 13), abdomen (n
= 4), and pelvis (n = 5). Wherever there were two symmetric structures for the VOI
to be placed in (e.g. caudate nucleus), the one on the patient’s right was selected.
The relative error, E, was computed in each VOI. The statistical procedure for this
component of the analysis was the same as that described above, except since there
was only one dependent variable, the initial MANOVA was not necessary. Rather, the
initial test was a 14 (VOI excluding lesions) × 6 (µ-map) repeated measures ANOVA.
The lesions were analyzed separately, commencing with one-way ANOVAs.
4.3 Results
4.3.1 Overview
An example of the three classes of MRI-based µ-map, i.e. derived from mapping,
registration, or segmentation, is shown with the associated CT-based µ-map in Figure
4.1. The results of the global and local analyses are presented in Figure 4.2 and Figure
4.3, respectively. The data used to derive the linear relationship between MRI and
CT lung signal that was used in the mapping technique are presented in Figure 4.4.
The equation we calculated was CT = 3.28×MRI− 864.
4.3.2 Global
The statistical results of the global analysis are as follows. The 4 (tissue) × 6 (µ-map)
repeated measures MANOVA revealed a significant multivariate within-subjects effect
for tissues (Wilks’ λ = 0.01, F (9, 75.596) = 47.032, p < 0.0005), for µ-maps (Wilks’
159
Figure 4.1: Coronal slice through µ-maps from subject one. Superimposed in colour
are the relative errors in the corresponding PET reconstructions. Blue represents
underestimated activity and red overestimated activity, from ?50% to +50% error.
(A) CT-based µ-map. (B) MRI-based µ-map obtained via mapping. A large portion
of the skull is missing (white arrow), resulting in underestimated activity in the head.
Also, parts of the vertebrae are filled with air (black arrow). (C) MRI-based µ-map
obtained via registration. The skull is present (white arrow), and error in the head
is low. However, the patient’s hilar mass is not reproduced (black arrow), invok-
ing underestimated activity. Further, large errors are present throughout the lung
parenchyma (green arrow) from mismatches in vasculature between the patient and
template. (D) MRI-based µ-map obtained via segmentation. The skull is segmented
(white arrow), but cranial activity is underestimated because the assigned bone µ-
coefficient is too low. Mis-segmentations are also visible: bone is oversegmented in
the hilar mass (black arrow), and undersegmented in the scapula (green arrow), with
associated errors in activity. Additionally, the impact of classifying fat as water is an
overestimate of activity (pink arrow).
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Figure 4.2: Results of the global analysis, broken down by tissue type. All values are
mean ± SD. (A) Accuracy, i.e. D2y=x. (B) Precision, i.e R2. (C) Relative error, i.e. E.
The results of statistical testing are indicated by the sets of parallel horizontal lines
commencing with a green dot. The comparisons were made between all six µ-maps
for a given tissue and metric. Along a particular line, the green dot represents the
µ-map being compared to the others, and red dots indicate significant differences.
Each dot is vertically aligned with the µ-map it refers to.
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Figure 4.3: Results of the local analysis. All values are mean ± SD. (A) Coronal and
(B) sagittal slices though subject five’s PETCT depicting VOI placement. Relative
error in VOIs placed in (C) lung, (D) soft tissue, (E) bone, and (F) lesions. The results
of statistical testing are indicated by the sets of parallel vertical lines commencing
with a green dot. The comparisons were made between all six µ-maps for a given
VOI. Along a particular line, the green dot represents the µ-map being compared
to the others, and red dots indicate significant differences. Each dot is horizontally
aligned with the µ-map it refers to.
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Figure 4.4: Joint histogram of CT versus MRI lung signal. The mapping derived
from this data was CT = 3.28×MRI− 864.
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Table 4.1: Results of 4 (tissue) × 6 (µ-map) repeated measures ANOVAs for the
global analysis. The p values are reported before correction for multiple comparisons.
Factor Measure Hypothesis df Error df  F p
Tissue D2y=x 2.063 22.695 0.688 16.665 < 0.0005
Tissue R2 1.180 12.980 0.393 201.591 < 0.0005
Tissue E 1.068 11.753 0.356 15.777 0.001
µ-map D2y=x 1.996 21.960 0.399 4.198 0.029
µ-map R2 1.045 11.469 0.209 5.352 0.039
µ-map E 1.237 13.608 0.247 31.270 < 0.0005
Tissue*µ-map D2y=x 3.639 40.032 0.243 8.640 < 0.0005
Tissue*µ-map R2 1.112 12.227 0.074 6.307 0.025
Tissue*µ-map E 1.226 13.491 0.082 13.009 0.002
λ = 0.12, F (15, 146.711) = 11.287, p < 0.0005), and their interaction (Wilks’ λ =
0.181, F (45, 485.012) = 8.387, p < 0.0005). Every follow up 4 × 6 repeated measures
ANOVA was also significant for tissues, µ-maps, and their interactions (Table 4.1).
Given the significant interaction terms, one-way (factor = µ-map) repeated measures
ANOVAs were carried out for each metric and tissue (Table 4.2). Concerning both
D2y=x and E, the only tissue in which there were no significant differences between
the µ-maps was lung. For R2, however, it was only water that had no significant
differences. The results of the post-hoc paired-sample t-tests are presented visually
in Figure 4.2.
The statistical testing revealed that in lung, there was no difference between the
µ-maps in terms of accuracy or relative error, though PETmap was more precise than
the rest.
Conversely, in fat, precision was essentially constant amongst the µ-maps, but
there were significant effects in accuracy and relative error. In particular, PETreg
outperformed the other µ-maps, while assigning larger µ-coefficients to bone deteri-
orated PETseg’s quality.
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Table 4.2: Results of the one-way (factor = µ-map) repeated measures ANOVAs
for the global analysis. The p values are reported before correction for multiple
comparisons.
Tissue Measure Hypothesis df Error df  F p
Lung D2y=x 2.020 22.222 0.404 1.950 0.166
Lung R2 1.041 11.449 0.208 5.137 0.043
Lung E 1.079 11.866 0.216 1.597 0.233
Fat D2y=x 1.273 14.001 0.255 33.504 < 0.0005
Fat R2 1.464 16.101 0.293 4.737 0.033
Fat E 1.259 13.847 0.252 53.105 < 0.0005
Water D2y=x 1.488 16.369 0.298 4.0009 0.049
Water R2 1.110 12.212 0.222 1.545 0.241
Water E 1.283 14.109 0.257 42.862 < 0.0005
Bone D2y=x 1.153 12.686 0.231 4.854 0.043
Bone R2 1.205 13.254 0.241 60.360 < 0.0005
Bone E 1.905 20.958 0.381 219.133 < 0.0005
In water, neither accuracy nor precision displayed any significant effects, but both
PETreg and PETseg0 achieved significantly less error than the others. As with fat, the
higher the µ-coefficient assigned to bone, the worse PETseg’s quality.
Finally, in bone, accuracy was significantly deteriorated in PETseg0, while preci-
sion was sequentially deteriorated further and further in PETseg300, PETseg600, and
PETseg900. PETreg achieved the lowest relative error in bone, while the PETseg series
went from negative to positive error as a function of the bone µ-coefficient assignment.
4.3.3 Local
For the local analysis, the initial 14 (VOI excluding lesions) × 6 (µ-map) repeated
measures ANOVA revealed a significant effect of VOIs ( = 0.278, F (3.620, 39.816) =
11.167, p < 0.0005), of µ-maps ( = 0.328, F (1.638, 18.019) = 125.084, p < 0.0005),
and their interaction ( = 0.075, F (4.845, 53.296) = 16.167, p < 0.0005). Of the
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Table 4.3: Results of one-way (factor = µ-map) repeated measures ANOVAs for local
analysis. The p values are reported before correction for multiple comparisons.
VOI Hypothesis df Error df  F p
Upper lung 1.371 15.080 0.274 2.830 0.104
Lower lung 1.253 13.786 0.251 1.548 0.241
Caudate nucleus 1.987 21.852 0.397 104.049 < 0.0005
Cerebellum 1.455 16.008 0.291 23.051 < 0.0005
Aortic arch 1.283 14.116 0.257 10.592 0.004
Cardiac septum 1.059 11.651 0.212 1.253 0.289
Liver 1.488 16.369 0.298 8.237 0.006
Spleen 1.321 14.535 0.264 5.041 0.033
Iliacus 1.496 16.460 0.299 3.840 0.053
Sigmoid colon 1.469 16.154 0.294 20.654 < 0.0005
Occipital protuberance 1.876 20.638 0.375 14.875 < 0.0005
Vertebral body of T8 1.404 15.443 0.281 46.602 < 0.0005
Spinous process of L2 1.480 16.277 0.296 86.380 < 0.0005
Iliac crest 1.841 20.256 0.368 26.532 < 0.0005
Thoracic lesions 1.801 21.610 0.360 91.509 < 0.0005
Abdominal lesions 1.261 3.784 0.252 9 0.041
Pelvic lesions 1.584 6.337 0.317 24.324 0.001
one-way ANOVAs in each VOI (including lesions) with µ-map as the factor (Table
4.3), those in the lower and upper lung, cardiac septum, and iliacus did not show a
significant effect. The results of the post-hoc testing are shown in Figure 4.3.
The VOIs in the lung tended to have means close to zero, but exhibited large
standard deviations. Notably, PETmap had about half the standard deviation of the
others in both the upper and lower lung.
In soft tissue, again most of the errors were relatively small, with the exception
of sigmoid colon. Though often small, many VOIs showed a significant effect of
what µ-coefficient was assigned to bone in PETseg. PETreg had a mean error most
consistently close to zero, but oftentimes the highest standard deviation.
The VOIs in bone exhibited the largest errors, generally with a pronounced impact
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of the µ-map. Again, PETreg was typically closest to zero, followed by PETmap.
Which PETseg scan performed the best was a function of the VOI (i.e. PETseg900 in
the external occipital protuberance, PETseg300 in T8 and L2, and PETseg0 at the iliac
crest).
In lesions, activity tended to be overestimated in all reconstructions, save PETreg.
4.4 Discussion
4.4.1 Overview
In this work, we illuminate some strengths and weaknesses of three approaches to
MRI-based AC: segmentation, registration, and mapping. Our analysis comprised
global and local components to assess performance in healthy tissue and pathological
lesions. We discuss our results in tissues and lesions, comment on hybridizing the
approaches, and conclude with limitations stemming from image registration.
4.4.2 Lungs
The lungs are a challenge for MRI-based AC as their µ-coefficients vary widely both
between [5] and within [11] patients, while conventional pulse sequences yield little
signal. Previously [15] we established a linear mapping between MRI and CT in dogs
and now extend it to humans (Figure 4.4). Thus, our mapping-based µ-maps captured
relative µ-coefficient variation in the lungs, so PETmap exhibited the highest precision
(Figure 4.2). However, no benefit in accuracy was observed, likely because the patients
were not at identical states of respiration during the CT and MRI. Accordingly, overall
lung density varied between the CT and MRI, leading to erroneous mean µ-coefficient
assignments. Unfortunately, strict respiratory control was not possible as several
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patients were unable to hold their breath for the duration of the CT scan, (thirty
seconds). Nonetheless, in the lung VOIs (Figure 4.3C), the relative error in PETmap
was more tightly clustered about zero than the other approaches, as indicated by the
reduced standard deviation.
4.4.3 Fat
In fat the differences between the µ-maps were in accuracy and relative error (Figure
4.2). Unsurprisingly, accuracy was poor for the PETseg series as fat was not in-
cluded as a tissue class, so activity was universally overestimated (Figures 4.1D and
4.2C). Interestingly, accuracy deteriorated in proportion to the µ-coefficient assigned
to bone, mainly due to fat being misclassified as bone; the degree of overestimation is
determined by bone’s µ-coefficient. This was a recurring theme in the data and can
be seen in the (global) relative error in fat and water, as well as in the sigmoid colon
VOI, an area susceptible to mis-segmentation. It also featured in the lesion VOIs,
though only significantly in the thorax.
PETreg, in contrast to the PETseg series, included fat in the template µ-maps and
had a much improved accuracy and relative error. The mapping approach incorpo-
rated fat to some degree (Figure 4.1B), but the SVM lacked sufficient information
to do it properly. A useful addition would be a pulse sequence capable of fat/water
separation, as has been proposed by Martinez-Mo¨ller et al [17] and validated by Eiber
et al [4].
4.4.4 Water
Of all the tissues, water had the best precision and accuracy, with no significant
differences in either (Figure 4.2). Though there were some significant differences in
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relative error, the magnitude of the errors was small, under 10% for all µ-maps. This
agrees with the VOI data, which demonstrated small errors in all cases except the
sigmoid colon, wherein bowel gas created problems. Oftentimes, bowel gas present
in the sigmoid colon during the CT had migrated elsewhere during the MRI, and
as a result was erroneously deemed soft tissue. This is unavoidable in experiments
comparing MRI-based to CT-based AC algorithms, but not a problem in true simul-
taneous PET/MRI systems. That said, MRI-based AC algorithms must account for
bowel gas. Not doing so leads to apparently increased activity in the colon wall, an
artifact that may be confused with colon cancer in suspect patients.
4.4.5 Bone
Predictably, in bone, accuracy is worst when bone is ignored, as it was in PETseg0
(Figure 4.2). Additionally, if the mean µ-coefficient of bone is overestimated, as in
PETseg900, accuracy also suffers. Precision also deteriorates because properly seg-
mented bone voxels receive a larger magnitude of AC than mis-segmented ones.
The estimated activity in these groups of voxels diverges as a function of bone’s
µ-coefficient, decreasing precision. Regarding relative error, PETreg was closest to
0%, perhaps because it not only included the entire skeleton in the µ-map template,
but it effectively accounted for the intrinsic variability of bone density within a given
individual.
Segmentation is incapable of doing the latter. This is best illustrated by the
VOI analysis: in bones with low density, such as the vertebral body of T8, µ-maps
with lower bone µ-coefficients (e.g. PETseg300) had less error than those with high
bone µ-coefficients (e.g. PETseg900). Conversely, in dense bone, like the external
occipital protuberance, the pattern is reversed. Simply put, tuning the µ-coefficient
of bone to work well in one area will inevitably lead to failures in other areas with
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different bone density. Segmentation is therefore ill suited to MRI-based AC in bone.
Incidentally, like registration, mapping can theoretically model bone well, but in our
implementation, it did not perform as well as registration (Figure 4.1B versus Figure
4.1C).
4.4.6 Lesions
The local analysis included VOIs over lesions of a pathological nature. Unlike the
VOIs in normal soft tissue (Figure 4.3D), the activity in lesions was generally over-
estimated (Figure 4.3F). In retrospect, most of the normal soft tissue VOIs, save
the sigmoid colon, were in structures predominantly composed of water. In contrast,
many of the lesions were surrounded by fat, and as described above, PETreg proved
the best at incorporating fat into its µ-map. It is therefore unsurprising that PETreg
exhibited the lowest errors in lesions, especially in the abdomen and pelvis where fat
is abundant.
4.4.7 Hybrid Approaches
If one was forced to choose a “victor” of the three MRI-based AC approaches, reg-
istration was arguably the most effective overall, though its capacity to handle fat
gave it an edge. However, a more instructive conclusion is that each approach has
advantages and disadvantages. Segmentation was generally excellent in water, and
likely would have been so in all soft tissue had fat been included as a tissue class.
Registration had low mean errors in general, but it has the capacity to introduce
large errors as evidenced by its large standard deviations. This is especially true
when patient and template anatomy differ, as is the case in the lung. Mapping was
best in the lungs and reasonable in bone, but requires some improvements to make it
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more robust. Likely, the key to effective MRI-based AC is the hybridization of these
approaches.
There are many ways segmentation, registration, and mapping can be combined;
one example is Hofmann et al ’s “atlas registration and pattern recognition” approach
[6, 8] which makes use of all three with excellent results. Briefly, the approach is based
on mapping via supervised learning, but registration is used to put the MRI/CT
pairs used for training into a common coordinate system with the patient, while some
features are drawn from a segmented version of the patient MRI. Segmentation is also
used in a post-processing step to override the mapping in certain cases for fat, water,
and bowel gas.
We propose some suggestions for future research in hybridized approaches. First,
air, water, and fat are all amenable to segmentation as their µ-coefficient is essen-
tially constant and they are easily identifiable using the appropriate pulse sequences.
Lungs and bones, however, have broad µ-coefficient distributions, and are ill suited
to segmentation. Lungs are easy to locate, and likely a preliminary segmentation
followed by mapping is the most straightforward path [15]. The complex anatomy
of the skeleton, however, is not easy to determine on MRI, and registration likely
has a role to play in locating it. Unfortunately, a template µ-map can only capture
general trends of µ-coefficient variation in space; ultimately, some patient-specific
measures will be required in bone to generate realistic µ-maps. Perhaps ultrashort
echo time sequences have a role to play in determining the µ-coefficient distribution
on a patient-by-patient basis [2].
4.4.8 Errors from Image Registration
A limitation of this work not mentioned heretofore is that the registration of MRI-
based µ-maps to CT-based µ-maps is imperfect. Therefore, the observed error is
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a function not only of actual differences between the µ-maps, but of any misalign-
ments as well. As these were non-rigid registrations, quantifying the error is difficult.
However, the global analysis spanned entire tissues, likely suppressing the impact of
localized registration error. As for the local analysis, we looked for registration er-
ror about each VOI, but found none so large that we thought our results would be
compromised.
4.5 Conclusion
The performance of each MRI-based AC approach was tissue and location dependent.
Segmentation is appropriate for tissues with a constant µ-coefficient, but mapping
and/or registration are more suitable otherwise. The most effective MRI-based AC
algorithms will hybridize these approaches in such a way that each method’s strengths
are exploited.
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Chapter 5
Expanding Horizons
5.1 MRI-Based AC in SPECT
5.1.1 Where We Stand
In Chapter 2, I explored the relationship between MRI-based attenuation correction
of PET versus SPECT. I found that when a three tissue segmentation algorithm
was used to convert the MRI images to µ-maps, MRI-based AC produced superior
quantitative results in SPECT compared to PET. This was true both globally across
specific tissues including lung, soft tissue, and bone, as well as locally in VOIs placed
in standard anatomic positions. The result held for both animal and phantom studies.
Further, SPECT proved more resistant to small changes to the MRI-based µ-maps
than did PET. I hypothesized that the findings were due to PET’s tendency to have
larger attenuation correction factors than are generally found in SPECT.
5.1.2 Where To Go
Though my study suggests that SPECT may be more quantitatively accurate when
using MRI-based AC MRI-based AC than PET, much work remains to be done. Of
particular importance, there are potentially circumstances under which my conclu-
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sions will prove false. For instance, I only tested one MRI-based AC algorithm, which
in turn approximates the true µ-map in a particular way. As we have seen, there are
innumerable other algorithms to choose from. Some, like the one I used, employ seg-
mentation [9, 31, 39, 49, 52, 57], but not all use the same tissue classes [9, 31, 39, 57].
Others, rely primarily or registration [38, 48] or mapping [3, 27, 28], which estimate
the true µ-map by different means than segmentation. Perhaps the discrepancy be-
tween MRI-based AC’s efficacy in SPECT and PET is a function of the algorithm
itself. If that’s the case, there may be ramifications for which class or implementa-
tion of an algorithm is the best choice for SPECT/MRI systems [19, 22]. Additional
studies are needed to address this issue. It would also be of benefit to increase the
sample size. This pilot study provides the data necessary to make informed power
calculations.
Furthermore, though PET is always conducted at 511 keV, SPECT is capable of
imaging tracers with a range of energies [43]. My SPECT imaging used 99mTc as the
radioisotope, which releases photons at 140 keV, but there are other choices, some
with higher energies and some with lower energies. As attenuation correction factors
are energy dependent, it is likely that MRI-based AC’s quality in SPECT is as well.
Studies with tracers aside from 99mTc would help characterize this relationship.
Another major factor that was not examined in my study were the reconstruction
algorithms. SPECT and PET data may be reconstructed via multiple approaches,
and most approaches have free parameters [45]. It is entirely possible that my findings
would change were a different reconstruction algorithm chosen, or even if the param-
eters I chose (i.e. number of iterations and subsets) were altered. This brings up the
interesting question of which class of reconstruction algorithm is most likely to gener-
ate quantitatively accurate SPECT or PET images when applying MRI-based AC, a
critical practical consideration. In other words, some reconstruction algorithms may
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be more robust to approximate µ-maps. The same may be true of how AC is imple-
mented in SPECT, which unlike PET, is nontrivial [1]. To the best of my knowledge,
these issues have not as of yet received any attention.
As a final note, it may be of value to frame the problem of using approximate
µ-maps in SPECT versus PET in a formal mathematical framework. Specifically, it
would be interesting to understand how different types of errors in the µ-map are
reflected in the emission images, both in terms of appearance and magnitude. Such
studies might help us predict the maximum expected errors given a particular MRI-
based AC algorithm and emission image reconstruction algorithm. Though there
is extensive literature concerning the mathematics of emission tomography and its
reconstruction [41], comparison between the two major nuclear medicine imaging
modalities is generally not emphasized.
5.2 MRI-Based AC in the Lungs
5.2.1 Where We Stand
In Chapter 3, I devised and tested a method of determining the lungs’ µ-coefficients
with MRI. Though the pulse sequence I selected was not able to provide reliable
T2* (and hence extrapolated proton density) images, I nonetheless demonstrated an
approximately linear correlation MRI and CT signal in the lungs. Though spatial
averaging reduced the variance of said correlation, it came at the expense of reduced
spatial information. When using the correlations to map MRI into pseudo-CTs which
were subsequently used to perform AC on PET images, it was found that maintaing
spatial information was more valuable than reducing noise by voxel averaging. In
fact, the voxel-by-voxel mapping (as opposed to slice-by-slice or whole-lung mapping)
yielded the best quantitative results in the lungs with respect to accuracy, precision,
178
and root mean squared error. Moreover, quantitative benefits extended to structures
adjacent to the lungs, including the heart. However, these benefits quickly diminished
as the distance from the lungs increased.
Also, though Chapter 4 did not focus on lung imaging, I nonetheless adapted the
method described in Chapter 3 to humans. Some benefits in the quantification of
PET images was observed, but the approach’s full potential was not realized owing
to a lack of respiratory matching between the patients’ CT and MRI scans.
5.2.2 Where To Go
The most challenging aspect of MRI-based AC in the lungs is finding a pulse sequence
that yields signal from lung tissue that is consistently relatable to µ-coefficients. It
is difficult to do so with even a moderate signal-to-noise ratio (SNR) given lung’s
low proton density and short T2*, especially at high main magnetic field strengths
[8, 24, 25]. I elected to use a single-shot gradient echo sequence which have been used
extensively for lung imaging [5, 17, 24], but turbo spin echo sequences are another
viable option [25, 34, 37], and perhaps even ultrashort TE sequences [53, 55]. An
alternate (or better optimized) sequence may provide more useful images than the
one I chose. In particular, a sequence capable of reliably estimating T2 or T2* is able
to generate pure proton density images, free from the effects of magnetic relaxation
times that add undesirable variability to the MRI signal [24].
Additional complications arise when adapting pulse sequences from (smaller) an-
imals to humans. For example, I found that when the sequence I used was used on
humans, the SNR decreased, and Gibbs ringing appeared at the lungs’ edges. Thus,
for any sequences that have not been validated in humans, some work will be required
to make the leap. This will prove especially challenging for ultrashort TE sequences
[53, 55] which struggle with large fields of view. Once the leap is made, however, the
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human study must be done with appropriate respiratory matching between MRI and
CT, lest the correlation between the signals be masked.
An important extension of the work presented in Chapter 3 is to validate that the
relationship between MRI and CT signal in the lungs is maintained in disease states.
It is well documented that lung density is a function of pathology [23, 30, 33], and
therefore it is essential that the correct µ-coefficients can be estimated if lung disease
is present (which it is in many, many patients). Perhaps a formal model of how MRI
signal and CT signal in the lungs are related would shed some light on this issue.
Finally, a critical consideration when imaging the lungs with PET is that they
are not stationary. The PET scan usually takes several minutes, and the patient
breathes throughout. Therefore, the application of a static µ-map is fundamentally
flawed, and leads to localization and quantification errors [16, 20]. The so-called
emission/transmission mismatch is best addressed by using a dynamic µ-map. MRI
is well suited to capture the motion of the lungs [14, 21], but not for capturing the
associated variations in lung density, which is exactly what my method is designed
to do. A fascinating contribution to the field of MRI-based AC would be to combine
the method described in Chapter 3 with lung motion estimates to eliminate the
emission/transmission mismatch.
5.3 MRI-Based AC Algorithms
5.3.1 Where We Stand
In Chapter 4, I examined the performance of three classes of MRI-based AC algorithm,
namely those relying on segmentation, registration, or mapping. I found that the best
approach depended on the tissue under consideration. Specifically, mapping yielded
the best results in lung tissue, registration was best in fat (though segmentation
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likely would have performed as well or better if a fat category had been included),
segmentation was best in water, and registration was best in bones.
Also, the MRI-based AC algorithm using segmentation was the first of its kind to
include a bone class. Therefore, I tested the effects of assigning different µ-coefficients
to bone. Though globally, quantification in bone was optimized using the µ-coefficient
corresponding to a CT number of 600 HU, it was evident that no single µ-coefficient
could yield low errors in all bones. This is unsurprising since bones have variable µ-
coefficients within and between subjects [35]. Further, including bone as a tissue class
actually deteriorated quantitative fidelity in other tissues including fat and water due
to oversegmentation (i.e. bone segmented where it is not actually present). In brief,
segmentation is not well suited for bones.
The conclusions of this study can be summarized as follows: segmentation is use-
ful for tissues with relatively constant µ-coefficients, mapping using patient specific
measurements is ideal in the lungs, and registration will play a key role in the treat-
ment of bone. Thus, hybrid approaches are critical to the success of MRI-based AC
algorithms.
5.3.2 Where To Go
Arguably the most important recommendation stemming from the work in Chapter 4
is that hybrid MRI-based AC algorithms should be pursued. The question is how go
about hybridizing segmentation, registration, and mapping. One group has proposed
an algorithm that uses segmentation and registration implicitly as inputs to a mapping
function, and then uses segmentation again in a post-processing step [27]. There are
other possibilities though. For instance, each approach could be implemented as a
separate step; e.g. one could start with segmentation of air, fat, and water, then apply
mapping to the lungs, and then registration for the bones. Alternatively, mapping
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could be carried out first, and segmentation and registration used to modify voxels
that the mapping was “uncertain” of. There are many combinations and permutations
that could be explored, begetting possibilities for new research.
Another area that will surely receive attention is in the improvement of individual
algorithmic classes. There are multiple ways to accomplish segmentation [4, 42, 51],
registration [13, 26, 44, 58], and mapping [2, 10, 15, 29, 40, 50, 54], and only a few
of these have yet been explored in the context of MRI-based AC. It is essential to
determine which algorithms are the most effective for the task at hand so that when
they’re combined, the best possible results are realized.
Moreover, each individual algorithmic class has general unanswered questions as-
sociated with it. For example, if using segmentation, which tissue classes should
be included [32]? For registration, what should the template µ-map be [38]? For
mapping, what features are the most informative? At present our answers to these
questions are incomplete at best.
Also, no current MRI-based AC algorithm is able to make patient specific mea-
sures of bone density, which as I have repeatedly indicated, is highly variable [35]. At
present, since bones have such a short T2, the only feasible way of extracting bone
density information via MRI is with ultrashort TE sequences [7, 46]. However, at
present these sequences are not fit for whole-body imaging. Perhaps as a first step a
small proportion of the patients’ bones could be imaged, and based on said images,
average bone density could be extrapolated. In the future, with the aid of improve-
ments in imaging speed via techniques such as parallel imaging [6] and compressed
sensing [36], ultrashort TE sequences may be adapted to larger fields of view.
Finally, when attempting to validate any whole-body MRI-based AC algorithm,
there is a confounder that always taints the results. In order to conduct such an
experiment, three sets of images are required: PET, MRI, and some gold standard
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µ-map, usually derived from CT. Since there is no imaging system that incorporates
all of PET, MRI, and CT, generally the patient is imaged using PET/CT and then
MRI or PET/MRI. This gives rise to the inevitable confounder: the MRI-based µ-
map must be registered to the CT-based µ-map, an imperfect process that propagates
errors into the PET reconstructions that are not due to imperfections of the MRI-
based µ-map. Separating registration errors from true errors is extremely challenging.
In fact, characterizing the errors present in registrations is a field of study unto itself
[11, 12, 18, 47, 56]. Nonetheless, an exposition on how registration error impacts the
validation of MRI-based AC algorithms would be a welcome contribution to the field.
5.4 Conclusion
PET/MRI and SPECT/MRI are exciting technologies, ushering in a new set of pos-
sibilities for data collection in medical imaging. However, without proper attenuation
correction, the emission images lose much of their value. Though turning MRI im-
ages into µ-maps is no easy task, MRI-based AC has come a long way in just a few
years. Nonetheless, much remains to be done, and I suspect that research concerning
MRI-based AC will remain captivating for many years to come.
The overarching objective of this thesis was to improve MRI-based AC. I have done
so by identifying that SPECT is more robust to MRI-based AC than PET, devising a
procedure for estimating µ-coefficients in the lungs, and exploring the strengths and
limitations of three methods for converting MRIs into µ-maps.
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